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ABSTRACT 
 
 Drug designing usually encounters two major difficulties: construction of small 
molecules and target finding for the molecules. This is frustrating because either one 
requires tremendous effort. My research focused on how well-known methods such as 
asymmetric hydrogenation and organocatalysis can facilitate organic synthesis and how 
EKO aided us to find protein targets for small molecules.  
 Synthesis of Z-allylic diols was a starting project. The beauty of trisubstituted 
allylic diols is that it can be converted to a lot of useful building blocks of organic 
molecules, such as 4,5-disubstituted furanone and 2,3-disubstituted furan. The 
construction of the scaffold needed an undervalued intermediate, vinylaluminate, which 
was developed decades ago. Treated with red-aluminum, 2-butyn-1-ol can be converted 
to a five-membered ring vinylaluminate intermediate. The only application of this 
intermediate was the conversion to vinyl iodide. We found a more valued application: 
reaction with aldehydes to form a Z-allylic diol scaffold. 
 The ideal was carried on further. Combination of two well-known methodologies, 
asymmetric hydrogenation and organocatalysis can result in the production of 
particularly high-value chirons. We prepared optically pure homo-Roche ester by 
asymmetric hydrogenation of a α,β-unsaturated ester. And chlorination, fluorination and 
amination of the ester product formed a series of useful chirons. 
The two projects, though not directly related, but conceptually guided the third 
project: design and synthesis of small molecules that can disrupt protein-protein 
interactions, because we are eager to illustrate the merits of our novel approaches, EKO 
and EKOS. EKO is a computational program that can overlay small molecules over tens 
of thousands of protein-protein interfaces and find the best fit PPIs for the molecule. We 
used cyclic tetrapeptide and oxopiperazine dimers as examples to illustrate how EKO 
and EKOS work. And we also designed an expedient large-scale synthesis of cyclic 
tetrapeptide as probes to illustrate the idea that using creative computational methods for 
molecular design will have a large impact on contemporary life science.  
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CHAPTER I 
INTRODUCTION 
 
1.1 New Methodology For Synthetically Useful Building Blocks 
Creativity in organic synthesis can be interpreted in two aspects. In one aspect, it 
is to find a new reaction or new synthetic route that is never reported before. In the other 
aspect, it is to apply well-known reactions or intermediates to improve existing synthesis. 
Half of my master research focuses on the second aspect.  
Treated with aluminum hydride, 2-butynol can afford a 5-membered ring vinyl 
aluminate intermediate which can be quenched by iodine to afford a well-known useful 
vinyl iodide species.1-3 It is useful because it can generate a regiospecific Z-allylic 
alcohol intermediate which can be used as building blocks in organic synthesis. However, 
in all reported work, this vinyl aluminate intermediate needed to be converted to vinyl 
iodide first. There is no precedent work showing a direct reaction with electrophiles 
other than iodine (Figure 1.1). Therefore, nearly half of my master research was devoted 
on exploring new applications of this useful vinylaluminate intermediate. 
 
 
Figure 1.1. Vinyl aluminate attacks electrophiles to generate Z-allylic alcohol. 
 
Chiral analogs of Crabtree’s catalyst, ie N,P-Ir complexes have been recognized 
as the most useful catalyst that can use for hydrogenation of olefin without coordinating 
functional groups.4-6 There is even a greater deal of enamine catalyst by simple catalyst 
OH
NaH2Al(OR)2
O
(RO)2Al
E
OH
Na+
I
OH
well-known
vinylaluminate
intermediate
E
I2
 2 
such as proline.7 Combination of two can lead to a methodology not reported before. 
Organocatalytic transformations of the homo-Roche aldehydes, which are obtained from 
asymmetric hydrogenation, are good illustrations of the idea. Asymmetric hydrogenation 
routes to homologs of Roche ester tend to be restricted to hydrogenations of itaconic 
acid derivatives, ie substrates that contain a relatively unhindered, 1,1-disubstituted, 
alkene. This is because in hydrogenations mediated by RhP2 complexes, the typical 
catalysts, it is difficult to obtain high conversions using the alternative substrate for the 
same product, the isomeric trisubstituted alkenes (Figure 1.2). However, chemoselective 
modification of the identical functional groups in itaconic acid derivatives are difficult, 
hence it would be favorable to use the trisubstituted alkene. Trisubstituted alkene 
substrates can be hydrogenated with high conversions using chiral analogs of Crabtree’s 
catalyst of the type IrN(carbene).  
 
 
Figure 1.2. Combination of asymmetric hydrogenation and organocatalysis leads to 
useful homo-Roche ester derivatives. 
 
My work demonstrates such reactions are scalable and can be manipulated to 
give optically pure homo-Roche ester derivatives with two chiral centers and α,ω-groups 
that provide extensive scope for modifications. A synthesis of (S,S)- and (R,S)-γ-
hydroxyvaline was performed to illustrate one application of the amination product. 
 
 
 
organocatalysis CO2RFGCO2RFG
homo-Roche
ester
X
X = F, Cl, N
CO2RRO2C
CO2MeHO
hydrogenationknown with
RhP2 cat.
here
Ir(N,Carbene) cat.
more
accessible
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1.2 Synthesis And Conformational Analysis Of CTPs  
Cyclic tetrapeptides (CTPs) have been known for decades, mostly as natural 
products.8-10 Previous syntheses of CTPs involve proline and/or glycine. Proline 
facilitates syntheses of CTPs because cis-conformations are far more thermodynamically 
accessible, and this “forces” the peptide to turn, so that C- and N-termini can come 
together for cyclization.11-13 Glycine residues, having no side-chains, similarly allow 
conformations that are favorable for cyclization because a greater range of ψ and φ 
angles are available around Gly than for any other amino acid. Combinations of Pro-Gly 
in linear precursors to CTPs are particularly favorable because that motif is highly 
conducive to turn conformers that facilitate cyclization. For these reasons, the 
overwhelming majority of synthetic CTPs reported contain Pro and/or Gly. CTPs that 
have been made via peptide syntheses which do not contain Pro or Gly are rarely 
reported.14-17  
The second half of my master research was focused on (i) developing an efficient 
solution phase synthesis of CTPs based upon Li’s innovation and (ii) conformational 
analysis of CTPs. The conformations of CTPs are determined by a non-commercial 
program called, quenched molecular dynamics (QMD), devised by Dr. Monte Pettitt.18,19  
 
1.3 Side-chain Matching And Mining On Protein-protein Interaction With EKO 
And EKOS 
Our group published on two techniques called EKO (Exploring Key 
Orientations)20 and EKOS (Exploring Key Orientations on Secondary-structures)21 to 
help us to design small molecules that are semi-rigid scaffolds bearing three amino acid 
side-chains to resemble protein fragments. These methods enable us to explore 
orientations of side-chains that could result in conformations adopted by these 
molecules. Then data mining can match these side-chain orientations with protein 
fragments that fit. In this project, EKO and EKOS are performed on CTPs and 
oxopiperazine dimers. In EKOS, the interface regions of crystallographically 
characterized protein-protein interactions (PPIs) of ideal secondary structures are 
 4 
targeted. EKO works in the same way as EKOS, except that the secondary structure 
database is replaced by one covering interface regions in crystallographically 
characterized PPIs.  
 
1.4 Conclusion 
My master degree research focused on two parts. The first was to develop simple 
new methods for synthesis of molecules that can be useful as synthetic building blocks 
and the second half was to synthesize cyclic tetrapeptides and determine their 
conformations, and finally explore their potential as small molecules to disrupt protein-
protein interactions via computational analysis. 
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CHAPTER II 
REGIO- AND STEREOSELECTIVE SYNTHESIS OF TRISUBSTITUTED (Z)- 
ALLYLIC ALCOHOLS VIA TRANS- HYDROALUMINATION/VINYL 
ADDITION 
 
2.1  Introduction  
Degree of difficulty in trisubstituted allylic alcohol syntheses correlates with the 
alkene stereochemistry. Reactions of stabilized phosphonate reagents22,23 with 
aldehydes, followed by hydride reductions, to afford A and B are so generally reliable 
that it is usually unnecessary to look to the obvious alternatives.24-29 Motifs C and D, 
however, are significantly less accessible. Preparations of these have been achieved via 
alkyne hydroalumination30-34 or hydromagnesiation,35 but if the starting material is a 
propagrylic alcohol, using the disconnection implied in blue, then several more steps are 
needed. For example, fragments C can be made via conversion of the hydroalumination 
products to aluminate anions, then to cuprates, which are eventually reacted with 
activated alkyl halides.36 Synthons D can be made via iodine quench of the same 
intermediate, lithium-halide exchange, then reaction with an epoxide.36 
 
 
Figure 2.1. Trisubstituted allylic alcohol synthons. 
 
Other routes to C and D involve catalyzed additions of organoboranes to dienes then 
oxidation,37-38 but these approaches require stereoselective syntheses of the appropriate 
dienes (Figure 2.1). To address some of these difficulties, a previous student Dr. Ye Zhu 
invented a means to synthesize compounds F, which represent a highly functionalized, 
OH
OH
OH
OH
A B C D
2 2
33
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and therefore particularly useful, subset of the coveted motifs D via the simple process 
outlined in Scheme 2.1.  
 
 
Scheme 2.1. trans-Hydrometalation/vinyl addition reaction. 
 
2.2     Results And Discussion 
2-Butynol corresponds to the carbon framework of motif D, hence we 
hypothesized that the most direct way to add this fragment to an aldehyde would be via 
addition of its hydroalumination product with sodium bis(2-methoxyethoxy)aluminum 
hydride (Red-Al).1 However, the literature on addition of this vinyl aluminate 
intermediate to aldehydes gave no direct indication this would work. Additions of 
dialkyl(alkenyl)alanes to aldehydes are known,30-34 but it has often been found necessary 
to form the trialkyl(alkenyl)aluminate anions to induce transfer of the vinyl group.40-41 
We could find no reference to direct addition of propargylic alcohol hydroalumination 
products to aldehydes. Consequently, when we tried to react the hydroalumination 
products using benzaldehyde as a substrate, we were encouraged to see some product 
form, and delighted to optimize it to good yields (Table 2.1).  
 
Table 2.1. Optimization of trans-hydrometalation/vinyl addition reaction. 
 
 
 
 
 
OH
NaH2Al(OR)2
O
(RO)2Al
R1 O
OHOH
R1
Na+
R=MeO(CH2)2O
Red-Al
solvent
23 oC, t1
Ph
OH OHOH O
(RO)2Al
Na+ - (i) quench0 oC, 20 min
(ii) PhCHO
 23 oC, 12 h
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Table 2.1.  Continued. 
entry solvent Red-Al (eq.) t1 (h) 
quench PhCHO yield 
(eq.)  (eq.) (%)a 
      
       
1 CH2Cl2 2 12 
EtOAc 
(1.0) 2 <5 
2 tBuOMe 2 12 EtOAc (1.0) 2 44 
3 THF 2 12 EtOAc (1.0) 2 63 
4 Et2O 2 12 
EtOAc 
(1.0) 2 66 
5 hex. 2 12 EtOAc (1.0) 2 78 
6 hex. 2 4 EtOAc (1.0) 2 77 
7 hex/THF 2 4 EtOAc (1.0) 2 66 (5:1) 
8 hex/THF 1.25 4 EtOAc (0.25) 2 70 (5:1) 
9 hex/THF 1.25 4 EtOAc (0.25) 1.2 74 (5:1) 
10 THF 1.25 4 EtOAc (0.25) 1.2 58 
11 Toluene 1.50 4 none 2 88 
 
a Determined by HPLC using 4-hydroxyphenethyl alcohol as internal standard, and 
based on the alcohol starting material; hex = hexane. 
 
 
Entries 1 – 4 show how increased yields of 2a approximately correlated with decreasing 
solvent polarities. This is consistent with literature reports that the reactivity of 
organoaluminum reagents is increased in apolar solvents.41 However, the reactions in 
hexane tended to form gels and reproducibility problems were encountered. For this 
reason, a mixed solvent system with 20% THF was tested and found (entry 7) to give 
yields similar to the highest in pure hexane, but more consistently. Entry 10 was 
performed simply to check that if pure THF solvent would give better results under the 
 8 
modified conditions; surprisingly, increased yield was observed when excess 
benzaldehdye was used without adding EtOAc (entry 11). The first ten entries were 
investigated by Dr. Ye Zhu and I modified the process and the optimized condition was 
reported in entry 11. And the preliminary studies extrapolated to other substrates as 
shown in Table 2.2.  
 
Table 2.2. One-pot synthesis of (Z)-trisubstituted allylic alcohols.a 
 
2 R isolated yield (%)   2 R 
isolated 
yield (%) 
  
  
 
  
  
a 
 
88b 
 
b 
 
85b 
  
  
 
  
  
  
  
 
  
  
c 
 
55 
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67 
  
  
 
  
  
  
  
 
  
  
e 
 
58 
 
f 
 
76 
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63 
 
h 
 
67 
  
  
 
  
  
  
  
 
  
  
i 
 
51 
 
j 
 
74 
1.25 Red-Al
Hex/THF
(5:1)
23 oC, 4 h R
OH OHOH O
(R1O)2Al
Na+ - (i) 0.25 EtOAc0 oC, 20 min
(ii) 1.2 RCHO
 23 oC, 12 h
2
Br
I O2N
MeO
NO2
OMe OMe
O2N
Ph Ph
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Table 2.2.  Continued. 
2 R isolated yield (%)   2 R 
isolated 
yield (%) 
k 
 
36 
 
l 
 
58c 
              
a 2-Butyn-1-ol (2.0 mmol, 1.0 eq) was used; b condition of entry 11 was used; c the 
aldehyde was dissolved in hexanes and added to the reaction mixture slowly via a 
syringe pump.  
 
 
Several trends are illustrated for application of this reaction to substrates 1. Aryl 
bromide (b) and iodide (c) functionalities were tolerated, the reaction worked well for 
benzaldehyde derivatives with electron withdrawing (c) or donating (d) groups, even in 
the 2-position for which steric hinderance could have been an issue (substrates f - h).  
Ethyl glyoxylate (k) gave a somewhat reduced yield of the secondary product 
corresponding to spontaneous lactonization.  This methodology is less robust for 
aliphatic aldehydes.  Where there is α-branching in the substrate, and presumably slower 
rates of competing self-condensation processes, as for 2-methylpropanal 2l then good 
yield of product could be obtained by slow addition of the aldehyde to the 
hydroalumination product (thus disfavoring aldehyde self condensation). Figure 2.2 
illustrates two simple applications of the products 2.  The first illustrates oxidation then 
cyclization to the unsaturated butyrolactone 3, and the second shows cyclization then 
oxidation to the 2,3-disubstitued furan 4. 
 
 
O
EtO
 10 
 
Figure 2.2. One step applications of allylic alcohols 2. 
 
2.3    Conclusions 
Treated with aluminum hydride, 2-butynol can afford a 5-membered ring vinyl 
aluminate intermediate, which can be quenched by iodine to afford a well-known useful 
vinyl iodide species.1-3 It is useful as it can generate a regiospecific Z-allylic alcohol 
intermediate. We are the first group who applied the intermediate in direct synthesis to 
build synthetically useful trisubstituted allylic alcohols, which can be readily converted 
to lactones, furans and polyketides via hydrogenation. 
 
  
OH OH
Br
0.2 TMEPO
2.2 PhI(OAc)2
CH2Cl2:H2O (3:1)
23 ˚C, 1 h
Br
O O
OH OH
Br
1.2 IBX, DMSO
23 ˚C, 2 h
Br
O
2b
2b
90 %
65 %
3
4
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CHAPTER III 
HOMO-ROCHE ESTER DERIVATIVES BY ASYMMETRIC 
HYDROGENATION AND ORGANOCATALYSIS
* 
 
3.1 Introduction  
Roche ester derivatives E are some of the most widely appreciated chirons in 
organic syntheses42-45 because such compounds have both terminal functional groups 
that allow modification and homologation in bidirections, especially for incorporating 
methyl-substituted chiral centers. It seems logical that the homologous chirons F would 
be similarly useful as chirons E if they were more readily available. For the purposes of 
this study we refer to the generic class of fragments F as homo-Roche ester derivatives 
(Figure 3.1).  
 
 
 Figure 3.1. Structure of Roche ester and homo-Roche ester derivatives. 
 
Scalable syntheses of chirons F have not gained much attention in the literature. 
The most directing route should be a homologation of the parent chirons E46 which is 
probably not the best option to obtain chirons F, even though they only contain one more 
skeletal carbon than E because the Roche ester is not a cheap starting material; small 
quantities tend to cost more than $1 per gram. Another approach is via asymmetric 
hydrogenations of itaconic acid or the corresponding diesters to give the C5-building 
                                                
* Reprinted in part with permission from “Homo-Roche Ester Derivatives by Asymmetric Hydrogenation 
and Organocatalysis”, Sakunchai Khumsubdee, Hua Zhou and Kevin Burgess, J. Org. Chem. 2013, 78, 
11948-11955.  Copyright 2013 American Chemical Society. 
PO FG
E
Roche ester 
derivatives
PO
F
homo-Roche ester 
derivatives
FG
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blocks G.47,48 Bidirectional homologation of chirons G requires efficient chemoselective 
modification of one of the two esters; we are aware of only one method for doing this, 
and it features a relatively expensive lipase in a chemoenzymatic hydrolysis to achieve a 
pure single monoester.47 It is possible to instead begin with a monoester of itaconic acid 
and hydrogenate that, but in fact the enantioselectivities for this process tend to be less 
than the diacid or the diester.47,49 Alternatively it is possible to begin the syntheses with 
monoesters of itaconic acid, and indeed some of these are commercially available 
(Figure 3.2). However, these starting materials are expensive so, overall, it is better to 
avoid this strategy. Any strategy that uses hydrogenation of itaconic acid, in fact, is 
vulnerable to the types of deactivation pathways that have been documented 
previously.50,51 Another route to chirons I is via asymmetric additions of cuprates to α,β-
unsaturated thioesters.52  
 
 
Figure 3.2. Hydrogenation substrates to obtain compound G. 
 
Both the hydrogenation syntheses of chirons F described above feature 
bisphosphite complexes formed from Rh(COD)2+ in situ. Hydrogenation of type H 
trisubstituted alkenes would give products that are chemically related to G, but these 
types of transformations tend to be difficult to achieve using RhP2 complexes because 
the double bonds are hindered.53 In fact, the preferred catalysts for the trisubstituted 
alkenes H tend to be N,P-Ir complexes, ie chiral analogs of Crabtree’s catalyst.53 
Consequently, my work in this project was to use our particular chiral analog of 
Crabtree’s catalyst, (S)-1,54,55 to reduce H -type substrates via scalable transformations 
RO2C
G
hydrogenation 
products from 
previous work
CO2RRO2C
itaconates
hydrogenation
substrates
in previous work
CO2R PO
H
hydrogenation
substrates
in this work
FG
hydrogenation
easier
hydrogenation
harder
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to obtain single enantiomer of chirons H.  The hydrogenated product was then further 
applied to obtain all stereoisomeric forms of the 2-substituted chirons I via 
organocatalytic modifications of the homo-Roche ester derivatives F (Figure 3.3). 
Similar reactions of achiral substrates via organocatalytic are well known, but finding 
appropriate organocatalysts to overcome the stereochemical bias exerted by the C3 chiral 
center was an open issue. 
 
 
Figure 3.3. Structure of catalyst (S)-1 used for hydrogenation and general structure of 
organocatalysis product I. 
 
3.2     Results and discussion 
3.2.1 Synthesis of hydrogenation substrate 
The synthesis of up to ester 9 was accomplished by previous graduate student, 
Dr. Sakunchai Khumsubdee. The synthesis is as follows. Following a literature 
procedure, glyoxylic acid monohydrate was converted to the α,β-unsaturated ester J.56 
The first new step in this work was to chemoselectively reduce the ester group of J in the 
presence of its carboxylic acid functionality57 to give the hydroxyacid 558,59 which was 
isolated via acid-base extraction. Subsequently, the hydroxyacid 5 was esterified to give 
the known60 hydroxyester 6. None of the steps described in Scheme 3.1 involve column 
chromatography, and the synthesis can give tens of grams of the product 6. 
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Scheme 3.1. Scalable synthesis of the hydrogenation substrate 6. 
 
Hydrogenation of alkene 6 is the key transformation in this project (Scheme 3.2). 
Under the conditions shown in Scheme 3.2, approximately 15 g of the hydroxyester 6 
can be hydrogenated with complete conversion to give 7 (a type F chiron), and the 
catalysts are still active at the end of this transformation. Even though the hydrogenation 
worked perfectly, only high, but not perfect, enantioselectivities were obtained. The 
acyclic product 7 was then lactonized to 8 then efficiently recrystallized under cold 
conditions to give optically pure material. For subsequent applications of these products 
(here and perhaps elsewhere), the lactone 8 was converted to two other potentially useful 
acyclic chirons, the alcohol 7 (now as one enantiomer) and the silyl ether 8.  
 
 
 
 
Scheme 3.2. Asymmetric hydrogenation of alkene 6, then recrystallization and TBDPS-
protection to obtain ester 9. 
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The ester 9 was given to me to perform the application via organocatalysis as 
described below in this chapter. To obtain an aldehyde 10, the ester 9 was reduced using 
Brookhart’s catalytic silylation/hydrolysis procedure61 (reaction 3.1). This reduction 
afforded the aldehyde 10 in good yield for elaboration via organocatalytic processes 
involving iminium and enamine intermediates. 
 
reaction 3.1 
 
3.2.2 Application With Organocatalysis 
To the best of our knowledge, organocatalytic transformations of the homo-
Roche aldehydes 10 have not been reported before. However, there is precedent for 
electrophilic α-substitutions of β-chiral aldehydes,62 and, of course, a great deal of 
literature for the parent reactions of acyclic non-chiral aldehydes.63 Catalysts and 
reagents for the organocatalytic transformation were chosen from a known literature64-66 
for each particular electrophiles then applied them to homo-Roche ester 9 (Figure 3.4). 
 
 
Figure 3.4. Catalysts and reagents used in organocatalysis. 
 
Scheme 3.3 shows the data accumulated for the organocatalytic transformations 
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M•TFA67 (a commercial sample of the hydrochloride catalyst did not work in this 
reaction, so it was converted to the trifluoroacetate, ie the salt used by MacMillan’s 
group). It emerged that the (S)-enantiomer of the catalyst matched64 the substrate bias 
and gave an excellent stereoselectivity for the syn-isomer of 11 after borohydride 
reduction. However, in the mismatched case (R)-M•TFA overwhelmed the substrate 
bias hence a 10:1.0 ratio in favor of anti-7 was observed. Similarly, MacMillan’s 
fluorination procedure65 using (R)-M•Cl2HCCO2- gave even better matched and 
mismatched selectivities in catalyst-controlled reactions to give the 2-fluoroalcohols 12 
after reduction. For amination reactions it was desirable to use dibenzyl azocarboxylate 
rather than other alkyl derivatives for the reasons indicated below (Scheme 3.4), so we 
used List’s procedure that described application of exactly that electrophile.66 Just as in 
the chlorination and fluorination reactions, the aminations were catalyst-controlled. 
These transformations gave superb selectivity in the matched case for syn-13, and a 
13:1.0 ratio for the anti-isomer via the mismatched process.  
 
 
Scheme 3.3. Asymmetric transformations of substrates 10: a chlorination; b fluorination; 
and, c amination. Throughout, selectivities were determined via analytical HPLC on a 
Chiralcel-OD column. 
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Scheme 3.3. Continued. 
 
 
 
Scheme 3.4. Syntheses of α-N-γ-O-protected forms of γ-hydroxyvaline. 
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Reactions 3.2 and 3.3 showed how the isomeric 2-chloroalcohols 11 were 
efficiently ring closed to the corresponding epoxides 14. These reactions were performed 
because the epoxides 14 are valuable chirons, but their use has been limited by the fact 
that syntheses of these materials require multiple steps and some routes are only 
practical for one or two of the four possible stereoisomers.68-70 
 
 
reaction 3.2 
 
 
reaction 3.3 
 
 
Figure 3.5. Structure of γ-hydroxyvaline P. 
 
Finally, derivatives of γ-hydroxyvaline P (Figure 3.5) were prepared to illustrate 
how the amination products 13 could be used in a novel short synthesis. γ-
hydroxyvalines are naturally occurring amino acids that have been associated with 
stimulation of insulin secretion.71 Hydrogenolysis of the benzyl protecting groups of 13 
and simultaneous homolysis of the N-N bond gave the N-protected amino alcohols 15 
after addition of Fmoc (Scheme 3.4). Catalytic oxidation of those alcohols gave the N-
Fmoc-g-silyl protected amino acid 16. All four stereoisomers of 16 could be obtained 
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using this route, and one enantiomer of each of the syn- and anti-forms was made to 
prove this. The final products 16 are suitably protected for many peptide synthesis 
strategies, so no attempt was made to obtain the corresponding g-hydroxyvalines since 
we have no immediate application for these. The synthesis of the 2S,3S-syn-isomer was 
performed on a large enough scale to obtain 0.42 g of product. Previous syntheses of g-
hydroxyvaline derivatives required either 12 steps to obtain an enantiomer of the N-
BOC-O-PMB-protected form of the reduced product (ie alcohol not carboxylic acid),72 
or via multistep routes to syn,anti-mixtures of various protected derivatives that were 
then separated (via crystallization of diastereomeric copper complexes,73 or via column 
chromatography74). 
 
3.3 Conclusions 
The pivotal observation in this paper is that we may use type-H trisubstituted 
alkenes, specifically 9, to give the same product that would be formed from 
hydrogenation of itaconic acid (or the diester) and differentiation of the two carboxylate 
groups (then reduction). Key to this study is the fact that chiral Crabtree’s analogs like 
(S)-1 can mediate hydrogenations of trisubstituted alkenes without suitable coordinating 
functional groups (CFGs) for binding Rh-centers. Fortunately, the starting material 9 is 
also easy to make and this facilitates the whole process. 
Prior to our studies, Alexakis and Mazet elegantly combined enantioselective 
iridium-mediated isomerization reactions75-78 with organocatalytic functionalization of 
aldehydes to form two chiral centers.62 The work we have performed here is 
conceptually similar except that it is based on production of a particularly high-value 
chiron, the homo-Roche ester, and elaboration of that in distinct steps.  
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CHAPTER IV 
SYNTHESIS AND CONFORMATIONAL ANALYSIS OF CYCLIC 
TETRAPEPTIDE 
 
4.1 Introduction  
Cyclic tetrapeptides (CTPs) have been known for decades, mostly as natural 
products.8-10 However, to the best our knowledge, there are no applications of CTPs as 
probes for targeting proteins in living cells. Several reasons for this include but not 
limited to: inefficient synthesis, instability to hydrolysis/metabolism, and conformational 
heterogeneity in water.9,79,80 Therefore, this chapter will disclose research works on 
molecular design and synthesis of CTPs.   
 
4.1.1 Synthesis of CTPs 
Previous syntheses of CTPs involve proline and/or glycine. Proline facilitates 
syntheses of CTPs because cis-conformations are far more thermodynamically 
accessible, and this “forces” the peptide to turn, so that C- and N-termini can come 
together for cyclization.11-13 Glycine residues, having no side-chains, similarly allow 
conformations that are favorable for cyclization because a greater range of φ and ψ 
angles are available around Gly than for any other amino acid. Combinations of Pro-Gly 
in linear precursors to CTPs are particularly favorable because that motif is highly 
conducive to turn conformers that facilitate cyclization. For these reasons, the 
overwhelming majority of synthetic CTPs reported contain Pro and/or Gly. 
CTPs that have been made via conventional peptide syntheses which do not 
contain Pro or Gly, are rarely reported. Specifically, Ngu-Schwemlein prepared c{Leu-
dAla-X-dAla} where X is Leu, Lys, and Glu via solution phase synthesis.14  
In 2003, Smythe made a breakthrough in CTP synthesis by ring contraction.15 
Smythe’s approach, however, had serious weaknesses and limitations. One problem was 
that the contraction intermediate seemed to reform under the conditions for photolytic 
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cleavage, leading to hydrolysis. It represents a step towards solving the problem of 
forming CTPs not containing Gly or Pro. 
In 2013, there is a paper on syntheses of CTPs17 that introduced a breakthrough 
synthesis. Li’s innovation was to prepare tetrapeptides with N-terminal Ser or Thr, and 
C-terminal phenolic esters derived from salicylic aldehyde; the aldehyde can condense 
with N-terminal Ser or Thr. Subsequent O,N-migration, then acidolysis gives the CTPs 
as illustrated in Figure 4.1. A critical feature of this sequence is that the aminal formed 
after condensation/O,N-migration can, like Pro, easily access cis-amide conformers and 
this facilitates its formation. Li made nine cyclic tetrapeptides that do not contain Pro or 
Gly using this method. 
 
 
 
Figure 4.1. Li’s ligation method forms a proline like intermediate from a salicylic 
aldehyde ester. 
 
Li’s method is not flawless. Ozonolysis is required to cleave the intermediate 
molecules off the solid phase support. This step will also oxidize Trp, Cys, and Met 
residues. This is unfortunate because Met and Trp are common residues in PPI 
O OO
NH2
OH
Ser -X-X-X-ester
N-terminal
Ser (or Thr)
C-terminal
carboxybenzene
ester
condensation
O O
NH
O
16
O,N-migration N
O
O
HO
12
acidolysis
N
HOH
O
12
 22 
interfaces,81 and we need to include these in our probes. After cleavage via ozonolysis, 
the linear peptide precursor is purified via reverse phase HPLC, then rpHPLC is used 
again to purify the cyclized form. One rpHPLC purification is tolerable in solid phase 
syntheses, but two tend to give poor overall yields and slow the whole process. We 
therefore propose an efficient solution phase synthesis of CTPs. Our proposed solution 
phase synthesis of CTPs will also be the favored route for scaled-up (larger scale) 
synthesis.  
 
4.1.2 Conformational Analysis Of CTP 
In terms of conformational analysis, our interpretation of the literature is that 
CTPs which contain Gly and/or Pro are conformationally heterogeneous. It is supported 
by the work of Smythe who made 46 CTPs, all but one contained Gly and/or Pro, and 
only the one that did not was conformationally homogeneous.16 Provided we have not 
missed a reference, these are the CTPs without Gly and Pro that have been prepared to 
date: c{Leu-dAla-X-dAla} (X = Leu, Lys, and Glu) by Ngu-Schwemlein,14 Smythe’s 
c{His-dArg-Phe-dTrp},16 and nine others by Li. Of these, only c{Leu-dAla-X-dAla} (X 
= Leu, Lys, and Glu) and c{His-dArg-Phe-dTrp} have been studied to elucidate their 
conformations; Li did not comment on analyses for CTPs conformations. In other words, 
the only CTPs for which the conformations have been studied are the four cases listed 
above, and these are the ones which have alternating D- and L-amino acids. 
We propose that CTPs, which do not contain Gly and/or Pro, are 
conformationally homogeneous. This chapter discloses our investigation on how 
stereochemistry of side-chains affects the conformation.  QMD calculations18,19 allow us 
to elaborate on this hypothesis, and make some predictions with a high degree of 
confidence. QMD can equilibrate conformations of minimalist mimics (semi-rigid small 
molecule scaffolds bearing amino acids side-chains) which can resemble several 
different secondary structures simultaneously.17 QMD is ideal for simulating large 
numbers of conformers at a high temperature then instant cooling to 0 K. Typically 
QMD can reveal over 1000 conformers within 3 kcal/mol of the apparent global minima, 
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whereas other techniques might converge to just a few, or even just one, preferred 
conformer.  The rapid cooling makes sure we can obtain thousands of accessible 
conformations in solution. Specifically, all diastereomers of c{Ala-Ala-Ala-Ser} were 
examined via QMD using a continuous dielectric medium of 80. Three Ala residues 
were chosen to represent the Cα-Cβ vectors of three side chains (this is the key predictor 
of side-chain orientations). QMD runs for each stereoisomer to give 1500 conformations. 
In each case, all the conformers generated within 3 kcal•mol-1 of the lowest energy one 
identified (>1000 in each case) overlaid with each other within and RMSD of 0.1 Å 
based on the side-chain Cα-Cβ vectors: on the basis of this observation we hypothesize, 
with a high degree of confidence, that each diastereomer is conformationally 
homogeneous. 
 
4.1.3 EKO Analysis On CTPs As Small Molecules 
The project will be to improve design methods for discovery of selective 
pharmacological probes based on CTPs for disruption of PPIs involved in cell signaling 
processes. We published a technique called EKO (Exploring Key Orientations), that can 
be used to match certain small molecule chemotypes to particular PPI interfaces. It is a 
strategy that uses QMD to sample a large number (eg 1500) of accessible conformers of 
a chemotype, and stores α,β-coordinates for each three side-chain set in a database, 
which covers interface regions in crystallographically characterized PPIs. Then in a data 
mining operation, an algorithm systematically overlays each set of coordinates from the 
accessible conformations with each set of side-chain coordinates, produces root mean 
square deviations (RMSD Å) for the overlays, ranks goodness of fit, and notes the 
relative energy of that conformation.  
EKO begins with semi-rigid small scaffolds that bear at least three amino acid 
side-chains. Those chemotypes are not new; there are numerous reports of such 
minimalist secondary structure mimics (reviewed by us)113 and some of them have been 
applied to perturb PPIs. However, we pointedly exclude ones that are too flexible (more 
than 4 or 5 freely rotating bonds in the scaffold is not ideal). We also exclude minimalist 
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mimics that cannot be prepared with side-chains corresponding to most of the 
genetically encoded amino acids; many of the published minimalist mimic designs are 
difficult to functionalize in this way.  We suggested that molecules of this kind (ie within 
the limitations above) are preferred chemotypes for perturbing PPIs irrespective of the 
secondary structures at the interfaces.  
EKO can be used in complementary ways that we call biology- and chemistry-
centered. The biology-centered approach selects one PPI of particular interest, and 
evaluates accessible conformations for several mimics against the interface region(s) 
involved.  Like high throughput screening, the target is decided first then researchers try 
to find chemistry to fit. 
Chemistry-centered implementations of EKO compare conformations of one 
molecule with vast numbers of crystal structures of PPI interface regions. This is like 
affinity chromatography of cell lysates using a small molecule bait. When we reported 
EKO earlier this year, the database that we used contained 53,000 crystallized PPIs 
(those in the PDB up to the end of 2007) and a supercomputer employed to do the data 
mining. Due to recent developments, we are now able to evaluate over 120,000 
structures involving PPIs (2012) on a desktop computer in about 6 – 10 h.  Expansion of 
the PPI database to cover 2008-2012 is highly significant because the most interesting 
structures tend to be the newest ones.  Additionally, now we can conveniently extract the 
more interesting heterodimeric PPI hits from the homooligomers whereas this was not an 
option before.   
Our preferred mode of action is to find PPI targets using the chemistry-driven 
approach, then elaborate on the results using the biology-centered strategy using the hit 
PPIs; that means the hits follow naturally from the proposed chemotypes, and we are not 
trying to force the chemistry onto particular PPIs. This was the strategy used for in the 
current application to identify the featured PPIs. This strategy is also logical from a 
computational perspective. EKO in the chemistry-centered approach uses less 
conformers (select ones sorted for diversity) than when it is run in the biology-centered 
way.  Our hypotheses for CTPs that will perturb TNF-TNFR2 emerged because from 
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chemistry-centered hits for one mimic; then we used the more thorough biology-centered 
strategy to evaluate all 8 diastereomers of c{Ala-Ala-Ala-dSer} as interface mimics for 
this PPI.  
 
4.1.4 CTPs Targeting TNF-TNFR2 As Small Molecules 
TNF•TNFR2 was a heterodimeric protein complex that EKO highlighted by 
matching conformers of the fundamental CTP scaffold with the 120,000 PPI interface 
database in a chemistry-centered approach. TNF, a pleiotropic cytokine, is overproduced 
in secretory fluids of patients with chronic inflammatory diseases, and is implicated in 
angiogenesis.83,84 Most TNF-related toxicities are mediated through activation of the 
nuclear transcription factor, NF-κB85-87 which regulates the expression of various genes 
that play critical roles in apoptosis, viral replication, tumorigenesis, autoimmune 
diseases, and inflammation. Activation of TNFR2 is thought to be associated with 
autoimmune diseases.88 Blocking TNF induced inhibition of NF-κB is therefore a good 
in vitro model for anti-inflammation. Another good indication of anti-inflammatory 
activity by TNF antagonists is downregulation of c-Jun kinase. This is one of the 
mitogen-activated protein (MAP) kinases involved in a variety of cellular responses 
mediated by cytokines (including TNF), hormones, and stress-inducing reagents.89 The 
activator protein-1 (AP-1), a transcription factor, is regulated, at least in part, by 
phosphorylation mediated by c-Jun kinase.90 c-Jun also plays an important role in the 
regulation of cellular proliferation.91  
CTPs can be potential small molecule probes to selectively perturb TNF-TNFR2 
PPI. To the best of our knowledge, the only small molecule inhibitor of TNF-α was 
developed by Cunningham’s group.109 The compound composed of 
trifluoromethylphenyl indole and dimethyl chromone moiety linked by a dimethylamine 
spacer. It inhibited TNF-α binding to its receptor 1 (TNFR1) by displacing one of the 
subunits from the TNF-α trimer. The resulting TNF-α dimer maintained the same basic 
structural subunit fold as the trimer, but it lost the ability to bind to TNFR1. And to date, 
there is no small molecule that can inhibit TNF-a binding to TNFR2. Therefore, we are 
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pleased to see that CTPs have the potential to disrupt TNF-TNFR2 PPI. The biology-
centered approach of EKO also suggested that CTPs not only overlays on TNF-TNFR2 
interface, it can also overlay on TNF-α trimer.  
 
4.2 Results And Discussion 
4.2.1 Synthesis Of CTPs 
A key feature of our strategy toward CTP synthesis is the use of methyl 3,4-
diaminobenzoate 17 as N-terminal (Scheme 4.1). This was incorporated because 
conversion to the derivative 22 would afford a leaving group as described by Dawson.82 
It is encouraging to see that, the solubility characteristics of the 3,4-diaminobenzoate 
moieties are such that the intermediates can be precipitated from dichloromethane 
solution in high purity (NMR) and with good recovery; this greatly expedites the 
synthesis. Phenylalanine is introduced to increase the solubility of the product. 
Intermediate 20 therefore would not precipitate out of dichloromethane. Fortunately, 
these intermediates are generally insoluble in diethyl ether regardless of amino acid side 
chains. After work-up and removal of solvent, and the product was washed by diethyl 
ether. It is pure without further purification. Linear tetrapeptide 21 was converted to 23 
via a 3-step one-pot reaction. Acetal 23 was purified by flash chromatography, and then 
global deprotection followed by ligation afforded ligated product 24, which was 
converted to final CTP 25 by acidolysis. 
 
 
Scheme 4.1. Solution phase synthesis of c{Ala-Ala-Phe-Ser}. 
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Scheme 4.1. Continued. 
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a. coupling condition: 1.1 Boc protected amino acid, 1.2 HOBt, 1.2 EDCI, 5.0 Et3N, 
CH2Cl2, 12 h. 
Scheme 4.1. Continued. 
 
CTP 26 with three methyl side chains was the first targeted final product (Figure 
4.2), because the same side chains are used in QMD studies. Unfortunately, due to the 
solubility and purification problems, CTP 26 has poor solubility in any solvent, which 
makes purification difficult. Li also made aldehyde 27 and proceeded to the ligation 
product, but no explanation was provided regarding why he did not pursue the final 
product.  
 
 
Figure 4.2. Preparation of c{Ala-Ala-Ala-Ser} 26. 
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syntheses of all the isomers in one enantiomeric series of c{Ala-Ala-Phe-Ser}. These 
compounds are necessary for the conformational studies.  
 
 
 
 
Figure 4.3. Preparation of other CTP precursors. 
 
 
 
Figure 4.4. Divergent synthesis of 8 diastereomers of CTPs. 
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Figure 4.4. Continued. 
 
4.2.2 Conformational Analysis Of CTP 
The divergent synthesis then motivated us to explore whether CTPs exist in one 
predominant conformation, and, if so, can that be correlated with the stereochemistries 
of the amino acids in the macrocycle.  
The features of conformation of each diastereomer is as follows: off-axis-top, 
and equatorial side, views of the anticipated preferred conformations of each c{Ala-Ala-
Ala-Ser}diastereomer are shown in Figure 4.5. Throughout, L-amino acids are colored 
purple, D-isomers are shown in green, and the LSer residue is oriented on the “Eastern” 
side of the molecule. For c{Ala-Ala-Ala-Ser} (abbreviated to LSerLLL in Figure 4.5.) all 
the NH atoms are pointing towards the North pole, and all the side-chains are splayed 
out in equatorial positions skewed towards the Northern hemisphere. In LSerLLD, the 
methyl group of the DAla is in an equatorial position but skewed towards the Southern 
hemisphere, and the NH atom of that amino acid now points towards the South pole. All 
the methyl groups and NH atoms for the other, L-stereochemistry, amino acids remain 
oriented as they are in the parent structure, LSerLLL. Careful consideration of all the 
other diastereomers in the series show the same trend: when the conformers are oriented 
with the Ser in the Eastern position and the Ser side-chain equatorial in the Northern 
hemisphere, then: (i) all the LAla residues have NH atoms that point towards the North 
pole, and methyl groups in equatorial positions over the Northern hemisphere; and, quite 
logically, (ii) all the DAla residues have NH atoms that point towards the South pole, and 
methyl groups in equatorial positions over the Southern hemisphere. This bias is true for 
all the diastereomers, irrespective of how many D-amino acids are incorporated. 
!!! !
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B-LADA
B-LALA
B-LADALA
B-LADADA
B-LALALA
B-LALADA
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c{LALALALS}
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B-DALA
B-DADALA
B-DALALA
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B-DADADALS
B-DALALALS
B-DALADALS
c{DADALALS}
c{DADADALS}
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c{DALADALS}
B-DADA
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LSerLDL
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Mathematically, that means φ,ψ, (Table 4.1) are uniformly ca -140, -18 degrees for L-
amino acids, and +140, +18 for their D-isomers (within about 15° tolerance, maximum, 
shown in Table 4.1). The φ and ψ angles in the CTPs adjust so that the N-H bond vector 
always dissects Me-αC-CO, and the C=O vector similarly dissects Me-αC-H, 
irrespective of the amino acid stereochemistry.  
 
 
 
Figure 4.5. Systematic stereomutation of amino acids in CTPs causes the preferred 
conformers to invert in logical stages from dome to basin shapes. L-amino acid is 
colored purple and D-amino acid is colored green.  
 
Table 4.1. Phi/Psi angle measurement of each c{Ala-Ala-Ala-dSer} diastereomer. 
 
 
LSerLDL
LSerLDLLSerLLL LSerLLD LSerLDD
LSerDDD LSerDDL LSerDLD LSerDLL
side views
1
2
3
4
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Table 4.1. Continued. 
 
  
 To test our hypothesis regarding correlation of stereochemistry and preferred 
conformations of non-Pro/Gly CTPs, we propose to: assign all proton NMR peaks using 
HSQC and COSY; measure NH to αCH 3J coupling constants; measure through-space 
inter-residue contacts via 2D-NOESY (large NH to NH and small NH to αCH cross 
peaks are expected in cases where the NH atoms point to the same pole, but we predict 
NH to NH interactions will be reduced and NH to αCH interaction will be increased 
between amino acids of different stereochemistries). 
 
4.2.3 EKO Analysis On CTPs As Small Molecules 
When EKO was applied to all 8 stereomers of c{Ala-Ala-Ala-dSer} screening 
over 120,000 PPI interfaces,  we found about 6,500 protein targets and they were further 
  Ha phi (˚) psi (˚) 
NH-Ha 
(Å) 
 
  Ha phi (˚) 
psi 
(˚) 
NH-Ha 
(Å) 
DDD 
1 -148 27.8 2.82 
 
LDL 
1 -136 -11.8 3.35 
2 140 21.6 3.43 
 
2 -143 34.5 2.74 
3 136 12.9 3.37 
 
3 147 -29.9 2.82 
4 141 -33 2.77 
 
4 -140 -21.5 3.42 
DDL 
1 -143 32 2.74 
 
LLD 
1 -140 -19.5 3.41 
2 144 20.4 3.43 
 
2 -137 -13.9 3.37 
3 143 -35.8 2.71 
 
3 -142 -35.3 2.73 
4 -143 -18.6 3.42 
 
4 147 -29.6 2.79 
DLD 
1 -142 29 2.8 
 
LDD 
1 -143 -19.3 3.4 
2 143 -30.4 2.79 
 
2 -143 34.3 2.73 
3 -143 29.9 2.8 
 
3 142 19.6 3.41 
4 143 -30 2.79 
 
4 143 -35.1 2.72 
DLL 
1 143 32.5 2.75 
 
LLL 
1 -137 -21.7 3.37 
2 148 -29 2.81 
 
2 -138 -15.4 3.39 
3 -140 -21.1 3.42 
 
3 -135 -14.7 3.38 
4 -136 -12.5 3.37 
 
4 -138 -14.5 3.39 
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narrowed down to about 300 heterodimeric protein targets (Appendix D). A brief 
summary of targets is shown in Table 4.2.  
 
Table 4.2. Summary of mining results of c{Ala-Ala-Ala-dSer} with RMSD< 0.3 Å. 
CTP Interesting Targets pdb ID 
LLL none   
LLD HIV-1 reverse transcriptase 1hys 
LDL Human alpha thrombin 1bhx 
  Serine/threonine kinnase PAK1 1f3m 
  Extracellular domain of human EGF 1nql 
LDD CDK2/Cyclin 1h1q 
  HIV-1 reverse transcriptase 1hys 
  Paf-AH Holoenzyme 1vyh 
DLD Human alpha thrombin 1bhx 
  CDK2/Cyclin interface 1h1q 
DLL Human Angiogenin 1h0d 
  IL4-IL4R-IL13Ra ternary complex 3bpn 
  PCSK9 3h42 
DDL Protein phosphatase 2A core enzyme 2ie3 
  TNF-TNFR2 complex 3alq 
  PCSK9 3h42 
DDD Human alpha thrombin 1bhx 
 
 
We find that CTPs can overlay with loop regions with i, i +1, i + 2 arrangement. 
Three targets are chosen as examples shown in Figure 4.6.  
Interleukin-4 is a cytokine critical to the development of T cell mediated humoral 
immune responses, which are associated with allergy and asthma. The actions of 
interleukin-4 were exerted through different combinations of shared receptors.110 
Therefore, disruption of the interaction between interleukin and its receptor can inhibit 
activities of interleukin-4. IL4-IL4R complex was recrystallized with 2.9 Å resolution.  
c{dAla-Ala-Ala-dSer} overlaid on receptor IL-4Ra (light blue) at Lys-290, Leu-291 and 
Cyc-292 of its interface with IL4 (green).  
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Low-density-lipoprotein (LDL) receptor-related proteins 5 and 6 (LRP5/6) are 
Wnt co-receptors essential for Wnt/β-catenin signaling. Human LRP6 complexed with 
Dickkopf 1 (Dkk1) was recrystallized with 2.8 Å resolution. Dkk1 inhibits Wnt 
signaling by interacting with the extracellular domains of LRP5/6, which is a drug target 
for multiple diseases.111 c{Ala-dAla-dAla-dSer} overlaid on LRP6 at Asp-191, Thr-192, 
and Asn 193 of its interface with Dkk1.  
 
i. 
 
ii. 
 
Figure 4.6. i. c{dAla-Ala-Ala-dSer} overlaid on crystal structure of the IL4-IL4R 
ternary complex; ii. c{Ala-dAla-dAla-dSer} overlaid on crystal structure of LRP6-Dkk1 
complex, it is low density lipoprotein complex; iii-a Target PPI interaction sites to 
perturb the TGF•EGFR interactions are boxed.  From EKO, we hypothesize that CTPs 
can be made to perturb: iii-b the EGFR•TGF, and iii-c EGFR•EGFR interfaces.  
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iii. 
 
Figure 4.6. Continued. 
 
Epidermal growth factor (EGF) receptor is the prototype of the ErbB (HER) 
family receptor tyrosine kinases (RTKs), which regulate cell growth and differentiation 
and are implicated in many human cancers. The majority of small molecules designed to 
influence EGFR target the kinase domains,99,104,105 not the PPIs.106  When these are used 
as probes they can only shut down the tyrosine kinase activity, and most do this non-
selectively (ie inhibit other kinases).  Another probe class is large cyclic peptides that 
perturb the EGFR•EGFR interface; these have been shown to inhibit 
autophosphorylation of the Tyr-kinase and subsequent signaling.107,108 The non-ligated, 
“inactive” form of EGFR (1IVO) rests in an autoinhibited conformation.  On 
introduction of transforming growth factor-α (TGFα; 1MOX) (or EGF, not the focus 
here), the ligand binds two identical domains along the periphery of the EGFR dimer and 
causing conformational changes, but the EGFR•EGFR interface is maintained.109,110 
Mutagenesis studies on TGFα implicate Arg42 and Leu48 as key residues involved in 
binding EGFR.111 
 
 
 
EGFR
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interface
a b
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binding site
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4.2.4 CTPs Targeting TNF-TNFR2 As Small Molecules 
TNFR2 is one of the promising targets EKO found for CTP. Based on EKO 
c{dAla-dAla-Ala-dSer} overlays on TNF at the TNF-TNFR2 interface region: Phe-144, 
Ala-145, Glu-146 (RMSD 0.223 Å). Interestingly, TNF-TNFR2 interface has two hot-
spot regions.108 Region 1 consists of Asp54, Glu57, Glu70; Ser72 and Ser73 of TNFR2 
forms H bond with Arg32 of TNF. Region 2 consists of Arg77, Lys108, Arg133; Arg113 
and Arg77 of TNFR2 formed close contacts to Asp143, Gln149 and Glu23 of TNF. 
Loop 143-149 is believed to be a key interface region, because it is in a molecular pocket 
and is interesting target for TNF inhibition.108 EKO analysis showed that CTP overlays 
on TNF at Phe-144, Ala-145 and Glu-146, which is located right on the loop.  
We are therefore encouraged to apply EKO on TNF-TNFR2 for a thorough 
analysis. The results showed that the following CTPs have potential to bind at interfaces 
of TNF-TNFR2: c{dF-A-E-S}, c{dE-dA-F-S}, c{dY-dS-dV-S}, c{V-S-Y-S}, c{dY-dS-
dV-S}, c{dE-dA-F-dS}, c{dF-A-E-dS}, c{dV-dS-dY-dS}, c{dY-dS-V-dS}, c{dV-S-Y-
dS}, c{V-S-Y-dS}. It is interesting the EKOS finds pairs of hits like c{dY-dS-dV-S} 
and c{V-S-Y-S} where the sequence and stereochemistries are reversed as in retro-
inverso peptides.98 EKO analysis showed that c{E-dP-dL-dS} and c{dL-P-E-dS} can 
also overlay at the interface that forms the TNF trimer (Figure 4.7d ~ f). 
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Figure 4.7. a. Structure of TNF•TNFR2 (3ALQ);99 b. Interface regions where CTPs are 
hypothesized to bind; c. Structure of the TNF trimer (top view, 3ALQ) showing where a 
CTP is predicted to perturb formation of the trimer; d – f. Expanded views of the CTPs 
overlaid on the relevant PPI regions. 
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4.3 Conclusions 
The liquid phase reaction is a 12-step synthesis, which requires one step of flash 
chromatography and one prep HPLC purification process.  The only drawback is that the 
poor solubility of cyclized intermediate in most solvent makes purification difficult. 
QMD study suggested that CTPs with no Pro/Gly are conformationally stable.  It also 
provided insights on how side-chain orientations can change conformation of CTP 
scaffold. 
CTPs are suggested to be good loop mimics by EKO analysis. EKO analysis also 
showed that CTP is a good interface mimic as it overlays on about 300 heterodimeric 
PPIs, some of which are related with cancer, obesity, HIV, etc. TNF-TNFR2 is a 
particularly interesting target found by EKO. Previous studies suggested that loop 143-
149 on TNF is a key interaction region with TNFR2. Small molecules that overlay on 
this loop will be potential inhibitors of TNF-TNFR2 interaction. It is therefore 
encouraging to see that CTPs overlays right on this loop. The significance of this project 
is to show practical routes to small molecule probes that can be used to study cell 
signaling, and to inspire interest in design of molecules for biomedical applications. 
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CHAPTER V 
EKO AND EKOS ANALYSIS ON OXOPIPERAZINE DIMERS 
 
5.1 Introduction 
Oxopiperazine dimers are molecules developed by Paramjit Arora as α-helical 
mimics.102 He used macromodel MMFF force field to find the most stable conformations 
of oxopiperazine dimers and suggested they are α-helical mimics. He further suggested 
that a trans-amide bond geometry (Figure 5.1) was preferred over cis geometry and 
would place three side chains of the molecule in orientations to reproduce the 
arrangement of i, i+4, i+7 residues on an α-helix. Their molecular modeling studies of 
oxopiperazine dimers were supported by NOESY experiment, which showed that the 
cis-amide isomer did not exist; and the CD studies, which demonstrated that 
oxopiperazine dimers adopted stable α-helical conformation.  
Oxopiperazine dimers were then studied by Dr. Arora as PPI inhibitors by a 
computational approach for peptidomimetic design called Rosetta,112 and the 
oxopiperazine scaffold was first proved to be a p53/Mdm2 inhibitor. P53 activation 
domain targets Mdm2 with residues Phe19, Trp23, and leu26. The three residues formed 
key contacts between p53 and Mdm2. The modeling study suggested that if the side-
chains are R1=Phe, R2=Trp, and R4=Leu, the oxopiperazine dimers overlayed well at 
these three residues of Mdm2. The study was supported by binding affinity studies. If 
the Phe, Trp, and Leu residues at R1, R2, and R4 were replaced by other amino acids such 
as alanine or lysine, it led to significant decrease in the binding affinities of the scaffold 
to Mdm2. The results suggested that the side chains in these positions on the 
oxopiperazine dimer are making substantial contact with the target interface. 
 
 
Figure 5.1. Oxopiperazine dimer developed by Paramjit Arora. 
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 Oxopiperazine derivatives were also proved to be a HIF1α/p300(CBP) inhibitor.114 
HIF1α had four helical residues (Leu818, Leu822, Asp823, and Gln824) closely 
contacted with p300/CBP, and Rosetta study predicted that oxopiperazine dimers could 
mimic three residues, Leu818, Leu822 and Gln 824. The Rosetta prediction was further 
proved by fluorescence-binding assay and NMR studies.  
 Oxopiperazine dimers were proved to be a set of molecules that are α-helix mimics 
and are able to mimic α-helical interfaces of PPIs. However, Dr. Arora did not consider 
all stereochemistry possibilities of the scaffold. When the stereochemistry varies, it is 
possible to result in different conformation, which leads to different secondary structure 
mimicry. We therefore introduce EKOS analysis to explore the full potential of 
oxopiperazine dimers as ideal secondary protein structure mimics.  
 EKOS (Exploring Key Orientations on Secondary-structures) was another 
technique published in our group.21 Similar to EKO, EKOS begins with semi-rigid small 
scaffolds that bear at least three amino acid side-chains. EKOS also uses QMD (as 
described in previous chapter) to simulate a large number of accessible conformations 
for each minimalist mimic tested. Specifically, EKOS implements an algorithm that 
performs the following operations. For every secondary structure, EKOS determines α,β-
coordinates for each possible combination of three side-chains (ie 6 coordinates), and 
stores them in a database. EKOS then performs a similar process on all the accessible 
conformers of a test chemotype, and stores them in another database (eg 1000 x {3 x –
α,β coordinates} x {number of three side-chain combinations}, for 1000 conformers of a 
mimic with three side chains). Then, in a data mining operation, the algorithm 
systematically overlays each set of coordinates from each accessible conformation with 
each set of side-chain coordinates, produces a root mean square deviation (RMSD Å) for 
each overlay, ranks its goodness of fit, and notes the relative energy of that 
conformation. 
  EKO is also applied on oxopiperazine dimers to find potential PPIs. The three 
objectives of this chapter are: (i) EKOS analysis of oxopiperazine dimers to show 
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whether they can mimic on interfaces of other protein secondary structures besides α-
helix; (ii) to show whether EKO analysis can find protein targets Mdm2 and p300/CBP 
that has been found by Dr. Arora, and (iii) whether EKO analysis can find other protein 
targets for oxopiperazine dimers. 
 
5.2  Results And Discussion 
5.2.1 QMD And EKOS Analysis On Oxopiperazine Dimers 
Oxopiperazine dimers have four amino acid side chains. Dr. Arora’s study 
showed that side-chains 1, 2, and 4 played a pivotal role in forming the helical mimic 
and side-chain 3 is not involved (Figure 5.2). Thus, the same three side-chains were used 
during QMD analysis and overlay process of EKOS analysis. The two studies were then 
applied to all sixteen stereomers of oxopiperazine dimers. The studies on eight 
diastereomers (the stereochemistry of uninvolved side-chain is S) are included in the 
thesis; the other eight (enantiomers) were accomplished by graduate student Maritess 
Aranallo, which is not included in the thesis. 
When all three side-chains are derived from L-amino acid in the order of 1, 2, 4, 
the isomer is labeled as LLL; likewise when all three side-chains are derived from D-
amino acid in the same order, the isomer is labeled as DDD.  
 
 
Figure 5.2. Oxopiperazine dimers developed by Dr. Arora. a. Calculation results 
included in the thesis; b. Calculation done by Maritess Aranallo. 
 
QMD calculations were performed with energy cutoff of 3.0 Kcal/mol and 
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side chain 1, 2 and 4. The number of clusters represents the number of significantly 
different conformations. As the QMD results suggested in Table 5.1, all stereomers of 
oxopiperazine dimers can adopt several conformations. For each isomer, there is at least 
one major cluster. The LDD isomer is the only one that has one predominant cluster 
(224 structures). The second cluster is considered a minor cluster as it contains 64 
structures. The third cluster is insignificant as it only has 2 structures. The reason could 
be that the LDD isomer has four side chains with alternating stereochemistry (LDLD), if 
we include side chain 3. Such alternating stereochemistry may result in an extra stable 
conformation.  
 
Table 5.1. QMD calculation results of oxopiperazine dimers. 
Molecule 
ID 
# of 
structures 
# of 
clusters 
Ratio of structure # among 
clusters 
LLL 540 6 134:85:240:33:37:11 
LLD 621 8 129:48:34:39:211:27:131:2 
LDL 389 7 155:60:42:72:41:14:5 
LDD 294 3 224:68:2 
DLL 625 6 261:104:10:27:24 
DLD 741 9 189:122:86:101:60:53:10:10 
DDL 632 8 200:173:81:18:13:13:18 
DDD 325 3 104:203:18 
 
 
QMD results clearly illustrated that oxopiperazine dimers could adopt more than 
one stable conformation. Change in stereochemistry of side chains also caused the 
change of conformations. Different conformations will cause different overlaying results 
on secondary protein structures. We therefore performed EKOS analysis to explore 
various possibilities of oxopiperazine dimers as protein secondary structure mimics. 
EKOS analysis overlays oxopiperazine dimers onto seven ideal secondary 
structures: sheet-turn-sheet, antiparallel β-sheet, parallel β-sheet, β-strand, π-helix, α-
helix, and 310-helix. Results of EKOS analysis are summarized in Figure 5.3. The 
middle line represents the average RMSD value. Each colored bar represents the RMSD 
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value of an ideal secondary structure. If the bar points to left, it means the RMSD value 
is better than the average; if the bar points to right, it means the RMSD value is worse 
than the average. For example, the average RMSD value of DLD isomer overlaying on 
seven ideal secondary structures is 0.49 Å. The RMSD for sheet-turn-sheet overlay (red 
bar) is 0.2 Å on left; that means the actual RMSD value is 0.29 Å. Likewise, the RMSD 
for β-strand overlay (green bar) is 0.3 Å on right; the actual RMSD value is 0.79 Å.  
 
 
 
Figure 5.3. Matching results of oxopiperazine dimers on ideal secondary structures 
calculated by EKOS. 
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Figure 5.3. Continued. 
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Figure 5.3. Continued. 
 
EKOS showed that the oxopiperazine dimers are good π-helical and α-helical 
mimics with RMSD 0.33 ~ 0.59 Å. The LLL isomer is the best π-helical mimic (RMSD 
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= 0.33 Å) and LLD isomer is the best α-helical mimic (RMSD = 0.44 Å). EKOS analysis 
revealed that when side chain 2 (Figure 5.2) is derived from L-amino acid, 
oxopiperazine dimers are better π-helical and α-helical mimics (RMSD 0.33 ~ 0.41 Å); 
when side chain 2 is derived from D-amino acid, their fitness as π-helical and α-helical 
mimics are lowered as RMSD values increased (RMSD 0.53 ~ 0.59 Å).  For example, 
LLL isomer is the best π-helical mimic whereas LDL is the worst π-helical mimic. The 
only difference between two mimics is the stereochemistry of side chain 2. When the 
stereochemistry is flipped, the conformation of the scaffold changes, which results in 
changing the overlapping positions at interface of π-helix. Furthermore, the average 
RMSD for α-helical mimic is 0.53 Å. The LLL isomer is a good α-helical mimic (RMSD 
= 0.55 Å), but DDL, DLD, DLL, and LLD isomers are all better α-helical mimics than 
LLL isomers. Dr. Arora’s study suggested that the LLL isomer of oxopiperazine dimers 
was an α-helical mimic, EKOS study showed that it is also an excellent π-helical mimic. 
In addition, DDL and DLL isomers are good 310-helix mimics (RMSD ~ 0.5 Å), but the 
rest isomers are poor 310-helix mimics. 
Besides helical mimicry, DLD, DDL, LDL and LLD isomers are good parallel β-
sheet and sheet-turn-sheet mimics (RMSD = 0.20 ~ 0.40 Å). DLD isomer is the only 
good antiparallel β-sheet mimic (RMSD = 0.28 Å). Oxopiperazine dimers are generally 
poor β-strand mimics (RMSD > 0.80 Å).  
 
5.2.2 EKO Study On Oxopiperazine Dimers 
When EKO was applied to all 8 diastereomers of oxopiperazine dimers screening 
over 120,000 PPI interfaces. However, EKO did not find p53/Mdm2 and 
HIF1α/p300(CBP) as the targets. The possible reasons are (i) the RMSD value for EKO 
analysis is 0.3 Å, which might exclude these two targets; and (ii) only least amount of 
conformers of oxopiperazine dimers were used during chemistry-centered approach of 
EKO analysis, which is possible to miss interactions with other conformers. And yet, we 
still found 10,680 protein targets and they were further narrowed down to 610 
heterodimeric protein targets (Appendix E). A brief summary of targets is shown in 
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Table 5.2.Three protein complexes are used as examples to show how oxopiperazine 
dimers  overlay on PPIs.   
 
Table 5.2. Brief summary of mining results of oxopiperazine dimers. 
CTP Interesting Targets pdb ID 
LLL None   
LLD Human TGF-beta Type II Receptor 1ktz 
  
Human NFAT1 and Fos-Jun on the IL-2 ARRE1 
Site 1s9k 
  tumor-specific, MHC class II-restricted TCR 2iam 
LDL YSd1 Fab bound to DR5 (TNF) 1za3 
  PCSK9 3h42 
  Interleukin-1 receptor complex 3o4o 
LDD eIF4A-PDCD4 complex 2zu6 
DLL CD40L in complex with TNF 1i9r 
  TGF-beta signaling complex 2pjy 
  eIF4A-PDCD4 complex 2zu6 
DDL VEGF 1bj1  
  1n0w RAD51-BRCA2 BRC (breast cancer) 1n0w  
  HIV-1 reverse transcriptase 3lp0   
DLD VirA-Rab1  (Ras related)  4fmb   
DDD PCSK9:EGFA 3gcx   
  Caspase-9 1nw9   
   farnesyltransferase 1s63   
  TRAIL-SDR5(apoptosis, death receptor 5) 1du3   
 
 
BRCA2 is a breast cancer susceptibility protein that controls the function of 
RAD51, a recombinase enzyme, in pathways for DNA repair by homologous 
recombination.105 Mutations in the BRCA2 gene cause increased susceptibility to breast, 
ovarian and other cancer types. Cancer-associated mutations that affect the BRC repeat 
(blue) disrupt its predicted interaction with RAD51 (red), yielding structural insight into 
mechanisms for cancer susceptibility. RAD51-BRCA2 complex was recrystallized with 
1.7 Å resolution. There are three main points of contact involving residues Phe 1524, 
Ala 1527, Leu 1545 and Phe 1546 (gold color in Figure 5.4). The affinity between BRC4 
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and RAD51 is further enhanced by hydrophobic contacts involving residues IL3 1534 in 
the linker region.  
 
  
a     b 
Figure 5.4. a. Crystal structure of RAD51-BRCA2 complex; b. Oxopiperazine dimer 
overlays on BRCA2. 
 
DDL isomer of oxopiperazine dimer overlays on BRCA2 at Glu 1548, Phe 1546 
and Leu 1545, which is the hot spot of the complex. Small molecules overlaying on hot 
spot are expected to have interesting effects on PPIs. Other parts of the oxopiperazine 
dimer are not folded toward the interface, and therefore will not generate undesired 
interactions to push oxopiperazine dimer away from the expected binding site. 
Programmed cell death protein 4 (PDCD4)106 is a translation inhibitor that 
suppresses neoplastic transformation in cultured cells and transgenic mice. Loss or 
reduced expression of PDCD4 has been implicated in the development and progression 
of a variety of aggressive human cancers. PDCD4 is believed to perform its tumor 
suppressor function primarily through interaction with eIF4A and eIF4G, which are 
components of mRNA-binding complex eIF4. A crystal structure of PDCD4 with elF4A 
complex was obtained with 2.8 Å resolution. PDCD4 has two domains: mMA3 and 
cMA3 domains and only cMA3 domain (green in Figure 5.5) binds to one eIF4A (red). 
At the center of the interface, Glu-210, Glu-249, and Asp-253 in mMA3 form an ion pair 
network with Arg-110 and Arg-161 from eIF4A. Glu-183 and Glu-186 of mMA3 form a 
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network with Thr-281 and Arg-283 of eIF4A. Glu-111 and Asn-280 in eIF4A hydrogen 
bonded with Gln-173 and His-178 in mMA3. 
 
a. 
b.  
 
 
 
Figure 5.5. a. Crystal structure of PDCD4 with elF4A complex; b. Oxopiperazine dimer 
overlays on cMA3 domain of PDCD4. 
 
 The interface consists of two helical structures. The DLL isomer of 
oxopiperazine dimer overlays on helical part of cMA3 domain at Leu-252, Asp-253 and 
Pro-255. Asp-253 is the hot spot on cMA3 interacting with elF4A. It is consistent with 
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EKOS result, which suggests oxopiperazine dimer is a helical mimic. However, the 
unchanged side-chain is pointing toward elF4A, which may result in unexpected 
interaction with elF4A. When unexpected interaction occurs, small molecules may not 
overlay at the expected site.  
 LLD isomer of oxopiperazine dimer also showed interesting interaction between 
TGF-beta3 (blue in Figure 5.6) and its Type II receptor (green). The crystal structure of 
the complex was obtained by Hinck’s group with resolution of 2.1 Å.107 The interaction 
at the interface is hydropholic interactions (red). There is however a key hydrogen 
bonding interaction between Arg-94 on TGF-beta3 and Asp-32 on Type II receptor.  
 
a. 
 
b. 
 
Figure 5.6. a. Crystal structure of TGF-beta3(blue) and its Type II receptor(green); b. 
Oxopiperazine dimer overlays on Type II receptor. 
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LLD isomer of oxopiperazine dimer overlays on Type II receptor at Phe-30, Thr-51, and 
Ser-52. As shown in Figure 5.4b, oxopiperazine dimer overlays on the hydrophobic 
interface. There is no undesired interaction between small molecules and protein 
observed. Although oxopiperazine dimer is not shown to disrupt the key PPI, hydrogen 
bond between Arg-94 and Asp-32; it is likely that when oxopiperazine dimer interacts 
with Type II receptor on the hydrophobic region, it changes the conformation of the 
protein and therefore disrupt the key hydrogen bond interaction. 
 
5.3 Conclusions 
Oxopiperazine dimer is suggested to adopt one conformation and be a good α-
helical mimic by Dr. Arora’s work.102 Our studies broadened the scope of oxopiperazine 
dimers as both protein secondary structure mimics and small molecules that target PPIs. 
QMD study first showed that more than one conformation of oxopiperazine dimers 
could exist, which provided the molecules with more possibilities to mimic the protein 
secondary structures. EKOS then showed that the LLL isomer can be good mimics for 
both π and alpha-helix whereas Dr. Arora only suggested it is an α-helical mimic. In 
addition, when the stereochemistry of side chains changed, oxopiperazine dimers can be 
good mimics for other protein secondary structures such as β-sheet and sheet-turn-sheet. 
EKO is also practiced on oxopiperazine dimers to demonstrate how small molecules can 
quickly find potential targets. EKO study showed that oxopiperazine dimer is a good 
universal peptidomimetic scaffold as it overlays on about 600 heterodimeric PPIs among 
which there are proteins related with cancer, diabetes, HIV, etc. Therefore, 
oxopiperazine dimers are good protein interface mimics. 
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CHAPTER VI 
CONCLUSIONS AND OUTLOOK 
  
6.1 Conclusions 
6.1.1 Synthesis Of Trisubstituted Allylic Alcohols Via Hydroalumination/ 
Vinyl Addition 
The well-known vinyl aluminate intermediate was directly applied to synthesis of 
trisubstituted allylic alcohols, which are synthetically useful building blocks for 2,3 
disubstituted furans and 4,5 disubstituted furanones. The optimized condition was only 
applied to benzaldehyde and bromobenzaldehdye to obtain product 2a and 2b in high 
yield (Figure 6.1). The future work may include application of the optimized condition 
to the rest of substrates achieve higher yield and the reaction may also be done in low 
temperature with chiral catalyst to obtain optically enriched trisubstituted allylic 
alcohols. 
 
 
Figure 6.1. Trisubstituted allylic alcohols synthesized. 
 
6.1.2 Homo-Roche Ester Derivatives By Asymmetric Hydrogenation And 
Organocatalysis  
Catalyst 1 was applied to large-scale synthesis of homo-Roche ester which could 
be readily transformed to α-substituted homo-Roche ester derivatives via 
organocatalysis. The combination of asymmetric hydrogenation and organocatalysis 
illustrated the idea that two different, but well-known, methods can be applied to 
synthesis of useful chirons together. 
 
 
OH OH
2a
88 %
OH OH
2b
85 %
Br
OH OH
X
2c, X= I, 55 % 
2d, X= NO2, 67 %2e, X= OMe, 58 %
OH OHX
2f, X= NO2, 76 % 2g, X= OMe, 63 %
OH OH
Ph
X
OH OH
2h
58 %
2i, X= H, 57 % 
2j, X= Me, 74 %
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6.1.3 Synthesis And Conformational Analysis Of Cyclic Tetrapeptides  
We invented an expedient liquid phase synthesis of cyclic tetrapeptides, which 
could include amino acids that are common residues in PPI interfaces such as Trp, Cyc 
and Met. Although there is only one final product obtained, there are several advanced 
intermediates synthesized in gram-scale, which can be readily converted to the final 
products in three steps. A thorough computational analysis (QMD) of the conformation 
of CTPs were also completed, which correlated the stereochemistry to the preferred 
conformations of non-Pro/Gly CTPs. The future work may include assigning all proton 
NMR peaks using HSQC and COSY and measuring NH to αCH 3J coupling constants 
and through-space inter-residue contacts via 2D-NOESY. 
EKO analysis also suggested that TNF-TNFR2 is a promising target for CTPs. 
The future work may include cellular assays which will measure inhibition or promotion 
of TNF-induced cell death. 
 
6.1.4 EKO And EKOS Analysis On Oxopiperazine Dimers 
EKOS studies suggested that the LLL isomer of oxopiperazine dimers could be 
good mimics for both π and a-helixes. When the stereochemistry of the scaffold 
changed, oxopiperazine dimers could also mimic with other protein secondary structures 
such as β-sheet and sheet-turn-sheet. Oxopiperazine scaffold was proved to be a 
p53/Mdm2 inhibitor and HIF1α/p300 (CBP) inhibitor. However, EKO did not find these 
two targets, even through EKO study showed that oxopiperazine dimers could overlay 
on about 600 heterodimeric PPIs. The future work may include performing a thorough 
EKO analysis via biology-centered approach on p53/Mdm2 and HIF1α/p300 (CBP). 
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APPENDIX A 
GENERAL EXPERIMENTAL PROCEDURES 
 
All reactions were carried out under an atmosphere of dry nitrogen or argon. 
Glassware was oven-dried prior to use. Unless otherwise indicted, common reagents or 
materials were obtained from commercial source and used without further purification. 
All the solvents were used after appropriate distillation or purification. 
Flash column chromatography was performed using silica gel 60 (230-400 
mesh). Analytical thin layer chromatography (TLC) was carried out on Merck silica gel 
plates with QF-254 indicator and visualized by UV. IR spectra were recorded on a 
Bruker Tensor 27 spectrometer. Optical rotations were measured on Jasco DIP-360 
digital polarimeter. 1H and 13C spectra were recorded on Varian 300 (300 MHz 1H; 75 
MHz 13C), Avance 400 (400 MHz 1H; 100 MHz 13C) or Varian 500 (500 MHz 1H; 125 
MHz 13C) spectrometer at room temperature. Chemical shifts were reported in ppm 
relative to the residual CDCl3 (δ 7.28 ppm 1H; δ 77.0 ppm 13C), CD3OD (δ 3.31 ppm 1H; 
δ 49.0 ppm 13C) or d6-DMSO (δ 2.49 ppm 1H; δ 39.5 ppm 13C). Coupling constants (J) 
were reported in Hertz (Hz). The following abbreviations were used to explain the 
multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, dd = double doublet, dq = 
double quartet, m = multiplet, br = broad. 
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APPENDIX B 
EXPERIMENTAL FOR CHAPTER II 
 
A. Preparation of compounds 2a-2l 
 
General Procedure for (Z)-Allylic Diol Synthesis 
A Red-Al solution (3M in toluene) (7.5 mL, 2.5 mmol) was dissolved in 2 mL of 
hexanes/THF (5:1) mix-solvent. The solution was stirred at 0 ºC for 5 min, followed by 
slow addition of 2-butyn-1-ol (140 mg, 2.0 mmol). The solution was stirred at 23 ºC for 
4 h. EtOAc (0.98 mL, 1.0 mmol) was then added to the solution at 0 ºC. The solution 
was stirred for 1 min at room temperature, and the aldehydes (2.5 mmol) were added. 
The solution was stirred at 23 ºC for 12 h before quenched with 5 mL of HCl (1N). The 
mixture was diluted with EtOAc, and the organic layer was separated. The aqueous layer 
was extracted with EtOAc for 3 times. The combined organic layers were dried with 
MgSO4, and concentrated in vacuo. The residue was purified via flash chromatography 
(30% - 50% EtOAc/hexanes). 
 
(Z)-2-methyl-1-phenylbut-2-ene-1,4-diol (2a). Product was obtained as a white 
solid (260 mg, 1.48 mmol, 74%). 1H NMR (300 MHz, CDCl3) δ 7.40-7.26 (5H, m), 5.72 
(1H, s), 5.70-5.65 (1H, m), 4.48-4.38 (1H, m), 4.38-4.30 (1H, m), 2.38 (1H, br), 1.76 
(1H, br), 1.68 (3H, s); 13C NMR (75 MHz, CDCl3) δ 141.7, 141.4, 128.3, 127.2, 126.2, 
125.7, 71.4, 58.1, 18.4. HRMS (ESI, TOF): Exact mass calcd for C11H14LiO2[M+Li]
+ 
185.1154. Found 185.1146. 
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(Z)-1-(4-bromophenyl)-2-methylbut-2-ene-1,4-diol (2b). Product was obtained 
as a white solid (370 mg, 1.44 mmol, 72%). 1H NMR (300 MHz, CDCl3) δ 7.46 (2H, d, 
J = 6.0 Hz), 7.24 (2H, d, J = 12.0 Hz), 5.65 (2H, m), 4.44-4.36 (1H, dd, J =12.5, 7.8 Hz), 
4.28-4.24 (1H, dd, J =12.5, 7.5 Hz), 3.65 (2H, br), 1.60 (3H, s); 13C NMR (75 MHz, 
CDCl3) δ 141.1, 140.8, 131.4, 127.5, 126.6, 121.1, 71.0, 58.3, 18.3. HRMS (ESI, TOF): 
Exact mass calcd for C11H13BrLiO2[M+Li]
+ 263.0259. Found 263.0251. 
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(Z)-1-(4-iodophenyl)-2-methylbut-2-ene-1,4-diol (2c). Product was obtained as 
a yellow solid (330 mg, 1.10 mmol, 55%). 1H NMR (300 MHz, CDCl3) δ 7.66 (2H, d, J 
= 9.0 Hz), 7.08 (2H, d, J = 12.0 Hz), 5.63 (2H, m), 4.44-4.35 (1H, dd, J = 12.5, 7.5 Hz), 
4.23-4.17 (1H, dd, J = 12.5, 6.8 Hz), 3.10 (1H, br), 2.43 (1H, br), 1.58 (3H, s); 13C NMR 
(75 MHz, CDCl3) δ 141.5, 141.2, 137.3, 127.8, 126.5, 92.7, 70.9, 58.1, 18.3. HRMS 
(ESI, TOF): Exact mass calcd for C11H15O2[M+H]
+ 179.1072. Found 179.1069. 
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(Z)-2-methyl-1-(4-nitrophenyl)but-2-ene-1,4-diol (2d). Product was obtained 
as a yellow solid (300 mg, 1.34 mmol, 67%). 1H NMR (500 MHz, CDCl3) δ 8.23 (2H, d, 
J = 10.0 Hz), 7.59 (2H, d, J = 10.0 Hz), 5.85 (1H, s), 5.75 (1H, t, J = 5.0 Hz), 4.46 (1H, 
dd, J = 10.0, 15.0 Hz), 4.33 (1H, dd, J = 5.0, 10.0 Hz), 2.77 (1H, br), 1.89 (1H, br), 1.61 
(3H, s); 13C NMR (125 MHz, CDCl3) δ 149.1, 147.1, 140.8, 127.4, 126.6, 123.6, 70.6, 
58.2, 18.1. HRMS (ESI, TOF): Exact mass calcd for C11H13LiNO4[M+Li]
+ 230.1005. 
Found 230.0999. 
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(Z)-1-(4-methoxyphenyl)-2-methylbut-2-ene-1,4-diol (2e). Product was a white 
solid (240 mg, 1.16 mmol, 58%). 1H NMR (300 MHz, CDCl3) δ 7.27-7.24 (2H, m), 
6.87-6.85 (2H, m), 5.60 (2H, m), 4.37 (1H, dd, J =12.4, 7.8 Hz), 4.21 (1H, dd, J = 12.5, 
6.5 Hz), 3.78 (3H, s), 2.83 (1H, br), 2.33 (1H, br), 1.62 (3H, s); 13C NMR (75 MHz, 
CDCl3) δ 158.8, 141.4, 134.0, 127.0, 126.1, 113.7, 71.5, 58.3, 55.3, 18.6. HRMS (ESI, 
TOF): Exact mass calcd for C12H16LiO3[M+Li]
+ 215.1259. Found 215.1256. 
 
 
OH
Me
OH
MeO
OH
Me
OH
MeO
 68 
(Z)-2-methyl-1-(2-nitrophenyl)but-2-ene-1,4-diol (2f). Product was obtained as 
a white solid (340 mg, 1.52 mmol, 76%). 1H NMR (300 MHz, CDCl3) δ 7.91 (2H, dd, J 
= 9.0, 15.0 Hz), 7.66 (2H, t, J = 9.0 Hz), 7.44 (1H, t, J = 9.0 Hz), 6.23 (1H, s), 5.74-5.66 
(1H, m), 4.40-4.19 (2H, m), 3.31 (1H, br), 2.33 (1H, br), 1.48 (3H, s). 13C NMR (75 
MHz, CDCl3) δ 148.0, 138.5, 136.5, 133.2, 128.7, 128.5, 128.2, 124.5, 67.4, 58.4, 19.4. 
HRMS (ESI, TOF): Exact mass calcd for C11H13LiNO4[M+Li]
+ 230.1005. Found 
230.1016. 
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(Z)-1-(2-methoxyphenyl)-2-methylbut-2-ene-1,4-diol (2g). Product was 
obtained as a white solid (260 mg, 1.26 mmol, 63%). 1H NMR (300 MHz, CDCl3) δ 
7.50-7.47 (1H, m), 7.27-7.21 (1H, dt, J = 4.3, 2.8 Hz), 6.98 (1H, td, J = 7.5, 1.0 Hz), 
6.84 (1H, d, J = 8.2), 5.94 (1H, s), 5.62-5.60 (1H, m), 4.39 (1H, dd, J = 12.5, 8.1), 4.21-
4.14 (1H, m), 3.79 (3H, s), 3.36 (1H, br), 1.63 (3H, s); 13C NMR (75 MHz, CDCl3) δ 
156.1, 139.7, 129.9, 128.3, 127.1, 126.6, 120.7, 110.4, 66.8, 58.1, 55.3, 18.5. HRMS 
(ESI, TOF): Exact mass calcd for C12H16LiO3[M+Li]
+ 215.1259. Found 215.1256. 
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(Z)-1-(2-methoxy-4-nitrophenyl)-2-methylbut-2-ene-1,4-diol (2h). Product 
was obtained as a white solid (340 mg, 1.34 mmol, 67%) 1H NMR (300 MHz, CDCl3) δ 
7.90-7.87 (1H, m), 7.73-7.67 (2H, m), 5.95 (1H, s), 5.65 (1H, t, J = 7.1 Hz), 4.52-4.40 
(1H, m), 4.29-4.19 (1H, m), 3.91 (3H, s), 3.32 (1H, br), 2.07 (1H, br), 1.58 (3H, s); 13C 
NMR (75 MHz, CDCl3) δ 156.2, 148.1, 138.9, 137.4, 127.5, 127.4, 115.9, 105.2, 66.4, 
58.2, 56.0, 18.2. HRMS (ESI, TOF): Exact mass calcd for C12H15LiNO5[M+Li]
+ 
260.1110. Found 260.1107. 
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(2Z,5E)-3-methyl-6-phenylhexa-2,5-diene-1,4-diol (2i). Product was obtained 
as a white solid (210 mg, 1.02 mmol, 51%) 1H NMR (300 MHz, CDCl3) δ 7.61-7.40 
(2H, m), 7.34-7.21 (3H, m), 7.01 (1H, dd, J = 9.0, 15.0 Hz), 6.58 (1H, d, J = 15.0 Hz), 
6.33 (1H, d, J = 12.0 Hz), 4.30-4.23 (1H, m), 3.77-3.67 (1H, m), 3.65-3.54 (1H, m), 2.21 
(1H, br), 1.92 (1H, br), 1.88 (3H, s); 13C NMR (75 MHz, CDCl3) δ 137.4, 136.8, 132.9, 
128.6,126.4, 126.3, 124.2, 65.3, 13.7. HRMS (ESI, TOF): Exact mass calcd for 
C13H16LiO2 [M+Li]
 + 211.1310. Found 211.1300. 
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(2Z,5E)-3,5-dimethyl-6-phenylhexa-2,5-diene-1,4-diol (2j). Product was 
obtained as a white solid (320 mg, 1.48 mmol, 74%). 1H NMR (300 MHz, CDCl3) δ 
7.40-7.22 (5H, m), 6.72 (1H, s), 5.74 (1H, t, J = 6.0 Hz), 5.06 (1H, s), 4.39 (1H, dd, J = 
6.0, 15.0 Hz), 4.29 (1H, dd, J = 6.0, 15.0 Hz), 2.77 (1H, br), 1.81 (3H, s), 1.76 (3H, s), 
1.63 (1H, s); 13C NMR (75 MHz, CDCl3) δ 139.5, 137.6, 128.9, 128.1, 127.6, 126.4, 
125.0, 124.9, 74.8, 58.5, 18.7, 14.9. HRMS (ESI, TOF): Exact mass calcd for 
C14H18LiO2 [M+Li]
 + 225.1467. Found 225.1476. 
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3-hydroxy-4-methyl-3,6-dihydro-2H-pyran-2-one (2k’). Product was obtained 
as a colorless oil (92mg, 0.72 mmol, 36%). 1H NMR (300 MHz, CDCl3) δ 6.80-6.76 (1H, 
m), 5.17 (1H, s), 4.68-4.58 (1H, m), 4.42-4.32 (1H, m), 4.23 (1H, br), 1.85 (3H, s); 13C 
NMR (75 MHz, CDCl3) δ 192.4, 143.0, 131.6, 92.5, 61.5, 14.7. HRMS (ESI, TOF): 
Exact mass calcd for C6H8LiO3 [M+Li]
 + 135.0634. Found 135.0629.  
 
 
 
 
-20-100102030405060708090100110120130140150160170180190200210
f1 (ppm)
OO
OH
CH3
0.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.0
f1 (ppm)
OO
OH
CH3
OO
Me
HO
OO
Me
HO
 74 
(Z)-3,5-dimethylhex-2-ene-1,4-diol (2l). Product was obtained as a colorless oil 
(170mg, 1.16 mmol, 58%). 1H NMR (300 MHz, CDCl3) δ 5.53 (1H, m), 4.30-4.22 (1H, 
m), 4.04-3.92 (2H, m), 3.20 (2H, s), 1.79-1.70 (4H, m), 1.05-1.01 (3H, d), 0.73-0.70 
(3H, d); 13C NMR (75 MHz, CDCl3) δ 140.7, 126.5, 75.3, 57.6, 31.1, 19.3, 18.8, 18.0. 
HRMS (ESI, TOF): Exact mass calcd for C8H16LiO2[M+Li]
+ 151.1310. Found 151.1303. 
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 To a solution of 2b (307 mg, 1.20 mmol) in 7.5 mL of CH2Cl2 and 1.5 mL of H2O 
were added TEMPO (40 mg, 0.20 mmol) and PhI(OAc)2 (850 mg, 2.6 mmol). The 
reaction mixture was stirred for 1 h at 25 ºC, and then was quenched with saturated 
aqueous NaHCO3, extracted with CH2Cl2, washed with brine, dried over MgSO4, and 
concentrated. Purification by column chromatography (5% - 20% EtOAc-Hexane) 
afforded the desired lactone 3 (273 mg, 1.08 mmol, 90%) of as a colorless oil. 1H NMR 
(300 MHz, CDCl3) δ 7.54 (2H, d, J = 9.0 Hz), 7.12 (2H, d, J = 9.0 Hz), 5.95-5.93 (1H, 
m), 5.67 (1H, s), 1.92 (3H, s); 13C NMR (75 MHz, CDCl3) δ 173.0, 168.0, 133.4, 132.3, 
128.4, 123.5, 116.5, 85.7, 14.0. HRMS (ESI, TOF): Exact mass calcd for 
C11H10BrNO2[M+H]
+ 252.9864. Found 252.9861. 
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 To a solution of 2b (307 mg, 1.20 mmol) in 5 mL anhydrous DMSO was added 
IBX (403 mg, 1.44 mmol). The reaction mixture was stirred for 2 h at 23 ºC and then 
quenched with H2O (10 mL). The mixture was filtered through Celite and the filter cake 
was washed with CH2Cl2 and H2O. The layers were separated and the aquous phase was 
extracted with CH2Cl2. The combined organic phase was dried (Na2SO4) and 
concentrated. The residue was purified by column chromatography and the desired furan 
4 (180 mg, 0.780 mmol, 65%) was obtained as a colorless oil; 1H NMR (300 MHz, 
CDCl3) δ 7.56-7.50 (4H, m), 7.41 (1H, s), 6.36 (1H, s), 2.30 (1H, s); 13C NMR (75 MHz, 
CDCl3) δ 147.6, 140.9, 131.6, 130.2, 126.7, 120.4, 116.9, 115.3. HRMS (ESI, TOF): 
Exact mass calcd for C11H10BrO[M+H]
+ 236.9915. Found 236. 9910. 
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APPENDIX C 
EXPERIMENTAL FOR CHAPTER III 
 
A. Preparation of compound 6 
 
Preparation of (E)-Methyl 4-Hydroxy-3-methylbut-2-enoate 6 
 
 
(E)-4-Methoxy-3-methyl-4-oxobut-2-enoic acid (J). 
To a solution of (1-methoxy-1-oxopropan-2-yl)triphenylphosphonium bromide 
(42.9 g, 100 mmol) in dry MeCN (300 mL) was added triethylamine (13.2 mL, 95 
mmol) and glyoxylic acid monohydrate (8.74 g, 95 mmol) at 0 °C. The solution was 
further stirred at 0 °C for 2 h and at room temperature overnight. Half of the solvent was 
removed under reduced pressure, and ethyl acetate (100 mL) was added. The resulting 
solution was washed with saturated aqueous NaHCO3 (3 × 50 mL). The combined 
aqueous layers were extracted with ethyl acetate (2 × 50 mL), acidified (pH 1 - 2) at 0 
°C with concentrated HCl (50 mL) and extracted with ethyl acetate (3 × 50 mL). The 
combined organic layers were evaporated to dryness, yielding a clear oil J (10.5 g, 73%) 
which was used for the next reaction without further purification.  
 
(E)-4-Hydroxy-3-methylbut-2-enoic acid (5). 
LiBH4 (400 mmol) was added to (E)-4-methoxy-3-methyl-4-oxobut-2-enoic acid 
J (200 mmol) in THF (200 mL) at 0 °C. The reaction mixture was then allowed to 
HO
O
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ambient temperature and stirred for 12 h. The mixture was poured into 1N HCl and 
extracted with ethyl acetate (3 × 50 mL). The combined organic layers were dried over 
Na2SO4 and solvent was removed under reduced pressure to yield the product 5 as a 
white solid (16 g, 69%) which was used for the next reaction without further 
purification.  
 
(E)-Methyl 4-Hydroxy-3-methylbut-2-enoate (6). 
To a solution of H2SO4 in 50 mL of MeOH, (E)-4-hydroxy-3-methylbut-2-enoic 
acid 5 (150 mmol) was added at room temperature. The mixture was stirred and refluxed 
for 4 h. After cooling to ambient temperature, solvent was removed under reduced 
pressure. The residue was dissolved in CH2Cl2. The organic layer was washed with 
NaHCO3, brine and dried over Na2SO4. Solvent was removed under reduced pressure to 
obtain product 6 as a clear oil (12 g, 93 mmol, 62 %). 1H NMR (400 MHz, CDCl3) δ 
6.48 (1H, d, J = 4.7 Hz), 3.96 (2H, s), 3.63 (3H, s), 1.89 (3H, d, J = 6.6 Hz); 13C NMR 
(100 MHz, CDCl3) δ 167.2, 132.3, 119.7, 67.2, 58.3, 26.2. HRMS (ESI, TOF): Exact 
mass calcd for C6H11O3 [M+H]
+ 131.0708. Found 131.0711. 
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B. Catalytic Hydrogenation Conditions 
 
 
 
 (E)-Methyl 4-hydroxy-3-methylbut-2-enoate 6 (120 mmol) and (S)-1 (1 mol %) 
were dissolved in CH2Cl2 (0.5 M). The resulting mixture was degassed by three cycles 
of freeze-pump-thaw and then transferred to a Parr Bomb. The bomb was pressurized to 
50 bar with hydrogen and the mixture was stirred at 300 rpm for 24 h. The bomb was 
then vented and solvent was evaporated. The crude product was passed through a short 
silica plug using 10-30% EtOAc/hexanes as the eluent. The enantiomeric ratio was then 
measured through chiral GC analysis. 
 
Methyl (S)-4-Hydroxy-3-methylbutanoate (7). 
Colorless oil, 15.2 g, 114 mmol (95% isolated yield); 1H NMR (400 MHz, CDCl3) δ 
4.05 (3H, s), 3.35 (2H, dd, J = 6.6, 12 Hz), 2.48 (2H, m), 2.07 (1H, m), 0.92 (3H, d, J = 
6.6 Hz); 13C NMR (100 MHz, CDCl3) δ 171.0, 68.5, 62,1, 37.8, 32.5, 14.7. HRMS (ESI, 
TOF): Exact mass calcd for C6H13O3 [M+H]
+ 133.0865. Found 133.0864. 
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C. Preparation of (S)-4-Methyldihydrofuran-2(3H)-one (8) 
 
To a solution of methyl (S)-4-hydroxy-3-methylbutanoate 7 (12 g, 90 mmol) in 
30 mL of CH2Cl2, TsOH (0.95 equiv) was added at room temperature. The mixture was 
stirred for 6 h, then the organic layer was washed with H2O (3 × 30 mL), brine and dried 
over Na2SO4. Solvent was removed under reduced pressure to yield product as colorless 
oil (9.8 g, 98%). 
 
D. Recrystallization conditions 
 
(S)-4-Methyldihydrofuran-2(3H)-one 8 was dissolved in EtOAc and hexane and 
the mixture was cooled to -20 °C. After getting precipitation, solvent was decanted in 
low temperature and washed with cold hexane. 
 
E. Preparation of compound 9 
 
Preparation of Methyl (S)-4-((tert-Butyldiphenylsilyl)oxy)-3-methylbutanoate (9). 
To a solution of methyl (S)-4-hydroxy-3-methylbutanoate 7 (5.5g, 42 mmol) in 
30 mL of DMF, TBDPSCl (0.95 equiv) was added at room temperature. The mixture 
was stirred for 4 h, then solvent was removed under reduced pressure. The residue was 
dissolved in CH2Cl2. The organic layer was washed with H2O (3 × 30 mL), brine and 
dried over Na2SO4. Solvent was removed under reduced pressure and the crude was 
purified by chromatography using 5% EtOAc/hexane as eluent to obtain product 9 as a 
clear oil (15 g, 42 mmol, 99%). 1H NMR (400 MHz, CDCl3) δ 7.79-7.30 (10H, m), 3.69 
(3H, s), 3.59 (2H, dd, J = 3.3, 12 Hz), 2.63-2.60 (2H, m), 2.32-2.20 (1H, m), 1.09 (9H, 
s), 1.02 (3H, d, J = 6.6 Hz); 13C NMR (100 MHz, CDCl3) δ 173.5, 137.8, 133.8, 129.7, 
126.9, 68.7, 51.9, 38.7, 26.8, 19.7, 16.1. HRMS (ESI, TOF): Exact mass calcd for 
C22H31O3Si [M+H]
+ 371.0242. Found 371.0222. 
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F. Preparation of (S)-4-(tert-Butyldiphenylsilyloxy)-3-methylbutanal (10). 
 
A modification of reported procedure61 was used. Under an atmosphere of argon, 
to an oven dried flask was added [Ir(COD)Cl]2 (10 mg, 0.015 mmol) and 1.5 mL of 
CH2Cl2. Then diethyl silane (529 mg, 6.0 mmol) was added and the resulting mixture 
was stirred at 23 °C for 1 minute. After addition of methyl (S)-4-((tert-
butyldiphenylsilyl)oxy)-3-methylbutanoate 9 (3.0 mmol), the mixture was stirred at 23 
°C for 1 h. Then add another portion of [Ir(COD)Cl]2 (10 mg, 0.015 mmol) and diethyl 
silane (265 mg, 3.00 mmol) to the mixture and allow it to stir 23 °C for 2 h. The reaction 
was diluted with diethyl ether and quenched by 0.1 M HCl. After stirring for 20 minutes, 
the layers were separated and the aqueous layer was extracted with CH2Cl2. The 
combined organic layers were dried with MgSO4, and concentrated under vacuum. 
Purification of the residue by flash chromatography on silica gel using ~10%-15% 
CH2Cl2/hexanes as eluents gave the desired aldehyde 10 as colorless oil (766 mg, 2.25 
mmol, 75%). 1H NMR (400 MHz, CDCl3) δ 9.86 (1H, t, J = 2.1 Hz), 7.81-7.74 (4H, m), 
7.54-7.47 (6H, m), 3.70 (1H, dd, J = 9.9, 5.1 Hz), 3.57 (1H, dd, J = 9.9, 6.9 Hz), 2.69 
(1H, ddd, J = 15.9, 5.7, 2.1 Hz), 2.48-2.39 (1H, m), 2.35 (1H, ddd, J = 15.9, 7.2, 2.1 Hz), 
1.18 (9H, s), 1.05 (3H, d, J = 6.7 Hz); 13C NMR (100 MHz, CDCl3) δ 202.5, 135.6, 
135.6, 133.6, 133.5 129.8, 127.8, 68.5, 48.2, 31.3, 27.0, 19.3, 16.9. IR (CH2Cl2) n (cm-1) 
3070, 2931, 2858, 2360, 1724, 1469, 1427, 1111, 806.3, 740.7, 702.1. HRMS (ESI, 
TOF): Exact mass calcd for C21H28O2SiLi [M+Li]+ 347.2019. Found 347.2021. 
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G. Typical Procedure for a-Chlorination of the Aldehyde 
 
 A modification of reported procedure67 was used. 5-Benzyl-2,2,3,-
trimethylimidazolidin-4-one trifluoroacetic acid salt (13.5 mg, 0.050 mmol) in 
chloroform (1 mL) is cooled to -30 °C for five minutes prior to addition of 2,3,4,5,6,6-
hexachloro-2,4-cyclohexadien-1-one (181 mg, 0.60 mmol). The aldehyde 10 (170 mg, 
0.50 mmol) was added to the yellow mixture. The resulting mixture was stirred at -30 °C 
for 8 h. The reaction was then warmed to 0 °C and MeOH (1 mL) was added to the 
mixture, followed by NaBH4 (80 mg, 2 mmol). After stirring at 0 °C for 5 minutes, the 
reaction was quenched by 1 M KHSO4. The aqueous solution was extracted with EtOAc 
three times. The combined organic layers were dried with MgSO4, and concentrated in 
(i) 0.05 M•TFA 
CHCl3, - 30 °C
1.2 G, 8 h
(ii) 4.0 NaBH4
MeOH
O OH
Cl
syn-11
(S)-M•TFA
78 %
syn:anti  
18:1.0
anti-11
(R)-M•TFA
75 %
syn:anti  
1.0:10
OH
Cl
matched mismatched
OTBDPS TBDPSO TBDPSO
10
O
6
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vacuo. Purification of the residue by flash chromatography on silica gel, eluting with 
2.5%-5.0% EtOAc/hexanes gave the desired alcohol as colorless oil. 
 
H. Typical Procedure for Preparation Epoxides 
 
Under Ar, to a solution of 11 (75 mg, 0.20 mmol) in anhydrous THF was added 
NaH (10 mg, 0.40 mmol) and the mixture was stirred at 60 °C for 4 h. The reaction was 
quenched by 1 M KHSO4. The aqueous solution was extracted with CH2Cl2 three times. 
The combined organic layers were dried with MgSO4, and concentrated in vacuo. 
Purification of the residue by flash chromatography on silica gel, eluting with 
CH2Cl2/hexanes (20%) gave the desired epoxide as a colorless oil. 
(2S,3R)-4-((tert-Butyldiphenylsilyl)oxy)-2-chloro-3-methylbutan-1-ol (syn-11). 
The compound was prepared according to the typical a-chlorination procedure 
catalysed by (S)-5-benzyl-2,2,3,-trimethylimidazolidin-4-one trifluoroacetic acid salt. 
Purification by flash chromatography afforded syn-11 as a colorless oil (147 mg, 0.390 
mmol, 78% isolated yield). 1H NMR (400 MHz, CDCl3) δ 7.81-7.75 (4H, m), 7.54-7.44 
(6H, m), 4.49-4.45 (1H, m), 3.88-3.86 (2H, m), 3.71-3.62 (2H, m), 2.34 (1H, br), 2.22-
2.16 (1H, m), 1.12 (9H, s), 1.05 (3H, d, J = 6.7 Hz); 13C NMR (100 MHz, CDCl3) δ 
135.6, 135.6, 133.2, 129.8, 127.8, 66.5, 65.7, 65.7, 38.8, 26.9, 19.3, 11.8. IR (CH2Cl2) 
n (cm-1) 3356, 3071, 2932, 2859, 2361, 1470, 1427, 1377, 1111, 822. HRMS (ESI, 
TOF): Exact mass calcd for C21H30ClO2Si [M+H]
+ 377.1704. Found 377.1718. The 
diastereoselectivity was 18:1.0, determined by Chiral HPLC (Chiralcel OD, Hex/iPrOH 
99:1, 1 mL/min, 25 °C), tr 11.7 min (major diastereomer), tr 12.7 min (minor 
diastereomer).    
The product was converted to the epoxide according to the typical epoxidation 
procedure. Purification by flash chromatography afforded (2R,3R)-4-tert-
OH
Cl
2.0 NaH, THF
 
60 °C, 4 h O
14
95 %
TBDPSO TBDPSO
11
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butyldiphenylsilyloxy-1,3-epoxy-3-methylbutane (anti-14) as a colorless oil (67 mg, 
0.19 mmol, 95% isolated yield). 1H NMR (400 MHz, CDCl3) δ 7.70-7.67 (4H, m), 7.49-
7.38 (6H, m), 3.66 (2H, dd, J = 6.3, 1.6 Hz), 2.90-2.87 (1H, m), 2.79 (1H, dd, J = 4.9, 
4.1 Hz), 2.63 (1H, dd, J = 5.0, 2.8 Hz), 1.65-1.56 (1H, m), 1.09 (9H, s), 1.03 (3H, d, J = 
6.8 Hz); 13C NMR (100 MHz, CDCl3) δ 135.6, 133.6, 129.7, 127.7, 66.4, 55.1, 46.8, 
39.1, 26.8, 19.2, 13.3. IR (CH2Cl2) n (cm-1) 3070, 2927, 2859, 2338, 1462, 1427, 1389, 
1362, 1111, 933.6, 887.3, 821.7. HRMS (ESI, TOF): Exact mass calcd for C21H28O2SiLi 
[M+Li]+ 347.2019. Found 347.2020.  
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(2R,3R)-4-((tert-Butyldiphenylsilyl)oxy)-2-chloro-3-methylbutan-1-ol (anti-11). 
The compound was prepared according to the typical chlorination procedure 
catalysed by (R)-5-benzyl-2,2,3,-trimethylimidazolidin-4-one trifluoroacetic acid salt. 
Purification by flash chromatography afforded anti-11 as a colorless oil (141 mg, 0.374 
mmol, 75% isolated yield). 1H NMR (400 MHz, CDCl3) δ 7.74-7.68 (4H, m), 7.51-7.39 
(6H, m), 4.26-4.22 (1H, m), 3.95 (1H, dd, J = 12.2, 4.5 Hz), 3.87 (1H, dd, J = 12.2, 6.5 
Hz), 3.78 (1H, dd, J = 10.4, 5.9 Hz), 3.72 (1H, dd, J = 10.4, 4.3 Hz), 2.54 (1H, br), 2.27-
2.16 (1H, m), 1.10 (2H, s), 1.06 (1H, d, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 
135.6, 133.1, 129.8, 127.8, 67.4, 65.5, 65.1, 39.4, 26.9, 19.2, 14.6. IR (CH2Cl2) n (cm-1) 
3383, 3071, 2932, 2859, 2361, 1470, 1427, 1389, 1111. HRMS (ESI, TOF): Exact mass 
calcd for C21H30ClO2Si [M+H]
+ 377.1704. Found 377.1710. The diastereoselectivity was 
1.0:10 determined by Chiral HPLC (Chiralcel OD, Hex/iPrOH 99:1, 1 mL/min, 25 °C), 
tr 11.8 min (minor diastereomer), tr 12.8 min (major diastereomer).  
The product was then converted to the epoxide according to the typical 
epoxidation procedure. Purification by flash chromatography afforded (2S,3R)-4-tert-
butyldiphenylsilyloxy-1,3-epoxy-3-methylbutane (syn-14) as a colorless oil (61 mg, 0.18 
mmol, 90% isolated yield). The relative stereochemistry was determined by comparing 
with a known epoxide, which was reported previously.153 1H NMR (400 MHz, CDCl3) δ 
7.74-7.66 (4H, m), 7.48-7.38 (6H, m), 3.75 (2H, qd, J = 9.9, 5.1 Hz), 3.02-2.99 (1H, m), 
2.81-2.75 (1H, m), 2.57 (1H, dd, J = 5.0, 2.8 Hz), 1.68-1.60 (1H, m), 1.10 (9H, s), 1.03 
(3H, d, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 135.6, 133.8, 129.6, 127.6, 66.2, 
54.0, 45.6, 38.5, 26.9, 19.3, 12.6. IR (CH2Cl2) n (cm-1) 3071, 2928, 2859, 1470, 1427, 
1389, 1362, 1111, 933.6, 875.7, 821.7. HRMS (ESI, TOF): Exact mass calcd for 
C21H28O2SiLi [M+Li]
+ 347.2019. Found 347.2003. 
Relative stereochemistry determination of 11: the 1H NMR data of syn-14 
matched with reported data70 and differs from that of anti-14. Therefore, the relative 
stereochemistry assignment was confirmed. 
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I. Typical Procedure for a-Fluorination of the Aldehyde. 
 
A modification of reported procedure65 was used. 5-Benzyl-2,2,3,-
trimethylimidazolidin-4-one dichloroacetic acid salt (38 mg, 0.10 mmol) and N-
fluorobenzenesulfonimide (315 mg, 1.0 mmol) was dissolved in THF (4.5 mL) and 
iPrOH (0.5 mL). The mixture was cooled to -10 °C prior to addition of the aldehyde (170 
mg, 0.50 mmol). The resulting mixture was stirred at -10 °C for 16 h and was then 
warmed to 0 °C. To the mixture at 0°C was added 1 mL MeOH and NaBH4 (200 mg, 5 
mmol). After stirring at 0 °C for 5 minutes, the reaction was quenched by 1 M KHSO4. 
(i) 0.1 M•Cl2HCCO2- 
THF/iPrOH, - 10 °C 
2.0 H, 16 h
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O OH
F
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The mixture was diluted with water and the aqueous solution was extracted with EtOAc 
three times. The combined organic layers were dried with MgSO4, and concentrated in 
vacuo. The residue was redissolved in dichloromethane and the solid was filtered off on 
a small silica pad. The mixture was concentrated again in vacuo. Purification of the 
residue by flash chromatography on silica gel, eluting with ~5%-10% EtOAc/hexanes 
gave the desired alcohol as colorless oil. 
 
(2S,3R)-4-((tert-Butyldiphenylsilyl)oxy)-2-fluoro-3-methylbutan-1-ol (syn-12). 
The compound was prepared according to the typical a-fluorination procedure 
catalysed by (S)-5-benzyl-2,2,3,-trimethylimidazolidin-4-one dichloroacetic acid salt. 
Purification by flash chromatography afforded syn-12 as a colorless oil (162 mg, 0.449 
mmol, 90% isolated yield). 1H NMR (400 MHz, CDCl3) δ 7.72-7.69 (4H, m), 7.51-7.39 
(6H, m), 4.75-4.59 (1H, m), 3.96-3.68 (4H, m), 2.22-2.01 (2H, m), 1.11 (9H, s), 1.04 
(3H, d, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 135.6 (d, J = 2.3 Hz), 133.5 (d, J = 
3.1 Hz), 129.7 (d, J = 1.3 Hz), 127.7 (s), 95.4 (d, J = 170.3 Hz), 64.5 (d, J = 6.1 Hz), 
63.3 (d, J = 22.2 Hz), 37.1 (d, J = 18.9 Hz), 26.9 (s), 19.3 (s), 13.0 (d, J = 6.8 Hz); 19F 
NMR (282 MHz, CDCl3) δ -194.48 (dtd, J = 40.0, 25.3, 14.5 Hz). IR (CH2Cl2) n (cm-1) 
3364, 3071, 2928, 2855, 2361, 1470, 1427, 1393, 1362, 1111, 1049. HRMS (ESI, TOF): 
Exact mass calcd for C21H30FO2Si [M+H]
+ 361.1999. Found 361.2021. The 
diastereoselectivity was 22:1.0 determined by Chiral HPLC (Chiralcel OD, Hex/iPrOH 
99:1, 1 mL/min, 25 °C), tr 16.05 min (major diastereomer), tr 23.68 min (minor 
diastereomer). 
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(2R,3R)-4-((tert-Butyldiphenylsilyl)oxy)-2-fluoro-3-methylbutan-1-ol (anti-12). 
The compound was prepared according to the typical a-fluorination procedure 
catalysed by (R)-5-benzyl-2,2,3,-trimethylimidazolidin-4-one dichloroacetic acid salt. 
Purification by flash chromatography afforded anti-12 as a colorless oil (153 mg, 0.424 
mmol, 85% isolated yield). 1H NMR (400 MHz, CDCl3) δ 7.74-7.69 (4H, m), 7.51-7.41 
(6H, m), 4.82-4.63 (1H, m), 3.97-3.75 (2H, m), 3.67-3.64 (2H, m), 2.28 (1H, br), 2.11– 
2.00 (1H, m), 1.12 (9H, s), 0.99 (3H, dd, J = 7.0, 0.8 Hz); 13C NMR (100 MHz, CDCl3) δ 
135.6 (d, J = 4.5 Hz), 133.3 (d, J = 8.2 Hz), 129.8 (s), 127.8 (d, J = 1.6 Hz), 95.4 (d, J = 
171.0 Hz), 65.2 (d, J = 6.0 Hz), 63.7 (d, J = 22.6 Hz), 37.4 (d, J = 19.6 Hz), 26.9 (s), 
11.7 (d, J = 5.8 Hz); 19F NMR (282 MHz, CDCl3) δ -198.46 to -198.93 (m). IR (CH2Cl2) 
n (cm-1) 3356, 3071, 2932, 2859, 2361, 1470, 1427, 1389, 1362, 1111, 1034. HRMS 
(ESI, TOF): Exact mass calcd for C21H30FO2Si [M+H]+ 361.1999. Found 361.2035. The 
diastereoselectivity was 1.0:58, determined by Chiral HPLC (Chiralcel OD, Hex/iPrOH 
99:1, 1 mL/min, 25 °C), tr 16.05 min (minor diastereomer), tr 23.68 min (major 
diastereomer).  
Relative stereochemistry determination of 12: since both catalyst and reaction 
condition are identical to what has been reported, and the reaction is catalyst controlled; 
the stereochemistry was assigned according to MacMillan’s fluorinated product. The 
product cannot be easily converted to any known structure. 
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J. Typical Procedure for the a-Amination of the Aldehyde 
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A modification of reported procedure104 was used. Dibenzyl azodicarboxylate 
(90%, 1.29 g, 3.9 mmol) and proline (70 mg, 0.6 mmol) in MeCN (10 mL) were cooled 
down to -3 °C. The aldehyde (1.02 g 3.00 mmol) was then added and the mixture was 
stirred at -3 °C for 2 h. The reaction was gradually warmed to 20 °C within ca. 1 h. The 
mixture was then cooled to 0 °C, treated with MeOH (3 mL) and NaBH4 (240 mg, 6 
mmol) and was stirred for 5 min at 0 °C. The reaction was quenched by 1 M KHSO4. 
The aqueous solution was extracted with EtOAc three times. The combined organic 
layers were dried with MgSO4, and concentrated in vacuo. Purification of the residue by 
flash chromatography on silica gel, eluting with 15% EtOAc/hexanes gave the desired 
alcohol as white foamy solid.  
 
Dibenzyl 1-((2R,3S)-4-((tert-Butyldiphenylsilyl)oxy)-1-hydroxy-3-methylbutan-2-
yl)hydrazine-1,2-dicarboxylate (anti-13). 
The compound was prepared according to the typical a-amination procedure 
catalysed by (R)-Proline. Purification by flash chromatography afforded anti-13 as a 
white foamy solid (1.54 g, 2.40 mmol, 80% isolated yield). 1H NMR (400 MHz, CDCl3) 
δ 7.70-7.67 (4H, m), 7.50-7.27 (16H, m), 6.85 (1H, d, J = 31.1 Hz), 5.37-5.10 (4H, m), 
4.45-4.12 (2H, m), 3.80-3.41 (4H, m), 1.95-1.66 (1H, m), 1.12-1.09 (9H, m), 0.99-0.88 
(3H, m); 13C NMR (100 MHz, CDCl3) δ 159.1, 157.4, 135.6, 133.3, 133.2, 129.6, 129.8, 
128.7, 128.6, 128.2, 127.9, 127.8, 127.7, 68.6, 65.9, 65.6, 60.4, 35.6, 26.9, 19.3, 15.1. IR 
(CH2Cl2) n (cm-1) 3356, 3032, 2928, 1717, 1454, 1408, 1265, 1227, 1111, 1057. HRMS 
(ESI, TOF): Exact mass calcd for C37H45N2O6Si [M+H]+ 641.3047. Found 641.3078. 
10
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The diastereoselectivity was 1.0:13, determined by Chiral HPLC (Chiralcel OD, 
Hex/iPrOH 93:7, 1 mL/min, 25 °C), tr 10.3 min (minor diastereomer), tr 14.4 min (major 
diastereomer). 
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Dibenzyl 1-((2S,3S)-4-((tert-Butyldiphenylsilyl)oxy)-1-hydroxy-3-methylbutan-2-
yl)hydrazine-1,2-dicarboxylate (syn-13). 
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The compound was prepared according to the typical a-amidation procedure 
catalysed by (S)-Proline. Purification by flash chromatography afforded syn-13 as a 
white foamy solid (1.63 g, 2.54 mmol, 85% isolated yield). 1H NMR (400 MHz, CDCl3) 
δ 7.69-7.62 (4H, m, J = 13.5, 6.6 Hz), 7.50-7.24 (16H, m), 6.96 (1H, s), 5.30-5.22 (3H, 
m), 5.13 (1H, dd, J = 12.1, 9.6 Hz), 4.36-4.16 (2H, m), 3.86-3.70 (2H, m), 3.59-3.44 (2H, 
m), 1.80 (1H, br), 1.11-1.08 (9H, m), 0.93-0.90 (3H, m); 13C NMR (100 MHz, CDCl3) δ 
158.6 (d, J = 65.9 Hz), 156.6 (d, J = 27.3 Hz), 135.8, 135.6, 135.5, 135.4, 133.0, 130.1, 
129.9, 128.6, 128.5, 128.1, 127.9, 127.8, 68.3, 64.0, 63.2, 60.6, 35.5, 27.0, 19.2, 14.9. IR 
(CH2Cl2) n (cm-1) 3356, 3032, 2959, 1724, 1470, 1408, 1261, 1223, 1111, 1053. HRMS 
(ESI, TOF): Exact mass calcd for C37H45N2O6Si [M+H]+ 641.3047. Found 641.3063. 
The diastereoselectivity was 62:1.0, determined by Chiral HPLC (Chiralcel OD, 
Hex/iPrOH 93:7, 1 mL/min, 25 °C), tr 10.2 min (minor diastereomer), tr 14.3 min (major 
diastereomer). 
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K. Typical Procedure for the Hydrogenolysis and Benzylation of the Alcohol. 
 
To Raney–Nickel (~0.3 g, prewashed with dry MeOH) in MeOH (1 mL), was 
added AcOH (0.3 mL) and a solution of 13 (64 mg, 0.10 mmol) in MeOH (1 mL). The 
solution was degassed and stirred under a slightly positive pressure of hydrogen (balloon) 
at 23 °C for 16 h. The reaction was then filtered through a short pad of Celite, and 
washed with CH2Cl2. The mixture was concentrated in vacuo and the residue was 
redissolved in CH2Cl2 and was neutralized by anhydrous Na2CO3. The solvent was 
removed by vacuum and the crude product was subjected to benzyl protection without 
further purification. Under Ar atmosphere, to a solution of the hydrogenated crude 
product (0.15 mmol) in anhydrous THF was added NaH (4.8 mg, 0.4 mmol). After 
OBn
NH2
TBDPSO
OH
N N
H
BnO2C
CO2Bn
TBDPSO
(i) Raney Ni
1 bar H2 
MeOH, 23 °C, 16 h
(ii) 1.5 NaH
1.0 BnBr, 0.2 nBu4I
THF, 23 ˚C, 16 h
13 14
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stirring for 5 min, BnBr (19 mL, 0.15 mmol) and nBu4NI (11.1 mg, 0.03 mmol) was 
added and the mixture was stirred at 23 °C for 16 h. The reaction was quenched by 1 M 
KHSO4. The aqueous solution was extracted with EtOAc (three times). The combined 
organic layers were dried with MgSO4, and concentrated in vacuo. Purification of the 
residue by flash chromatography on silica gel, eluting with ~1.0% - 2.5% MeOH/CH2Cl2 
gave the desired product as a white foamy solid. 
 
(2S,3S)-1-(Benzyloxy)-4-((tert-butyldiphenylsilyl)oxy)-3-methylbutan-2-amine (syn-
14). 
The compound was prepared according to the typical hydrogenolysis and 
benzylation procedure. Purification by flash chromatography afforded syn-14 as a white 
foamy solid (22 mg, 0.050 mmol, 50% yield in two steps). 1H NMR (400 MHz, CDCl3) 
δ 7.71-7.65 (4H, m), 7.48-7.28 (11H, m), 4.55 (2H, d, J = 4.8 Hz), 3.77-3.60 (3H, m), 
3.47 (1H, dd, J = 9.3, 7.6 Hz), 3.18 (1H, td, J = 7.2, 3.4 Hz), 2.80 (2H, br), 1.90-1.79 
(1H, m), 1.08 (9H, s), 0.94 (3H, d, J = 7.0 Hz); 13C NMR (100 MHz, CDCl3) δ 138.1, 
135.6, 133.4, 133.3, 129.7, 128.4, 127.8, 127.7, 73.3, 72.8, 66.8, 53.9, 38.1, 27.0, 19.2, 
13.9.  
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(2R,3S)-1-(Benzyloxy)-4-((tert-butyldiphenylsilyl)oxy)-3-methylbutan-2-amine (anti-
14). 
The compound was prepared according to the typical hydrogenolysis and 
benzylation procedure. Purification by flash chromatography afforded anti-14 as a white 
foamy solid (22 mg, 0.050 mmol, 50 % yield in two steps). 1H NMR (400 MHz, CDCl3) 
δ 7.70-7.67 (4H, m), 7.49-7.28 (11H, m), 4.54 (2H, s), 3.68-3.58 (2H, m), 3.56-3.49 (1H, 
m), 3.38 (1H, dd, J = 10.2, 6.5 Hz), 3.26 (1H, br), 1.83 (1H, br), 1.51 (2H, br), 1.08 (9H, 
s), 0.92 (3H, d, J = 6.9 Hz); 13C NMR (100 MHz, CDCl3) δ 138.5, 135.6, 133.8, 133.7, 
129.6, 128.4, 127.7, 127.6, 74.3, 73.2, 66.8, 29.7, 26.9, 19.3, 11.7.  
Relative stereochemistry determination of 13: the 13C NMR data of syn-14 
matched with reported data103 and differ from that of anti-14. Therefore, the relative 
stereochemistry assignment was confirmed. 
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L. Typical Procedure for the Preparation of a-Amino Acid. 
 
 
To Raney–Nickel (~1.5 g, prewashed with dry MeOH) in MeOH (10 mL), was 
added AcOH (3 mL) and a solution of 13 (1.44 g, 2.25 mmol) in MeOH (10 mL). The 
solution was degassed and stirred under a slightly positive pressure of hydrogen (balloon) 
at 23 °C for 16 h. The reaction was then filtered through a short pad of Celite, and 
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FmocNH
TBDPSO
anti-15
95 %
OH
N N
H
BnO2C
CO2Bn
TBDPSO
(i) Raney Ni
1 bar H2 
MeOH, 23 °C, 16 h
(ii) 1.1 FmocOSu
3.0 Na2CO3
H2O/acetone
23 °C, 16 h13 syn-15
98 %
10.0 NaIO4
0.1 RuCl3
H2O/acetone
23 °C, 2 h
CO2H
NHFmoc
TBDPSO
anti-16
40 %
syn-16
49 %
CO2H
NHFmoc
TBDPSO
anti-14 
 114 
washed with CH2Cl2. The mixture was concentrated in vacuo and the residue was 
redissolved in CH2Cl2 and was neutralized by anhydrous Na2CO3. The solvent was 
removed by vacuum and the crude product was subjected to Fmoc-protection without 
further purification. To a solution of the above crude product in H2O (10 mL) and 
acetone (10 mL) was added FmocOSu (830 mg, 2.5 mmol) and Na2CO3 (715 mg, 6.7 
mmol). The reaction was stirred at 23 °C for 16 h. The mixture was extracted with 
EtOAc three times. The combined organic layers were dried with MgSO4, and 
concentrated in vacuo. Purification of the residue by flash chromatography on silica gel, 
eluting with ~10% - 20% EtOAc/hexanes gave 15 as a white foamy solid. To a solution 
of RuCl3 (29 mg, 0.14 mmol) and NaIO4 (2.95 g, 13.8 mmol) in water was added 12 
(800 mg, 1.4 mmol). The mixture was stirred at 23 °C for 2 h, and then added MeOH (2 
mL). The reaction was stirred until solid precipitation occurred. The solid was filtered on 
Celite and washed it with EtOAc. 1 M KHSO4 (3 mL) was added to the filtrate. Then, 
the aqueous phase was extracted by EtOAc. The combined organic layers were dried 
with MgSO4, and concentrated in vacuo. Purification of the residue by flash 
chromatography on silica gel, eluting with ~15% - 50% EtOAc/hexanes gave the desired 
acid as a white foamy solid. 
 
(9H-Fluoren-9-yl)methyl ((2S,3S)-4-((tert-Butyldiphenylsilyl)oxy)-1-hydroxy-3-
methylbutan-2-yl)carbamate (syn-15). 
Purification by flash chromatography afforded syn-15 as a white foamy solid 
(1.28 g, 2.20 mmol, 98 % yield in two steps). 1H NMR (400 MHz, CDCl3) δ 7.86-7.74 
(6H, m), 7.66 (2H, dd, J = 7.3, 3.6 Hz), 7.55-7.40 (8H, m), 7.34 (2H, t, J = 7.4 Hz), 6.05 
(1H, d, J = 6.7 Hz), 4.50 (2H, d, J = 6.5 Hz), 4.28 (1H, t, J = 6.8 Hz), 3.93-3.74 (4H, m), 
3.69 (1H, dd, J = 10.4, 4.5 Hz), 3.31 (1H, br), 2.05 (1H, br), 1.19 (9H, s), 1.13 (3H, d, J 
= 6.7 Hz); 13C NMR (100 MHz, CDCl3) δ 157.4, 144.1, 141.4, 135.7, 132.9, 130.0, 
127.9, 127.7, 127.1, 125.2, 120.0, 66.9, 66.0, 64.6, 56.7, 47.4, 35.7, 27.0, 19.2, 15.3. IR 
(CH2Cl2) n (cm-1) 3402, 3067, 2928, 1701, 1508, 1450, 1327, 1227, 1111, 1042. HRMS 
(ESI, TOF): Exact mass calcd for C36H42NO4Si [M+H]+ 580.2883. Found 580.2874.  
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(9H-Fluoren-9-yl)methyl ((2R,3S)-4-((tert-Butyldiphenylsilyl)oxy)-1-hydroxy-3-
methylbutan-2-yl)carbamate (anti-15). 
syn-15 
 
syn-15 
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Purification by flash chromatography afforded anti-15 as a white foamy solid 
(1.24 g, 2.14 mmol, 95 % yield in two steps). 1H NMR (500 MHz, CDCl3) δ 7.84-7.77 
(2H, m), 7.74 (4H, dd, J = 7.7, 6.7 Hz), 7.64 (2H, d, J = 7.4 Hz), 7.55-7.39 (8H, m), 7.33 
(2H, td, J = 7.5, 1.0 Hz), 5.85 (1H, d, J = 8.3 Hz), 4.51-4.43 (2H, m), 4.26 (1H, t, J = 6.9 
Hz), 3.90 (1H, dd, J = 11.2, 4.2 Hz), 3.83-3.80 (1H, m), 3.78-3.69 (2H, m), 3.63 (1H, dd, 
J = 10.7, 7.2 Hz), 3.34 (1H, br), 2.11-2.10 (1H, m), 1.15 (9H, s), 0.97 (3H, d, J = 7.2 
Hz); 13C NMR (125 MHz, CDCl3) δ 156.9, 144.0, 141.4, 135.7, 132.8, 130.1, 127.9, 
127.7, 127.1, 125.1, 120.0, 66.8, 66.1, 63.0, 56.3, 47.4, 37.2, 27.0, 19.2, 14.1. IR 
(CH2Cl2) n (cm-1) 3368, 3067, 2928, 1701, 1512, 1450, 1242, 1111. HRMS (ESI, TOF): 
Exact mass calcd for C36H42NO4Si [M+H]+ 580.2883. Found 580.2865. 
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(2S,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-((tert-butyldiphenyl-
silyl)oxy)-3-methylbutanoic acid (syn-16). 
Purification by flash chromatography afforded syn-16 as a white foamy solid 
(0.42 g, 0.70 mmol, 49% yield). 1H NMR (400 MHz, CDCl3) δ 7.89-7.60 (8H, m), 7.55-
7.29 (10H, m), 6.41 (1H, d, J = 8.4 Hz), 4.61-4.51 (7H, m), 4.34 (1H, t, J = 6.9 Hz), 3.88 
(1H, d, J = 8.5 Hz), 3.62 (1H, dd, J = 10.7, 5.1 Hz), 2.49 (1H, m), 1.25-1.09 (12H, m); 
13C NMR (100 MHz, CDCl3) δ 177.1, 156.9, 143.9, 141.3, 135.7, 132.6, 130.0, 127.9, 
127.7, 127.1, 125.3, 120.0, 67.4, 66.1, 58.1, 47.1, 36.4, 26.9, 19.2, 14.7. IR (CH2Cl2) 
n (cm-1) 3399, 3067, 2928, 1717, 1508, 1450, 1427, 1219, 1111, 1034. HRMS (ESI, 
TOF): Exact mass calcd for C36H39NaNO5Si [M+Na]+ 616.2495. Found 616.2552. 
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(2R,3S)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-4-((tert-butyldiphenyl-
silyl)oxy)-3-methylbutanoic acid (anti-16). 
Purification by flash chromatography afforded anti-16 as a white foamy solid 
(0.34 g, 0.56 mmol, 40% yield). 1H NMR (400 MHz, CDCl3) δ 7.81-7.56 (8H, m), 7.49-
7.27 (10H, m), 5.90 (1H, d, J = 8.2 Hz), 4.69 (2H, d, J = 6.2 Hz), 4.51-4.34 (2H, m), 
4.24 (1H, t, J = 6.5 Hz), 3.70-3.57 (2H, m), 2.43 (1H, br), 1.09 (9H, s), 0.95 (3H, d, J = 
6.7 Hz); 13C NMR (100 MHz, CDCl3) δ 156.4, 143.8, 141.3, 135.6, 133.0, 129.8, 127.8, 
127.7, 127.1, 125.1, 119.9, 67.3, 66.1, 56.1, 47.2, 37.9, 29.7, 26.8, 19.1. HRMS (ESI, 
TOF): Exact mass calcd for C36H40NO5Si [M+H]+ 594.2676. Found 594.2752. 
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APPENDIX D 
EXPERIMENTAL FOR CHAPTER IV 
 
A. Preparation of Compounds 17 
 
Methyl 3,4-diaminobenzoate (17). 
To a solution of 3,4-diaminobenzoic acid (3.6 g, 24 mmol) in dry MeOH (60 mL) 
was added SO2Cl (2.8 mL, 38 mmol) in 10 minutes at 23 °C. The solution was then 
refluxed for 3 h. Half of the solvent was removed under reduced pressure, and ethyl 
acetate (100 mL) was added. The resulting solution was washed with saturated aqueous 
NaHCO3. The aqueous layers were extracted with ethyl acetate (2 × 50 mL). The 
combined organic layers were dried and evaporated to dryness, yielding a brown solid 
(4.0 g, 23 mmol, 98%) which was used for the next reaction without further purification. 
1H NMR (400 MHz, CDCl3) δ 7.49 (1H, dd, J = 8.1, 1.9 Hz), 7.43 (1H, d, J = 1.9 Hz), 
6.69 (1H, d, J = 8.1 Hz), 3.87 (3H, s), 3.82 (2H, br), 3.36 (2H, br); 13C NMR (100 MHz, 
CDCl3) δ 167.3, 140.4, 133.1, 123.3, 121.2, 118.4, 114.9, 51.6. 
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B. Typical Procedure for Amide Coupling On The Linker 
Boc-protected amino acid (1.1 equiv), 17 (2.22 g, 13.3 mmol, 1 equiv), and 
HOBt (2.44 g, 16.0 mmol) were dissolved in anhydrous CH2Cl2 under Ar. The mixture 
was stirred for 2 min and then cooled to 0 ºC. Triethylamine (4.64 mL, 33.2 mmol) and 
EDCI (3.06 g, 16.0 mmol) were added to the solution at 0 ºC. The solution was then 
stirred at the room temperature for 12 h. Pure product precipitated out as white solid 
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without purification. A small amount of diethyl ether was added to the reaction mixture 
to allow more product precipitation. 
 
(S)-methyl 4-amino-3-(2-((tert-butoxycarbonyl)amino)propanamido)benzoate (18).  
18 was isolated as white solid (2.7 g, 8.0 mmol, 60% yield). 1H NMR (400 MHz, 
MeOD) δ 7.76-7.64 (2H, m), 6.79 (1H, d, J = 8.4 Hz), 4.17 (1H, q, J = 7.0 Hz), 3.84 
(3H, s), 1.48 (9H, s), 1.45 (3H, d, J = 7.2 Hz). 
 
 
 
 
(S)-methyl 4-amino-3-(2-((tert-butoxycarbonyl)amino)-3-
methylbutanamido)benzoate (32). 
32 was isolated as white solid (3.0 g, 8.2 mmol, 62% yield). 1H NMR (400 MHz, 
CDCl3) δ 7.82 (1H, s), 7.77 (2H, dd, J = 8.5, 1.8 Hz), 6.73 (1H, d, J = 8.4 Hz), 3.99 (1H, 
t, J = 7.2 Hz), 3.87 (3H, s), 2.28 (1H, dq, J = 13.7, 6.8 Hz), 1.09 (6H, dd, J = 16.4, 6.8 
Hz). 
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C. Typical Procedure for Amide Coupling On Amine Intermediates. 
Boc-protected amino acid (6.60 mmol, 1.1 equiv), hydrochloride salt of amine 
intermediate (6.00 mmol, 1 equiv), and HOBt (1.10 g, 7.20 mmol) were dissolved in 
anhydrous CH2Cl2 under Ar. The mixture was stirred for 2 min and then cooled to 0 ºC. 
Triethylamine (4.19 mL, 30.0 mmol) and EDCI (1.38 g, 7.20 mmol) were added to the 
solution at 0 ºC. The solution was then stirred at the room temperature for 12 h. Pure 
product then precipitated out as white solid without purification. A small amount of 
diethyl ether was added to the reaction mixture to allow more product precipitation. If no 
precipitation occurred, wash the organic mixture with 0.2M KHSO4 aqueous solution 
followed by sat. NaHCO3 solution. The organic layer was dried by sat. NaCl solution 
and MgSO4. Half of dichloromethane was removed under vacuum and diethyl ether was 
added to allow product precipitation. 
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Methyl 4-amino-3-((S)-2-((S)-2-((tert-butoxycarbonyl)amino)propanamido) 
propanemido)benzoate (19).  
19 was isolated as white solid (2.0 g, 4.9 mmol, 80% yield). 1H NMR (400 MHz, 
MeOD) δ 7.73 (1H, s), 7.69 (1H, dd, J = 8.5, 2.0 Hz), 6.79 (1H, d, J = 8.5 Hz), 4.45 (1H, 
q, J = 7.1 Hz), 4.09 (1H, q, J = 7.2 Hz), 3.84 (3H, s), 1.51 (3H, d, J = 7.2 Hz), 1.43 (9H, 
s), 1.35 (3H, d, J = 7.2 Hz). 
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 127 
Methyl 4-amino-3-((6S,9S,12S)-6-benzyl-2,2,9,12-tetramethyl-4,7,10-trioxo-3-oxa-
5,8,11-triazatridecanamido)benzoate (20).  
20 was isolated as off-white solid (1.2 g, 2.2 mmol, 85% yield). 1H NMR (400 
MHz, MeOD) δ 7.76 (1H, d, J = 2.0 Hz), 7.70 (1H, dd, J = 8.5, 2.0 Hz), 7.32-7.19 (6H, 
m), 6.80 (1H, d, J = 8.5 Hz), 4.43 (1H, q, J = 7.2 Hz), 4.38-4.28 (2H, m), 3.83 (3H, s), 
2.85 (1H, dd, J = 13.7, 9.8 Hz), 2.70-2.60 (1H, m), 1.51 (3H, d, J = 7.2 Hz), 1.39 (12H, 
m). 
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Methyl 4-amino-3-((6S,9S,12S,15S)-9-benzyl-6-(tert-butoxymethyl)-2,2,12,15-tetra-
methyl-4,7,10,13-tetraoxo-3-oxa-5,8,11,14-tetraazahexadecanamido)benzoate (21).  
21 was isolated as a foamy solid (0.90 g, 1.3 mmol, 79% yield). 1H NMR (400 
MHz, CDCl3) δ 8.17 (1H, s), 7.96 (1H, d, J = 1.9 Hz), 7.76 (1H, dd, J = 8.4, 2.0 Hz), 
7.44-7.29 (6H, m), 7.20-7.14 (2H, m), 6.71 (1H, d, J = 8.4 Hz), 6.56 (1H, s), 5.34 (1H, d, 
J = 2.8 Hz), 4.60-4.47 (4H, m), 4.43-4.33 (1H, m), 3.95 (1H, q, J = 4.1 Hz), 3.85 (3H, s), 
3.56 (2H, d, J = 4.3 Hz), 3.19 (1H, dd, J = 14.4, 4.8 Hz), 3.06 (1H, dd, J = 14.4, 7.7 Hz), 
1.59 (3H, d, J = 7.3 Hz), 1.45 (3H, d, J = 7.4 Hz), 1.40 (9H, s), 1.10 (9H, s). 
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Methyl 4-amino-3-((R)-2-((S)-3-(4-(benzyloxy)phenyl)-2-((tert-butoxycarbonyl) 
amino)propanamido)propanamido)benzoate (33).  
33 was isolated as white solid (2.1 g, 4.6 mmol, 82% yield). 1H NMR (400 MHz, 
CDCl3) δ 8.48 (1H, s), 7.86 (1H, d, J = 1.2 Hz), 7.71 (1H, dd, J = 8.4, 1.8 Hz), 7.48-7.29 
(6H, m), 7.08 (2H, d, J = 8.5 Hz), 6.88 (3H, d, J = 8.5 Hz), 6.66 (1H, t, J = 9.3 Hz), 5.00 
(2H, s), 4.60-4.47 (1H, m), 4.26 (1H, dd, J = 13.7, 6.7 Hz), 3.81 (3H, s), 2.98 (2H, qd, J 
= 13.8, 7.2 Hz), 1.33 (12H, m). 
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Methyl 4-amino-3-((6S,9R,12S,15R)-9-benzyl-12-(4-(benzyloxy)benzyl)-6-(tert-
butoxymethyl)-2,2,15-trimethyl-4,7,10,13-tetraoxo-3-oxa-5,8,11,14-tetraazahexa-
decanamido)benzoate (29).  
29 was isolated as white foamy solid (0.76 g, 0.86 mmol, 78% yield). 1H NMR 
(400 MHz, CDCl3) δ 7.88 (1H, s), 7.67 (1H, d, J = 8.4), 7.41-7.12 (11H, m), 6.99 (2H, d, 
J = 7.8 Hz), 6.84 (2H, d, J = 8.4 Hz), 6.64 (1H, d, J = 8.5 Hz), 4.95 (2H, s), 4.81 (2H, 
m), 4.60 (1H, m), 4.16 (1H, m), 3.81 (3H, s), 3.23 (2H, m), 3.16-3.03 (1H, m), 3.02-2.82 
(3H, m), 1.39 (9H, s), 1.31 (3H, d, J = 6.7 Hz), 1.09-0.94 (9H, s). 
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Methyl 4-amino-3-((S)-2-((S)-2-((tert-butoxycarbonyl)amino)propanamido)-3-
methylbutanamido)benzoate (35).  
35 was isolated as white solid (2.1 g, 4.8 mmol, 75% yield). 1H NMR (400 MHz, 
CDCl3) δ 8.34 (1H, br), 7.82 (1H, d, J = 1.7 Hz), 7.73 (1H, d, J = 8.4 Hz), 7.01 (1H, br), 
6.67 (1H, d, J = 8.4 Hz), 5.20 (1H, br), 4.46 (2H, s), 4.38 (1H, t, J = 6.7 Hz), 4.23-4.11 
(1H, m), 3.89-3.82 (3H, s), 2.42-2.29 (1H, m), 1.44-1.31 (12H, m), 1.07 (6H, dd, J = 
16.8, 6.8 Hz). 
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Methyl 4-amino-3-((6S,9S,12S)-6-(4-(benzyloxy)benzyl)-12-isopropyl-2,2,9-
trimethyl -4,7,10-trioxo-3-oxa-5,8,11-triazatridecanamido)benzoate (36).  
36 was isolated as white foamy product (1.5 g, 2.1 mmol, 82% yield). 1H NMR 
(400 MHz, MeOD) δ 7.81-7.64 (2H, m), 7.36 (5H, m), 7.12 (2H, d, J = 7.9 Hz), 6.92 
(2H, d, J = 8.2 Hz), 6.79 (1H, d, J = 8.6 Hz), 5.04 (2H, s), 4.34 (1H, d, J = 6.8 Hz), 4.27-
4.11 (2H, m), 3.82 (3H, s), 2.92 (2H, m), 2.29 (1H, m), 1.39 (9H, s), 1.19 (3H, d, J = 6.1 
Hz), 1.09 (6H, t, J = 6.5 Hz). 
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Methyl 4-amino-3-((6S,9S,12S,15S)-9-(4-(benzyloxy)benzyl)-6-(tert-butoxymethyl)-
15-isopropyl-2,2,12-trimethyl-4,7,10,13-tetraoxo-3-oxa-5,8,11,14-
tetraazahexadecanamido)benzoate (30).  
30 was isolated as white foamy solid (1.1 g, 1.3 mmol, 76% yield). 1H NMR 
(400 MHz, CDCl3) δ 9.11 (1H, s), 7.90 (1H, s), 7.82 (1H, s), 7.60 (2H, m), 7.35 (5H, m), 
7.09 (2H, d, J = 8.2 Hz), 6.87 (2H, d, J = 8.2 Hz), 6.58 (1H, d, J = 8.4 Hz), 5.41 (1H, s), 
4.99 (3H, m), 4.61 (4H, m), 4.17 (1H, s), 3.79 (3H, s), 3.50 (1H, dd, J = 13.6, 6.8 Hz), 
3.14 (1H, d, J = 38.3 Hz), 3.02 (2H, d, J = 5.3 Hz), 2.20 (1H, d, J = 5.7 Hz), 1.36 (9H, 
s), 1.23 (3H, d, J = 4.0 Hz), 1.10 (6H, dd, J = 19.1, 6.6 Hz), 1.00 (9H, s). 
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Methyl 4-amino-3-((R)-2-((S)-2-((tert-butoxycarbonyl)amino)-3-phenylpropan 
amido)propanamido)benzoate (37).  
37 was isolated as off-white foamy solid (1.7 g, 3.5 mmol, 85% yield). , 1H NMR 
(400 MHz, CDCl3) δ 8.36 (1H, s), 7.85 (1H, s), 7.73 (1H, dd, J = 8.4, 1.8 Hz), 7.36-7.22 
(5H, m), 7.19 (2H, d, J = 6.7 Hz), 6.68 (1H, d, J = 7.4 Hz), 6.57 (1H, s), 5.23 (1H, d, J = 
5.9 Hz), 4.57-4.38 (3H, m), 4.26 (1H, q, J = 7.1 Hz), 3.84 (3H, s), 3.14-2.98 (2H, m), 
1.33 (12H, m). 
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Methyl 4-amino-3-((6R,9S,12R)-9-(4-(benzyloxy)benzyl)-6-isopropyl-2,2,12-
trimethyl-4,7,10-trioxo-3-oxa-5,8,11-triazatridecanamido)benzoate (38).  
38 was isolated as white solid (0.90 g, 1.5 mmol, 78% yield). 1H NMR (400 
MHz, MeOD) δ 7.75 (1H, d, J = 2.0 Hz), 7.69 (1H, dd, J = 8.5, 2.0 Hz), 7.35-7.20 (5H, 
m), 6.79 (1H, d, J = 8.5 Hz), 4.48 (1H, t, J = 7.8 Hz), 4.31 (1H, q, J = 7.2 Hz), 3.88-3.81 
(4H, m), 3.15-3.01 (2H, m), 1.95 (1H, dd, J = 12.9, 7.1 Hz), 1.43 (9H, s), 1.27 (3H, d, J 
= 7.3 Hz), 0.88 (6H, dd, J = 18.3, 6.7 Hz). 
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Methyl 4-amino-3-((6S,9R,12S,15R)-12-benzyl-6-(tert-butoxymethyl)-9-isopropyl-
2,2,15-trimethyl-4,7,10,13-tetraoxo-3-oxa-5,8,11,14-tetraazahexadecanamido) 
benzoate (31).  
31 was isolated as white solid (0.42 g, 0.58 mmol, 77 % yield). 1H NMR (400 
MHz, DMSO) δ 9.27 (1H, s), 8.38 (1H, t, J = 17.3 Hz), 8.24 (1H, t, J = 18.4 Hz), 7.54 
(1H, d, J = 8.5 Hz), 7.31-7.09 (5H, m), 6.75 (1H, d, J = 8.5 Hz), 6.49 (1H, d, J = 8.1 Hz), 
5.78 (1H, m), 4.54 (1H, s), 4.41 (1H, m), 4.16-4.00 (3H, m), 3.75 (3H, s), 2.87 (2H, ddd, 
J = 32.9, 19.8, 9.2 Hz), 1.70 (1H, m), 1.37 (9H, s), 1.30 (3H, d, J = 7.0 Hz), 1.08 (9H, s), 
0.59 (6H, dd, J = 21.0, 6.7 Hz). 
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Methyl 4-amino-3-((R)-2-((2S,3S)-2-((tert-butoxycarbonyl)amino)-3-methylpenta 
namido)propanamido)benzoate (39).  
39 was isolated as white foamy solid (1.8 g, 3.9 mmol, 86% yield). 1H NMR 
(400 MHz, CDCl3) δ 8.76 (1H, s), 7.78 (1H, m), 7.64-7.53 (2H, m), 6.57 (1H, d, J = 8.5 
Hz), 5.61 (1H, d, J = 6.7 Hz), 4.71-4.60 (1H, m), 4.58 (2H, br), 3.93 (1H, dd, J = 14.9, 
7.3 Hz), 3.77 (3H, s), 1.76 (1H, d, J = 6.1 Hz), 1.53-1.23 (13H, m), 1.12-0.97 (1H, m), 
0.92-0.71 (7H, m); 13C NMR (101 MHz, CDCl3) δ 173.1, 171.9, 166.9, 156.2, 146.7, 
129.4, 128.7, 121.3, 118.9, 115.3, 80.1, 77.44 77.1, 76.8, 59.7, 51.5, 49.6, 36.9, 30.82, 
28.2, 28.2, 24.9, 17.7, 15.5, 15.4, 11.1, 11.0. 
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D. Typical Procedure for Boc Deprotection 
 To a solution of Boc-protected intermediate in methanol (50 equiv) was added 
acetyl chloride (10 equiv) in 5 min at 0 ºC. The mixture was stirred at 23 ºC for 15 min. 
Solvent was removed under vacuum and the crude product was stirred in diethyl ether 
until white solid precipitated. The product was filtered and used for the next step without 
further purification. 
 
Methyl 4-amino-3-((S)-2-((S)-2-((S)-2-amino-3-phenylpropanamido)propanamido) 
propanamido)benzoate (42). 1H NMR (400 MHz, DMSO) δ 9.51 (1H, s), 8.85 (1H, d, 
J = 7.4 Hz), 8.34 (2H, br), 7.86 (1H, d, J = 1.9 Hz), 7.37-7.21 (5H, m), 6.80 (1H, d, J = 
8.5 Hz), 4.43 (2H, dp, J = 21.3, 6.9 Hz), 4.14-4.04 (1H, m), 3.75 (3H, s), 3.22-3.12 (1H, 
m), 3.08-2.97 (1H, m), 1.37 (3H, d, J = 7.1 Hz), 1.28 (3H, d, J = 7.0 Hz). 
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(S)-methyl 4-amino-3-(2-amino-3-methylbutanamido)benzoate (43). 1H NMR (400 
MHz, MeOD) δ 8.02 (1H, s), 7.96 (1H, d, J = 8.4), 7.36 (1H, t, J = 7.0 Hz), 4.05 (1H, d, 
J = 5.7 Hz), 3.92 (3H, s), 2.42 (1H, dp, J = 13.4, 6.7 Hz), 1.19 (6H, dd, J = 17.8, 6.9 Hz). 
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Methyl 4-amino-3-((S)-2-((S)-2-((S)-2-amino-3-(4-(benzyloxy)phenyl)propanamido) 
propanamido)-3-methylbutanamido)benzoate (44). 1H NMR (400 MHz, MeOD) δ 
7.92 (1H, d, J = 1.9 Hz), 7.88 (1H, dd, J = 8.4, 1.9 Hz), 7.47-7.27 (5H, m), 7.25-7.16 
(3H, m), 7.00 (2H, d, J = 8.6 Hz), 5.11 (2H, s), 4.44-4.30 (2H, m), 4.07 (1H, t, J = 7.5 
Hz), 3.91 (3H, s), 2.32 (1H, dq, J = 13.6, 6.8 Hz), 1.26 (3H, d, J = 7.1 Hz), 1.10 (6H, dd, 
J = 6.8, 3.7 Hz). 
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E. Typical Procedure For Linear Tetrapeptidyl Acetal Preparation 
 To a solution of linear tetrapeptide intermediate (0.60 mmol, 1.0 equiv) in 12 mL 
dichloromethane and 36 mL THF was added p-nitrochloroformate (160 mg, 1.3 equiv) 
and sodium bicarbonate (100 mg, 2 equiv) at room temperature. The solution was stirred 
for 1 h and then DIPEA (0.2 mL, 1.5 equiv) was added. The solution was stirred for 
another 20 minutes. Then 2-(dimethoxymethyl)phenol (1.2 mmol, 2.0 equiv) and sodium 
carbonate (6 mmol, 10 equiv) were added to the mixture, which was allowed to stirred 
for 16 h. The reaction mixture was filtered on celite and the solvent was removed under 
vacuo. Purification by column chromatography afforded the desired acetal as a foamy 
solid. 
 
(6S,9S,12S,15S)-2-(dimethoxymethyl)phenyl 9-benzyl-6-(tert-butoxymethyl)-2,2,12, 
15-tetramethyl-4,7,10,13-tetraoxo-3-oxa-5,8,11,14-tetraazahexadecan-16-oate (50).  
50 was isolated as white foamy solid (0.43 g, 0.61 mmol, 75% yield). 1H NMR (400 
MHz, CDCl3) δ 8.13-8.06 (1H, m), 7.61 (1H, d, J = 7.7), 7.40-7.22 (6H, m), 7.21-7.15 
(2H, m), 7.09 (3H, dt, J = 8.0, 2.0 Hz), 6.96-6.89 (1H, m), 6.73 (1H, br), 5.50 (1H, s), 
5.34 (1H, d, J = 4.2 Hz), 4.76 (1H, t, J = 7.2 Hz), 4.70-4.56 (2H, m), 4.03 (1H, q, J = 4.8 
Hz), 3.93 (1H, dd, J = 8.3, 5.5 Hz), 3.64 (1H, dd, J = 9.3, 4.7 Hz), 3.50 (1H, dd, J = 8.9, 
5.8 Hz), 3.33-3.20 (7H, m), 3.08 (1H, dd, J = 14.1, 5.7 Hz), 1.62 (3H, d, J = 7.2 Hz), 
1.44-1.33 (12H, m), 1.14 (9H, s). 
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F. Results Of EKO Analysis On CTPs 
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1ava amy2/basi protein-protein complex from barley seed 
1awf novel covalent thrombin inhibitor from plant extract 
1bhx x-ray structure of the complex of human alpha thrombin WITH THE INHIBITOR 
SDZ 229-357 
1br1 smooth muscle myosin motor domain-essential light chain complex with 
mgadp.alf4 bound at the active site 
1e6y methyl-coenzyme m reductase from methanosarcina barkeri 
1eoc crystal structure of acinetobacter sp. Adp1 protocatechuate 3,4-dioxygenase in 
complex with 4-nitrocatechol 
1f3m crystal structure of human serine/threonine kinase pak1 
1fin cyclin a-cyclin-dependent kinase 2 complex 
1ghv methyl-coenzyme m reductase enzyme product complex 
1i3q rna polymerase ii crystal form i at 3.1 a resolution 
1icf crystal structure of mhc class ii associated p41 ii fragment in complex with 
cathepsin l 
1k8k Crystal Structure of Arp2/3 Complex 
1mmf Crystal structure of substrate free form of glycerol dehydrates 
1o2g Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active 
Site-Directed Serine Protease Inhibitors 
1okv cyclin a binding groove inhibitor h-arg-arg-leu-ile-phe-nh2 
1qhr novel covalent active site thrombin inhibitors 
1tbg beta-gamma dimer of the heterotrimeric g-protein transducin 
1tyg Structure of the thiazole synthase/ThiS complex 
1u2v Crystal structure of Arp2/3 complex with bound ADP and calcium 
1uc5 Structure of diol dehydratase complexed with (R)-1,2-propanediol 
1xf6 High resolution crystal structure of phycoerythrin 545 from the marine cryptophyte 
rhodomonas CS24 
2c5o differential binding of inhibitors to active and inactive cdk2 provides insights for 
drug design 
2cf4 pyrococcus horikoshii tet1 peptidase can assemble into a tetrahedron or a large 
octahedral shel 
2e2i RNA polymerase II elongation complex in 5 mM Mg+2 with 2'-dGTP 
70S T.Th. ribosome functional complex with mRNA and E- and P-site tRNAs at 4.5A. 
This entry contains 50S ribosomal subunit. The 30S ribosomal subunit can be found in 
PDB entry 
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2i40 Cdk2/Cyclin A complexed with a thiophene carboxamide inhibitor 
2icw Crystal structure of a complete ternary complex between TCR, superantigen, and 
peptide-MHC class II molecule 
2jkr ap2 clathrin adaptor core with Dileucine peptide RM(phosphoS)QIKRLLSE 
2jkt ap2 clathrin adaptor core with CD4 Dileucine peptide RM(phosphoS) EIKRLLSE Q 
to E mutant 
2p9k Crystal Structure of bovine Arp2/3 complex 
2pt7 phosducin/transducin 
2uze crystal structure of human cdk2 complexed with a thiazolidinone inhibitor 
2uzl crystal structure of human cdk2 complexed with a thiazolidinone inhibitor 
2wfy truncation and optimisation of peptide inhibitors of cdk2, cyclin a through structure 
guided design 
2wxv structure of cdk2-cyclin a with a pyrazolo(4,3-h) quinazoline-3-carboxamide 
inhibitor 
2xqy crystal structure of pseudorabies core fragment of glycoprotein h in complex with 
fab d6.3 
3dw8 Structure of a Protein Phosphatase 2A Holoenzyme with B55 subunit 
3dxk Structure of Bos Taurus Arp2/3 Complex with Bound Inhibitor CK0944636 
3dxm Structure of Bos taurus Arp2/3 Complex with Bound Inhibitor CK0993548 
3ej1 CDK2/CyclinA complexed with a pyrazolopyridazine inhibitor 
3euk Crystal structure of MukE-MukF(residues 292-443)-MukB(head domain)-
ATPgammaS complex, asymmetric dimer 
3gto Backtracked RNA polymerase II complex with 15mer RN 
3gyx Crystal structure of adenylylsulfate reductase from Desulfovibrio gigas 
3hiz Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha 
3k7a Crystal Structure of an RNA polymerase II-TFIIB complex 
3kow Crystal Structure of ornithine 4,5 aminomutase backsoaked complex 
3m1v Structural Insight into Methyl-Coenzyme M Reductase Chemistry using 
Coenzyme B Analogues 
3m2v Structural Insight into Methyl-Coenzyme M Reductase Chemistry using 
Coenzyme B Analogues 
3nbz Crystal structure of the HIV-1 Rev NES-CRM1-RanGTP nuclear export complex 
(crystal I) 
3nc1 Crystal structure of the CRM1-RanGTP complex 
3o4x Crystal structure of complex between amino and carboxy terminal fragments of 
mDia1 
3oe7 Structure of four mutant forms of yeast f1 ATPase: gamma-I270T 
3phf Crystal Structure of the Epstein-Barr virus gH and gL complex 
3q3o Toluene 4 monooxygenase HD complex with phenol 
3r66 RNA Polymerase II Initiation Complex 
3sdl Crystal structure of human ISG15 in complex with NS1 N-terminal region from 
influenza B virus, Northeast Structural Genomics Consortium Target IDs HX6481, 
HR2873, and OR2 
3sf5 Crystal Structure of Helicobacter pylori Urease Accessory Protein UreF/H complex 
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3sqg Crystal structure of a methyl-coenzyme M reductase purified from Black Sea mats 
3u9s Crystal structure of P. aeruginosa 3-methylcrotonyl-CoA carboxylase (MCC) 750 
kD holoenzyme, CoA complex 
4a0c structure of the cand1-cul4b-rbx1 complex 
4ds7 Crystal structure of yeast calmodulin bound to the C-terminal fragment of spindle 
pole body protein Spc110 
4g5r Structure of LGN GL4/Galphai3 complex 
4gq2 S. pombe Nup120-Nup37 complex 
 
 
 
 
 
 
 
1a14 complex between nc10 anti-influenza virus neuraminidase single chain antibody 
1a5k k217e variant of klebsiella aerogenes urease 
1a5l k217c variant of klebsiella aerogenes urease 
1a5m k217a variant of klebsiella aerogenes urease 
1a9x carbamoyl phosphate synthetase: caught in the act of glutamine hydrolysis 
1bpl glycosyltransferase 
1c30 crystal structure of carbamoyl phosphate synthetase: small subunit mutation c269s 
1c3o crystal structure of the carbamoyl phosphate synthetase: small subunit mutant 
c269s with bound glutamine 
1cc1 crystal structure of a reduced, active form of the ni-fe-se hydrogenase from 
desulfomicrobium baculatum 
1ce8 carbamoyl phosphate synthetase from escherichis coli with complexed with the 
allosteric ligand imp 
1cn4 erythropoietin complexed with extracellular domains of erythropoietin receptor 
1cs0 Crystal structure of carbamoyl phosphate synthetase complexed at CYS269 in the 
small subunit with the tetrahedral mimic l-glutamate gamma-semialdehyde 
1dtw human branched-chain alpha-keto acid dehydrogenase 
1ef2 crystal structure of manganese-substituted klebsiella aerogenes urease 
1efv three-dimensional structure of human electron transfer flavoprotein to 2.1 a 
resolution 
1ejs rystal Structure of the H219N Variant of Klebsiella Aerogenes Urease 
1f2u Crystal Structure of RAD50 ABC-ATPASE  
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1fwa klebsiella aerogenes 
1fwc klebsiella aerogenes 
1g8k crystal structure analysis of arsenite oxidase from alcaligenes faecalis 
1h0d crystal structure of human angiogenin in complex with fab fragment of its 
monoclonal antibody mab 26-2f 
1iwa rubisco from galdieria partita 
1jdb carbamoyl phosphate synthetase from escherichia coli 
1jju structure of a quinohemoprotein amine dehydrogenase with a unique redox cofactor 
and highly unusual crosslinking 
1jkh crystal structure of y181c mutant hiv-1 reverse transcriptase in complex with dmp- 
266(efavirenz) 
1jrh complex (antibody/antigen) 
1jw9 Structure of the Native MoeB-MoaD Protein Complex 
1jwa Structure of the ATP-bound MoeB-MoaD Protein Complex 
1kee Amidotransferase Activity of Carbamoyl Phosphate Synthetase by the Antibiotic 
Acivicin 
1krb crystal structure of klebsiella aerogenes urease, its apoenzyme and two active site 
mutants 
1krc crystal structure of klebsiella aerogenes urease, its apoenzyme and two active site 
mutants 
1lvc crystal structure of the adenylyl cyclase domain of anthrax edema factor (ef) in 
complex with calmodulin and 2' deoxy, 3' anthraniloyl atp 
1m6v crystal structure of the g359f (small subunit) point mutant of carbamoyl phosphate 
synthetase 
1mlc monoclonal antibody fab d44.1 raised against chicken egg-white lysozyme 
complexed with lysozyme 
1ni4 human pyruvate dehydrogenase 
1nmb comparison with the overlapping binding site of the nc41 antibody 
1nmc complex between nc10 anti-influenza virus neuraminidase single chain antibody 
with a 15 residue linker and influenza virus neuraminidase 
1occ structure of bovine heart cytochrome c oxidase at the fully oxidized state 
1oco bovine heart cytochrome c oxidase in carbon monoxide-bound state 
1ols roles of his291-alpha and his146-beta' in the reductive acylation reaction catalyzed 
by human branched-chain alpha-ketoacid dehydrogenase 
1pby Structure of the Phenylhydrazine Adduct of the Quinohemoprotein Amine 
Dehydrogenase from Paracoccus denitrificans at 1.7 A Resolution 
1pk0 Crystal Structure of the EF3-CaM complexed with PMEApp 
1qge new crystal form of pseudomonas glumae (formerly chromobacterium viscosum 
atcc 6918) lipase 
1rt4 hiv-1 reverse transcriptase complexed with uc781 
1rti high resolution structures of hiv-1 rt from four rt-inhibitor complexes 
1s26 Structure of Anthrax Edema Factor-Calmodulin-alpha,beta-methyleneadenosine 5'-
triphosphate Complex Reveals an Alternative Mode of ATP Binding to the Catalytic Site 
1t36 Crystal structure of E. coli carbamoyl phosphate synthetase small subunit mutant 
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C248D complexed with uridine 5'-monophosphate 
1t9g Structure of the human MCAD:ETF complex 
1tco ternary complex of a calcineurin a fragment, calcineurin b, fkbp12 and the 
immunosuppressant drug fk506 (tacrolimus) 
1u5b crystal structure of the human mitochondrial branched-chain alpha-ketoacid 
dehydrogenase 
1v11 crosstalk between cofactor binding and the phosphorylation loop conformation in 
the bckd machine 
1v16 crosstalk between cofactor binding and the phosphorylation loop conformation in 
the bckd machine 
1v1m crosstalk between cofactor binding and the phosphorylation loop conformation in 
the bckd machine 
1v54 bovine heart cytochrome c oxidase at the fully oxidized state 
1vrq crystal structure of heterotetrameric sarcosine oxidase from corynebacterium sp. U-
96 in complex with folinic acid 
1wci reactivity modulation of human molecular switch 
1wyw Crystal Structure of SUMO1-conjugated thymine DNA glycosylase 
1x31 Crystal Structure of Heterotetrameric Sarcosine Oxidase from Corynebacterium sp. 
U-96 
1xct Complex HCV core-Fab 19D9D6-Protein L mutant 
1yau Structure of Archeabacterial 20S proteasome- 
1yst structure of the photochemical reaction center of a spheroidene containing purple 
bacterium, rhodobacter sphaeroides y, at 3 angstroms resolution 
1zud Structure of ThiS-ThiF protein complex 
1zyr Structure of Thermus thermophilus RNA polymerase holoenzyme in complex with 
the antibiotic streptolydigin 
2b4j Structural basis for the recognition between HIV-1 integrase and LEDGF/p75 
2bfx mechanism of aurora-b activation by incenp and inhibition by hesperidin. 
2d07 Crystal Structure of SUMO-3-modified Thymine-DNA Glycosylase 
2d3c Crystal Structure of the Maize Glutamine Synthetase complexed with ADP and 
Phosphinothricin Phosphate 
2d6f Crystal structure of Glu-tRNA(Gln) amidotransferase in the complex with 
tRNA(Gln) 
2dd5 Thiocyanate hydrolase (SCNase) from Thiobacillus thioparus native holo-enzyme 
2dyr Bovine heart cytochrome C oxidase at the fully oxidized state 
2dys Bovine heart cytochrome C oxidase modified by DCCD 
2efc Ara7-GDP/AtVps9a 
2eho Crystal structure of human GINS complex 
2eij Bovine heart cytochrome C oxidase in the fully reduced state 
2eik Cadmium ion binding structure of bovine heart cytochrome C oxidase in the fully 
reduced state 
2fyn Crystal Structure Analysis of the double mutant Rhodobacter Sphaeroides bc1 
complex 
2gag Heteroteterameric sarcosine: structure of a diflavin metaloenzyme at 1.85 a 
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resolution 
2gah Heterotetrameric sarcosine: structure of a diflavin metaloenzyme at 1.85 a 
resolution 
2h1l The Structure of the Oncoprotein SV40 Large T Antigen and p53 Tumor 
Suppressor Complex 
2hjf Potassium channel kcsa-fab complex with tetrabutylammonium (TBA) 
2hwl Crystal structure of thrombin in complex with fibrinogen gamma' peptide 
2iaj Crystal Structure of K103N/Y181C Mutant HIV-1 Reverse Transcriptase (RT) in 
Complex with ATP 
2ie3 Structure of the Protein Phosphatase 2A Core Enzyme Bound to Tumor-inducing 
Toxins 
2ivf Ethylbenzene dehydrogenase from aromatoleum aromaticum 
2j9f human branched-chain alpha-ketoacid dehydrogenase-decarboxylase e1b 
2npp Structure of the Protein Phosphatase 2A Holoenzyme 
2nvx RNA polymerase II elongation complex in 5 mM Mg+2 with 2'-dUTP 
2nyl Crystal structure of Protein Phosphatase 2A (PP2A) holoenzyme with the catalytic 
subunit carboxyl terminus truncated 
2ozl Human pyruvate dehydrogenase S264E variant 
2r17 Functional architecture of the retromer cargo-recognition complex 
2v4j the crystal structure of desulfovibrio vulgaris dissimilatory sulfite reductase bound 
to dsrc provides novel insights into the mechanism of sulfate respiration 
2vg6 crystal structures of hiv-1 reverse transcriptase complexes with thiocarbamate non-
nucleoside inhibitors 
2vxq crystal structure of the major grass pollen allergen phl p 2 in complex with its 
specific ige-fab 
2vxt human il-18 complexed to murine reference antibody 125-2h fab 
2wbl structure of a binary rop-prone complex 
2wom crystal structure of uk-453061 bound to hiv-1 reverse transcriptase (k103n). 
2won crystal structure of uk-453061 bound to hiv-1 reverse transcriptase (wild-type). 
2wpn structure of the oxidised, as-isolated nifese hydrogenase from d. Vulgaris 
hildenborough 
2xsj structure of desulforubidin from desulfomicrobium norvegicum 
2xt9 crystal structure of mycobacterium smegmatis alpha-ketoglutarate decarboxylase in 
complex with gara. 
2y10 the crystal structure of ef-tu and trp-trna-trp bound to a cognate codon on the 70s 
ribosome. 
2y18 ef-tu and trp-trna-trp bound to a cognate codon on the 70s ribosome.  
2zt9 Crystal Structure of the Cytochrome b6f Complex from Nostoc sp. PCC 7120 
3alq Crystal structure of TNF-TNFR2 
3arc Crystal structure of oxygen-evolving Photosystem II at 1.9 angstrom resolution 
3b9k Crystal structure of CD8alpha-beta in complex with YTS 156.7 FAB 
3bpn Crystal structure of the IL4-IL4R-IL13Ra ternary complex 
3c5w Complex between PP2A-specific methylesterase PME-1 and PP2A core enzyme 
3clr Crystal structure of the R236A ETF mutant from M. methylotrophus 
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3clt Crystal structure of the R236E mutant of Methylophilus methylotrophus ETF 
3dbh Structural Dissection of a Gating Mechanism Preventing Misactivation of 
Ubiquitin by NEDD8's E1 (APPBP1-UBA3Arg190Ala-NEDD8Ala72Arg) 
3duf Snapshots of catalysis in the E1 subunit of the pyruvate dehydrogenase multi-
enzyme complex 
3ei3 Structure of the hsDDB1-drDDB2 complex 
3exe Crystal structure of the pyruvate dehydrogenase (E1p) component of human 
pyruvate 
3exf Crystal structure of the pyruvate dehydrogenase (E1p) component of human 
pyruvate dehydrogenase complex 
3f5w KcsA Potassium channel in the open-inactivated state with 32 A opening at T112 
3gtg Backtracked RNA polymerase II complex with 12mer RNA 
3gyx Crystal structure of adenylylsulfate reductase from Desulfovibrio gigas 
3h42 Crystal structure of PCSK9 in complex with Fab from LDLR competitive antibody 
3h9r Crystal structure of the kinase domain of type I activin receptor (ACVR1) in 
complex with FKBP12 and dorsomorphin 
3he6 Crystal structure of mouse CD1d-alpha-galactosylceramide with mouse Valpha14-
Vbeta8.2 NKT TCR 
3hpl KcsA E71H-F103A mutant in the closed state 
3i1q Crystal structure of the E. coli 70S ribosome in an intermediate state of ratcheting 
3jsm K65R mutant HIV-1 reverse transcriptase cross-linked to DS-DNA and complexed 
with tenofovir- diphosphate as the incoming nucleotide substrate 
3jvz E2~Ubiquitin-HECT 
3kow Crystal Structure of ornithine 4,5 aminomutase backsoaked complex 
3koy Crystal Structure of ornithine 4,5 aminomutase in complex with ornithine 
(Aerobic) 
3mm6 Dissimilatory sulfite reductase cyanide complex 
3mtu Structure of the Tropomyosin Overlap Complex from Chicken Smooth Muscle 
3oc3 Crystal structure of the Mot1 N-terminal domain in complex with TBP 
3oc6 Crystal structure of 6-phosphogluconolactonase from mycobacterium smegmatis, 
apo form 
3qa3 Crystal Structure of A-domain in complex with antibody 
3rzd RNA Polymerase II Initiation Complex with a 5-nt RNA 
3sn6 Crystal structure of the beta2 adrenergic receptor-Gs protein complex 
3uyf Crystal structure analysis of ribosomal decoding. this entry contains the 30s 
ribosomal subunit of the first 70s molecule in the asymmetric unit for the near-cognate 
trna-leu complex 
3v4y first Nuclear PP1 holoenzyme 
3vq2 Crystal structure of mouse TLR4/MD-2/LPS complex 
3ztx Aurora kinase selective inhibitors identified using a Taxol-induced checkpoint 
sensitivity screen. 
4a08 TRUCTURE OF HSDDB1-DRDDB2 BOUND TO A 13 BP CPD-DUPLEX 
(PURINE AT D-1 POSITION) AT 3.0 A 
4a1s Crystallographic structure of the Pins:Insc complex 
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4a3c RNA polymerase ii initial transcribing complex with a 5nt DNA-RNA HYBRID 
4a3l RNA polymerase ii initial transcribing complex with a 7nt dna-rna hybrid and 
soaked with ampcpp 
4a4b Structure of modified phosphoTyr371-c-Cbl-UbcH5B-ZAP-70 complex 
4al8 Structure of Dengue virus DIII in complex with Fab 2H12 
4ala Structure of Dengue virus DIII in complex with Fab 2H12 
4ap4 Rnf4 - ubch5a - ubiquitin heterotrimeric complex 
4ddg Crystal structure of human OTUB1/UbcH5b~Ub/Ub 
4erp Crystal structure of a gemcitabine-diphosphate inhibited E. coli class Ia 
ribonucleotide reductase complex 
4g8a Crystal structure of human TLR4 polymorphic variant D299G and T399I in 
complex with MD-2 and LPS 
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APPENDIX E 
EXPERIMENTAL FOR CHAPTER V 
 
 
A. EKO Results For Oxopiperazine Dimers 
 
 
DDL 
 
PDB 
ID RMSD Protein 
1hyr 0.20 ~0.30 
crystal structure of human mica in complex with natural killer 
cell receptor nkg2d 
1nu1 0.20 ~0.30 
Crystal Structure of Mitochondrial Cytochrome bc1 Complexed 
with 2-nonyl-4-hydroxyquinoline N-oxide (NQNO) 
1nw9 0.20 ~0.30 structure of caspase-9 in an inhibitory complex with xiap-bir3 
1s63 0.20 ~0.30 
Human protein farnesyltransferase complexed with L-778,123 
and FPP 
2h6i 0.20 ~0.30 
W102T/Y365F Protein Farnesyltransferase Double Mutant 
Complexed with a Geranylgeranylated DDPTASACVLS Peptide 
Product at 3.0A 
3gcx 0.20 ~0.30 PCSK9:EGFA 
3gtq 0.20 ~0.30 Backtracked RNA polymerase II complex induced by damage 
3ksq 0.20 ~0.30 Discovery of C-Imidazole Azaheptapyridine FPT Inhibitors 
3orv 0.20 ~0.30 
Crystal Structure of the Y294H-MauG/pre-Methylamine 
Dehydrogenase Complex 
3s1q 0.20 ~0.30 
RNA Polymerase II Initiation Complex with a 5-nt 3'-deoxy 
RNA soaked with ATP 
4gms 0.20 ~0.30 
Crystal structure of heterosubtypic Fab S139/1 in complex with 
influenza A H3 hemagglutinin 
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O
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DDD 
 
PDB 
ID RMSD Protein 
1acm 0.20~0.30 
arginine 54 in the active site of escherichia coli aspartate 
transcarbamoylase is critical for catalysis: a site-specific 
mutagenesis, nmr and x-ray crystallography study 
1at1 0.20~0.30 
crystal structures of phosphonoacetamide ligated t and 
phosphonoacetamide and malonate ligated r states of aspartate 
carbamoyltransferase at 2.8-angstroms resolution and neutral p*h 
1bhx 0.20~0.30 
x-ray structure of the complex of human alpha thrombin with the 
inhibitor sdz 229-357 
1bj1 0.20~0.30 
vascular endothelial growth factor in complex with a neutralizing 
antibody 
1dwb 0.20~0.30 
crystallographic analysis at 3.0-angstroms resolution of the 
binding to human thrombin of four active site-directed inhibitors 
1efv 0.20~0.30 
three-dimensional structure of human electron transfer 
flavoprotein to 2.1 a resolution 
1fzm 0.20~0.30 
mhc class i natural mutant h-2kbm8 heavy chain complexed with 
beta-2 microglobulin and vesicular stomatitis virus nucleoprotein 
1g20 0.20~0.30 
mgatp-bound and nucleotide-free structures of a nitrogenase 
protein complex between leu127del-fe protein and the mofe 
protein 
1g21 0.20~0.30 
mgatp-bound and nucleotide-free structures of a nitrogenase 
protein complex between leu127del-fe protein and the mofe 
protein 
1hhh 0.20~0.30 
the antigenic identity of peptide(slash)mhc complexes: a 
comparison of the conformation of five peptides presented by hla-
a2 
1hlt 0.20~0.30 
the structure of a nonadecapeptide of the fifth egf domain of 
thrombomodulin complexed with thrombin 
1hsb 0.20~0.30 
different length peptides bind to hla-aw68 similarly at their ends 
but bulge out in the middle 
1htl 0.20~0.30 
mutation of a buried residue causes lack of activity but no 
conformational change: crystal structure of e. coli heat-labile 
enterotoxin mutant val 97--> lys 
1i3q 0.20~0.30 RNA polymerase ii crystal form i at 3.1 a resolution 
1i6h 0.20~0.30 RNA polymerase ii elongation complex 
1jnr 0.20~0.30 
Structure of adenylylsulfate reductase from the hyperthermophilic 
Archaeoglobus fulgidus at 1.6 resolution 
1jnz 0.20~0.30 Structure of adenylylsulfate reductase from the hyperthermophilic 
N(R)N
O
O
(R)
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O
N(S)
O
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Archaeoglobus fulgidus at 1.6 resolution 
1jpf 0.20~0.30 
Crystal Structure Of The LCMV Peptidic Epitope Gp276 In 
Complex With The Murine Class I Mhc Molecule H-2Db 
1k8k 0.20~0.30 Crystal Structure of Arp2/3 Complex 
1kpu 0.20~0.30 
High resolution crystal structure of the MHC class I complex H-
2Kb/VSV8 
1lta 0.20~0.30 
2.2 angstroms crystal structure of e. coli heat-labile enterotoxin 
(lt) with bound galactose 
1n0w 0.20~0.30 Crystal structure of a RAD51-BRCA2 BRC repeat complex 
1n2c 0.20~0.30 
nitrogenase complex from azotobacter vinelandii stabilized by 
adp-tetrafluoroaluminate 
1ocr 0.20~0.30 bovine heart cytochrome c oxidase in the fully reduced state 
1ocz 0.20~0.30 bovine heart cytochrome c oxidase in azide-bound state 
1r0b 0.20~0.30 
Aspartate Transcarbamylase (ATCase) of Escherichia coli: A 
New Crystalline R State Bound to PALA, or to Product 
Analogues Phosphate and Citrate 
1s7s 0.20~0.30 
Crystal structures of the murine class I major histocompatibility 
complex H-2Kb in complex with LCMV-derived gp33 index 
peptide and three of its escape variants 
1tmb 0.20~0.30 
molecular basis for the inhibition of human alpha-thrombin by the 
macrocyclic peptide cyclotheonamide a 
1twc 0.20~0.30 RNA polymerase II complexed with GTP 
1twh 0.199 RNA polymerase II complexed with 2'dATP 
1u3h 0.20~0.30 
Crystal structure of mouse TCR 172.10 complexed with MHC 
class II I-Au molecule at 2.4 A 
1v55 0.20~0.30 Bovine heart cytochrome c oxidase at the fully reduced state 
1wby 0.20~0.30 
crystal structures of murine mhc class i h-2 db and kb molecules 
in complex with ctl epitopes from influenza a virus: implications 
for tcr repertoire selection and immunodominance 
1ya7 0.20~0.30 
Implications for interactions of proteasome with PAN and PA700 
from the 1.9 A structure of a proteasome-11S activator complex 
1yar 0.20~0.30 
Structure of Archeabacterial 20S proteasome mutant D9S- PA26 
complex 
1yau 0.20~0.30 Structure of Archeabacterial 20S proteasome- PA26 complex 
1yn6 0.20~0.30 
Crystal structure of a mouse MHC class I protein, H2-Db, in 
complex with a peptide from the influenza A acid polymerase 
1yn7 0.20~0.30 
Crystal structure of a mouse MHC class I protein, H2-Db, in 
complex with a mutated peptide (R7A) of the influenza A acid 
polymerase 
1zrt 0.20~0.30 
Rhodobacter capsulatus cytochrome bc1 complex with 
stigmatellin bound 
2a06 0.20~0.30 Bovine cytochrome bc1 complex with stigmatellin bound 
2b8k 0.20~0.30 12-subunit RNA Polymerase II 
2bto 0.20~0.30 structure of btuba from prosthecobacter dejongeii 
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2dyp 0.20~0.30 
Crystal Structure of LILRB2(LIR2/ILT4/CD85d) complexed with 
HLA-G 
2dys 0.20~0.30 Bovine heart cytochrome C oxidase modified by DCCD 
2e2i 0.200 
RNA polymerase II elongation complex in 5 mM Mg+2 with 2'-
dGTP 
2e2j 0.20~0.30 
RNA polymerase II elongation complex in 5 mM Mg+2 with 
GMPCPP 
2eij 0.20~0.30 Bovine heart cytochrome C oxidase in the fully reduced state 
2eim 0.20~0.30 
Zinc ion binding structure of bovine heart cytochrome C oxidase 
in the fully reduced state 
2esv 0.20~0.30 Structure of the HLA-E-VMAPRTLIL/KK50.4 TCR complex 
2fja 0.20~0.30 adenosine 5'-phosphosulfate reductase in complex with substrate 
2fjb 0.20~0.30 Adenosine-5'-phosphosulfate reductase im complex with products 
2fje 0.20~0.30 adenosine-5-phosphosulfate reductase oxidized state 
2fo4 0.186 
Enhanced MHC class I binding and immune responses through 
anchor modification of the non-canonical tumor associated 
MUC1-8 peptide 
2fp4 0.20~0.30 
Crystal structure of pig GTP-specific succinyl-CoA synthetase in 
complex with GTP 
2fpi 0.20~0.30 
Crystal structure of pig GTP-specific succinyl-CoA synthetase 
from polyethylene glycol 
2hsn 0.20~0.30 
Structural basis of yeast aminoacyl-tRNA synthetase complex 
formation revealed by crystal structures of two binary sub-
complexes 
2j01 0.20~0.30 
structure of the thermus thermophilus 70s ribosome complexed 
with mrna, trna and paromomycin (part 2 of 4). this file contains 
the 50s subunit from molecule i. 
2j03 0.20~0.30 
structure of the thermus thermophilus 70s ribosome complexed 
with mrna, trna and paromomycin (part 4 of 4). this file contains 
the 50s subunit from molecule ii. 
2j0s 0.20~0.30 
the crystal structure of the exon junction complex at 2.2 a 
resolution 
2j3t 0.20~0.30 the crystal structure of the bet3-trs33-bet5-trs23 complex. 
2ja5 0.20~0.30 CPD lesion containing RNA Polymerase II elongation complex A 
2ja6 0.20~0.30 CPD lesion containing RNA Polymerase II elongation complex B 
2nvq 0.20~0.30 
RNA Polymerase II Elongation Complex in 150 mM Mg+2 with 
2'dUTP 
2nvt 0.20~0.30 
RNA Polymerase II Elongation Complex in 150 mM Mg+2 with 
GMPCPP 
2nvx 0.20~0.30 
RNA polymerase II elongation complex in 5 mM Mg+2 with 2'-
dUTP 
2nxy 0.20~0.30 
HIV-1 gp120 Envelope Glycoprotein(S334A) Complexed with 
CD4 and Antibody 17b 
2ny4 0.20~0.30 
HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E268C, 
S334A, S375W) Complexed with CD4 and Antibody 17b 
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2p5e 0.20~0.30 
Crystal Structures of High Affinity Human T-Cell Receptors 
Bound to pMHC Reveal Native Diagonal Binding Geometry 
2p9p 0.20~0.30 
Crystal Structure of bovine Arp2/3 complex co-crystallized with 
ADP 
2qqn 0.20~0.30 Neuropilin-1 b1 Domain in Complex with a VEGF-Blocking Fab 
2r29 0.20~0.30 
Neutralization of dengue virus by a serotype cross-reactive 
antibody elucidated by cryoelectron microscopy and x-ray 
crystallography 
2r7z 0.20~0.30 
Cisplatin lesion containing RNA polymerase II elongation 
complex 
2r92 0.20~0.30 
Elongation complex of RNA polymerase II with artificial RdRP 
scaffold 
2rd5 0.20~0.30 
Structural basis for the regulation of N-acetylglutamate kinase by 
PII in Arabidopsis thaliana 
2uv8 0.20~0.30 
crystal structure of yeast fatty acid synthase with stalled acyl 
carrier protein at 3.1 angstrom resolution 
2wdl 0.142 
structure of the thermus thermophilus 70s ribosome in complex 
with mrna, paromomycin, acylated a- and p-site trnas, and e-site 
trna. this file contains the 50s subunit for molecule i. 
2wdn 0.143 
structure of the thermus thermophilus 70s ribosome in complex 
with mrna, paromomycin, acylated a- and p-site trnas, and e-site 
trna. this file contains the 50s subunit for molecule ii. 
3aec 0.20~0.30 
Crystal structure of porcine heart mitochondrial complex II bound 
with 2-Iodo-N-(1-methylethyl)-benzamid 
3c5z 0.20~0.30 
Crystal structure of mouse MHC class II I-Ab/3K peptide 
complexed with mouse TCR B3K506 
3d39 0.20~0.30 
The complex between TCR A6 and human Class I MHC HLA-
A2 with the modified HTLV-1 TAX (Y5(4-fluoroPhenylalanine)) 
peptide 
3dxm 0.20~0.30 
Structure of Bos taurus Arp2/3 Complex with Bound Inhibitor 
CK0993548 
3euh 0.20~0.30 Crystal Structure of the MukE-MukF Complex 
3fol 0.20~0.30 
Crystal structure of the Class I MHC Molecule H-2Kwm7 with a 
Single Self Peptide VNDIFERI 
3fqr 0.20~0.30 
Phosphorylation of self-peptides alters Human Leukocyte 
Antigen Class I-restricted antigen presentation and generates 
tumor specific epitopes 
3g43 0.20~0.30 
Crystal structure of the calmodulin-bound Cav1.2 C-terminal 
regulatory domain dimer 
3g5o 0.20~0.30 
The crystal structure of the toxin-antitoxin complex RelBE2 
(Rv2865-2866) from Mycobacterium tuberculosis 
3gso 0.20~0.30 
Crystal structure of the binary complex between HLA-A2 and 
HCMV NLV peptide 
3gtl 0.20~0.30 
Backtracked RNA polymerase II complex with 13mer with 
G<>U mismatch 
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3gtq 0.20~0.30 Backtracked RNA polymerase II complex induced by damage 
3how 0.20~0.30 
Complete RNA polymerase II elongation complex III with a T-U 
mismatch and a frayed RNA 3'-uridine 
3hoy 0.20~0.30 Complete RNA polymerase II elongation complex VI 
3i4m 0.20~0.30 
8-oxoguanine containing RNA polymerase II elongation complex 
D 
3jse 0.20~0.30 
Crystal structure of archaeal 20S proteasome in complex with 
mutated P26 activator 
3jvt 0.20~0.30 
Calcium-bound Scallop Myosin Regulatory Domain (Lever Arm) 
with Reconstituted Complete Light Chains 
3k7a 0.20~0.30 Crystal Structure of an RNA polymerase II-TFIIB complex 
3kir 0.137 
Structure of RelE nuclease bound to the 70S ribosome 
(precleavage state; Part 2 of 4) 
3kit 0.137 
Structure of RelE nuclease bound to the 70S ribosome 
(precleavage state; Part 4 of 4) 
3kiy 0.177 
Structure of RelE nuclease bound to the 70S ribosome 
(postcleavage state; Part 4 of 4) 
3kno 0.20~0.30 
The structures of capreomycin bound to the 70S ribosome. THIS 
FILE CONTAINS THE 50S SUBUNIT FOR MOLECULE II 
3l4m 0.204 
Crystal Structure of the MauG/pre-Methylamine Dehydrogenase 
Complex. 
3l4o 0.20~0.30 
Crystal Structure of the MauG/pre-Methylamine Dehydrogenase 
Complex After Treatment with Hydrogen Peroxide 
3loh 0.20~0.30 Structure of the insulin receptor ectodomain, including ct peptide 
3m3y 0.20~0.30 RNA polymerase II elongation complex C 
3m4o 0.20~0.30 RNA polymerase II elongation complex B 
3mrf 0.189 
Crystal Structure of MHC class I HLA-A2 molecule complexed 
with EBV bmlf1-280-288 nonapeptide T4P variant 
3mrn 0.20~0.30 
Crystal Structure of MHC class I HLA-A2 molecule complexed 
with HCV NS4b-1807-1816 decapeptide 
3n40 0.20~0.30 
Crystal structure of the immature envelope glycoprotein complex 
of Chikungunya virus. 
3n44 0.20~0.30 
Crystal structure of the mature envelope glycoprotein complex 
(trypsin cleavage; Osmium soak) of Chikungunya virus. 
3ndy 0.20~0.30 
The structure of the catalytic and carbohydrate binding domain of 
endoglucanase D from Clostridium cellulovorans 
3ndz 0.20~0.30 
The structure of the catalytic and carbohydrate binding domain of 
endoglucanase D from Clostridium cellulovorans bound to 
cellotriose 
3oat 0.20~0.30 
Crystal structure of the E. coli ribosome bound to telithromycin. 
This file contains the 50S subunit of the first 70S ribosome with 
telithromycin bound. 
3oh5 0.20~0.30 
Structure of the Thermus Thermophilus 70S ribosome complexed 
with chloramphenicol. This file contains the 50S subunit of one 
70S ribosome. The entire crystal structure contains two 70S 
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ribosomes. 
3ora 0.20~0.30 
Crystal structure of the E. coli ribosome bound to CEM-101. This 
file contains the 30S subunit of the second 70S ribosome. 
3po3 0.20~0.30 Arrested RNA Polymerase II reactivation intermediate 
3pxs 0.20~0.30 
Crystal Structure of Diferrous MauG in Complex with Pre-
Methylamine Dehydrogenase: 
3pxt 0.20~0.30 
Crystal Structure of Ferrous CO Adduct of MauG in Complex 
with Pre-Methylamine Dehydrogenase 
3pxw 0.20~0.30 
Crystal Structure of Ferrous NO Adduct of MauG in Complex 
with Pre-Methylamine Dehydrogenase 
3q7f 0.20~0.30 
Cryptococcus neoformans protein farnesyltransferase in complex 
with FPP and ethylenediamine inhibitor 1 
3qt1 0.20~0.30 
RNA polymerase II variant containing A Chimeric RPB9-C11 
subunit 
3rae 0.20~0.30 
Quinolone(Levofloxacin)-DNA cleavage complex of type IV 
topoisomerase from S. pneumoniae 
3raf 0.20~0.30 
Quinazolinedione-DNA cleavage complex of type IV 
topoisomerase from S. pneumoniae 
3rfr 0.20~0.30 
Crystal Structure of particulate methane monooxygenase 
(pMMO) from Methylocystis sp. strain M 
3rgb 0.20~0.30 
Crystal structure of particulate methane monooxygenase from 
Methylococcus capsulatus (Bath) 
3rlm 0.20~0.30 
Structure of the W199F MauG/pre-Methylamine Dehydrogenase 
complex after treatment with hydrogen peroxide 
3rmz 0.20~0.30 
Crystal Structure of the W199F-MauG/pre-Methylamine 
Dehydrogenase Complex 
3rn0 0.20~0.30 
Crystal Structure of the W199K-MauG/pre-Methylamine 
Dehydrogenase Complex 
3rn1 0.20~0.30 
Crystal Structure of the W199E-MauG/pre-Methylamine 
Dehydrogenase Complex 
3rzd 0.20~0.30 RNA Polymerase II Initiation Complex with a 5-nt RNA 
3rzo 0.20~0.30 RNA Polymerase II Initiation Complex with a 4-nt RNA 
3s15 0.194 RNA Polymerase II Initiation Complex with a 7-nt RNA 
3s16 0.20~0.30 RNA Polymerase II Initiation Complex with an 8-nt RNA 
3s17 0.20~0.30 RNA Polymerase II Initiation Complex with a 9-nt RNA 
3s1n 0.20~0.30 
RNA Polymerase II Initiation Complex with a 5-nt RNA (variant 
2) 
3s1q 0.20~0.30 
RNA Polymerase II Initiation Complex with a 5-nt 3'-deoxy RNA 
soaked with ATP 
3s1r 0.20~0.30 
RNA Polymerase II Initiation Complex with a 5-nt 3'-deoxy RNA 
soaked with GTP 
3s2d 0.195 
RNA Polymerase II Initiation Complex with a 5-nt RNA 
containing a 5Br-U 
3sic 0.20~0.30 
MOLECULAR RECOGNITION AT THE ACTIVE SITE OF 
subtilisin bpn': crystallographic studies using genetically 
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engineered proteinaceous inhibitor ssi (streptomyces subtilisin 
inhibitor) 
3sjl 0.20~0.30 
Crystal Structure of the P107S-MauG/pre-Methylamine 
Dehydrogenase Complex 
3svw 0.20~0.30 
Crystal Structure of the P107V-MauG/pre-Methylamine 
Dehydrogenase Complex 
3sws 0.20~0.30 
Crystal Structure of the Quinone Form of Methylamine 
Dehydrogenase in Complex with the Diferric Form of MauG 
3sxt 0.20~0.30 
Crystal Structure of the Quinol Form of Methylamine 
Dehydrogenase in Complex with the Diferrous Form of MauG 
3u9s 0.20~0.30 
Crystal structure of P. aeruginosa 3-methylcrotonyl-CoA 
carboxylase (MCC) 750 kD holoenzyme, CoA complex 
3utq 0.20~0.30 Human HLA-A*0201-ALWGPDPAAA 
3vh5 0.20~0.30 
Crystal structure of the chicken CENP-T histone fold/CENP-
W/CENP-S/CENP-X heterotetrameric complex, crystal form I 
3vj6 0.20~0.30 Structure of the MHC class Ib molecule Qa-1b 
3zvk 0.20~0.30 
Crystal structure of VapBC2 from Rickettsia felis bound to a 
DNA fragment from their promoter 
4a3e 0.20~0.30 
RNA polymerase ii initial transcribing complex with a 5nt dna-
rna hybrid and soaked with ampcpp 
4a3f 0.20~0.30 
RNA polymerase ii initial transcribing complex with a 6nt dna-
rna hybrid and soaked with ampcpp 
4a3g 0.20~0.30 
RNA Polymerase II initial transcribing complex with a 2nt DNA-
RNA hybrid 
4a3i 0.20~0.30 RNA Polymerase II binary complex with DNA 
4a3m 0.20~0.30 
RNA polymerase ii initial transcribing complex with a 4nt dna-
rna hybrid and soaked with ampcpp 
4b1o 0.20~0.30 Archaeal RNAP-DNA binary complex at 4.32Ang 
4b1p 0.20~0.30 Archaeal RNAP-DNA binary complex at 4.32Ang 
4ba1 0.20~0.30 
Archaeal exosome (Rrp4-Rrp41(D182A)-Rrp42) bound to 
inorganic phosphate 
4ba2 0.20~0.30 
Archaeal exosome (Rrp4-Rrp41(D182A)-Rrp42) bound to 
inorganic phosphate 
4dgl 0.20~0.30 Crystal Structure of the CK2 Tetrameric Holoenzyme 
4div 0.127 
The structure of a 1.8 MDa viral genome injection device 
suggests alternative infection mechanisms 
4elz 0.20~0.30 CCDBVFI:GYRA14VFI 
4fxe 0.20~0.30 
Crystal structure of the intact E. coli RelBE toxin-antitoxin 
complex 
4fxk 0.20~0.30 Human complement C4 
8atc 0.20~0.30 
complex of n-phosphonacetyl-l-aspartate with aspartate 
carbamoyltransferase. x-ray refinement, analysis of 
conformational changes and catalytic and allosteric mechanisms 
 
 
 
	   166	  
 
DLD 
 
PDB 
ID RMSD Protein 
1eiy 0.186 
the crystal structure of phenylalanyl-trna synthetase from thermus 
thermophilus complexed with cognate trnaphe 
1g20 0.20~0.27 
mgatp-bound and nucleotide-free structures of a nitrogenase 
protein complex between leu127del-fe protein and the mofe 
protein 
1jmu 0.20~0.27 Crystal Structure of the Reovirus mu1/sigma3 Complex 
1m1j 0.20~0.27 
Crystal structure of native chicken fibrinogen with two different 
bound ligands 
1o7g 0.20~0.27 
naphthalene 1,2-dioxygenase with naphthalene bound in the 
active site. 
1oco 0.20~0.27 
bovine heart cytochrome c oxidase in carbon monoxide-bound 
state 
1ocr 0.20~0.27 bovine heart cytochrome c oxidase in the fully reduced state 
1ocz 0.20~0.27 bovine heart cytochrome c oxidase in azide-bound state 
1qlb 0.20~0.27 
respiratory complex II-like fumarate reductase from Wolinella 
succinogenes 
1s9k 0.20~0.27 
Crystal Structure of Human NFAT1 and Fos-Jun on the IL-2 
ARRE1 Site 
1sqb 0.20~0.27 Crystal Structure Analysis of Bovine Bc1 with Azoxystrobin 
1sqq 0.20~0.27 
Crystal Structure Analysis of Bovine Bc1 with Methoxy Acrylate 
Stilbene (MOAS) 
1sqv 0.20~0.27 Crystal Structure Analysis of Bovine Bc1 with UHDBT 
1unn 0.20~0.27 
complex of beta-clamp processivity factor and little finger 
domain of poliv 
1ynj 0.20~0.27 Taq RNA polymerase-Sorangicin complex 
1zvy 0.20~0.27 
Crystal structure of the VHH D3-L11 in complex with hen egg 
white lysozyme 
2afh 0.20~0.27 Crystal Structure of Nucleotide-Free Av2-Av1 Complex 
2bs2 0.20~0.27 quinol:fumarate reductase from wolinella succinogenes 
2bs3 0.20~0.27 
glu c180 -> gln variant quinol:fumarate reductase from wolinella 
succinogenes 
2bs4 0.20~0.27 
glu c180 -> ile variant quinol:fumarate reductase from wolinella 
succinogenes 
2eim 0.20~0.27 
Zinc ion binding structure of bovine heart cytochrome C oxidase 
in the fully reduced state 
2gaf 0.20~0.27 Crystal Structure of the Vaccinia Polyadenylate Polymerase 
N(R)N
O
O
(S) N
O
N(S)
O
(R)CONH2
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Heterodimer (apo form) 
2ja5 0.20~0.27 CPD lesion containing RNA Polymerase II elongation complex A 
2ja8 0.20~0.27 cpd lesion containing rna polymerase ii elongation complex d 
2pjr 0.150 helicase product complex 
2qov 0.20~0.27 
Crystal structure of the bacterial ribosome from Escherichia coli 
in complex with spectinomycin. This file contains the 50S 
subunit of the first 70S ribosome. The entire crystal structure 
contains two 70S ribosomes. 
2qox 0.20~0.27 
Crystal structure of the bacterial ribosome from Escherichia coli 
in complex with spectinomycin. This file contains the 50S 
subunit of the second 70S ribosome. The entire crystal structure 
contains two 70S ribosomes. 
2r92 0.20~0.27 
Elongation complex of RNA polymerase II with artificial RdRP 
scaffold 
2vpy 0.20~0.27 
polysulfide reductase with bound quinone inhibitor, 
pentachlorophenol (pcp) 
2waq 0.20~0.27 
the complete structure of the archaeal 13-subunit dna-directed rna 
polymerase 
2wvr 0.20~0.27 human cdt1:geminin complex 
2xsj 0.20~0.27 structure of desulforubidin from desulfomicrobium norvegicum 
3gtg 0.20~0.27 Backtracked RNA polymerase II complex with 12mer RNA 
3gtm 0.20~0.27 Co-complex of Backtracked RNA polymerase II with TFIIS 
3hov 0.20~0.27 Complete RNA polymerase II elongation complex II 
3hox 0.200 Complete RNA polymerase II elongation complex V 
3hoy 0.20~0.27 Complete RNA polymerase II elongation complex VI 
3po2 0.20~0.27 Arrested RNA Polymerase II elongation complex 
3qjr 0.20~0.27 
The structure of and photolytic induced changes of carbon 
monoxide binding to the cytochrome ba3-oxidase from Thermus 
thermophilus 
3rzd 0.20~0.27 RNA Polymerase II Initiation Complex with a 5-nt RNA 
3s15 0.20~0.27 RNA Polymerase II Initiation Complex with a 7-nt RNA 
3s17 0.20~0.27 RNA Polymerase II Initiation Complex with a 9-nt RNA 
3s1m 0.20~0.27 
RNA Polymerase II Initiation Complex with a 5-nt RNA (variant 
1) 
3s3d 0.20~0.27 
Structure of Thermus thermophilus cytochrome ba3 oxidase 480s 
after Xe depressurization 
3s6n 0.20~0.27 
Crystal Structure of the Gemin2-binding domain of SMN, 
Gemin2 in Complex with SmD1/D2/F/E/G from Human 
3thm 0.194 
Crystal structure of Fas receptor extracellular domain in complex 
with Fab EP6b_B01 
3tje 0.20~0.27 
Crystal structure of Fas receptor extracellular domain in complex 
with Fab E09 
3uzv 0.140 
Crystal structure of the dengue virus serotype 2 envelope protein 
domain III in complex with the variable domains of Mab 4E11 
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4a3c 0.20~0.27 
RNA polymerase ii initial transcribing complex with a 5nt dna-
rna hybrid 
4a3g 0.20~0.27 
RNA Polymerase II initial transcribing complex with a 2nt DNA-
RNA hybrid 
4a3i 0.20~0.27 RNA Polymerase II binary complex with DNA 
4a3j 0.20~0.27 
rna polymerase ii initial transcribing complex with a 2nt dna-rna 
hybrid and soaked with gmpcpp 
4a3k 0.20~0.27 
RNA polymerase ii initial transcribing complex with a 7nt dna-
rna hybrid 
4a3l 0.20~0.27 
RNA polymerase ii initial transcribing complex with a 7nt dna-
rna hybrid and soaked with ampcpp 
4a3m 0.20~0.27 
RNA polymerase ii initial transcribing complex with a 4nt dna-
rna hybrid and soaked with ampcpp 
 
 
 
 
DLL 
 
PDB 
ID RMSD Protein 
1bmf 0.163 bovine mitochondrial f1-atpase 
1cow 0.140 bovine mitochondrial f1-atpase complexed with aurovertin b 
1e1q 0.153 bovine mitochondrial f1-atpase at 100k 
1e1r 0.20~0.21 
bovine mitochondrial f1-atpase inhibited by mg2+adp and 
aluminium fluoride 
1efr 0.154 
bovine mitochondrial f1-atpase complexed with the peptide 
antibiotic efrapeptin 
1g21 0.20~0.21 
mgatp-bound and nucleotide-free structures of a nitrogenase 
protein complex between leu127del-fe protein and the mofe 
protein 
1h8e 0.144 
(adp.alf4)2(adp.so4) bovine f1-atpase (all three catalytic sites 
occupied) 
1h8h 0.142 Bovine mitochondrial F1-Atpase at 100K 
1i3q 0.166 rna polymerase ii crystal form i at 3.1 a resolution 
1i9r 0.128 
structure of cd40l in complex with the fab fragment of humanized 
5c8 antibody 
1jyo 0.20~0.21 
Structure of the Salmonella Virulence Effector SptP in Complex 
with its Secretion Chaperone SicP 
1k83 0.20~0.21 
Crystal Structure of Yeast RNA Polymerase II Complexed with 
the Inhibitor Alpha Amanitin 
1ncd 0.20~0.21 
refined crystal structure of the influenza virus n9 neuraminidase-
nc41 fab complex 
N(S)N
O
O
(S) N
O
N(S)
O
(R) CONH2
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1oco 0.20~0.21 
bovine heart cytochrome c oxidase in carbon monoxide-bound 
state 
1ocr 0.20~0.21 bovine heart cytochrome c oxidase in the fully reduced state 
1ocz 0.20~0.21 bovine heart cytochrome c oxidase in azide-bound state 
1ohh 0.20~0.21 
bovine mitochondrial f1-atpase complexed with the inhibitor 
protein if1 
1ol5 0.193 
structure of aurora-a 122-403, phosphorylated on thr287, thr288 
and bound to tpx2 1-43 
1otc 0.20~0.21 
the o. nova telomere end binding protein complexed with single 
strand dna 
1ph5 0.20~0.21 
crystal structure of the oxytricha nova telomere end-binding 
protein complexed with noncognate ssdna ggggttttg(3dr)gg 
1pss 0.20~0.21 
crystallographic analyses of site-directed mutants of the 
photosynthetic reaction center from rhodobacter sphaeroides 
1qlb 0.20~0.21 
respiratory complex II-like fumarate reductase from Wolinella 
succinogenes 
1tb6 0.20~0.21 
2.5A Crystal Structure of the Antithrombin-Thrombin-Heparin 
Ternary Complex 
1tfk 0.20~0.21 
Ribonuclease from Escherichia coli complexed with its inhibtor 
protein 
1tfo 0.20~0.21 
Ribonuclease from Escherichia coli complexed with its inhibitor 
protein 
1tzh 0.20~0.21 Crystal Structure of the Fab YADS1 Complexed with h-VEGF 
1v55 0.20~0.21 Bovine heart cytochrome c oxidase at the fully reduced state 
1v74 0.20~0.21 ribonuclease-inhibitor complex 
1w0j 0.186 Beryllium fluoride inhibited bovine F1-ATPase 
1xx9 0.20~0.21 
Crystal Structure of the FXIa Catalytic Domain in Complex with 
EcotinM84R 
1xxd 0.20~0.21 
Crystal Structure of the FXIa Catalytic Domain in Complex with 
mutated Ecotin 
1xxf 0.20~0.21 
Crystal Structure of the FXIa Catalytic Domain in Complex with 
Ecotin Mutant (EcotinP) 
1yq4 0.20~0.21 
Avian respiratory complex ii with 3-nitropropionate and 
ubiquinone 
2a0l 0.20~0.21 Crystal structure of KvAP-33H1 Fv complex 
2aep 0.20~0.21 
An epidemiologically significant epitope of a 1998 influenza 
virus neuraminidase forms a highly hydrated interface in the NA-
antibody complex. 
2aeq 0.20~0.21 
An epidemiologically significant epitope of a 1998 influenza 
virus neuraminidase forms a highly hydrated interface in the NA-
antibody complex. 
2b1x 0.20~0.21 
Crystal structure of naphthalene 1,2-dioxygenase from 
Rhodococcus sp. 
2bki 0.20~0.21 myosin vi nucleotide-free (mdinsert2-iq) crystal structure 
2bs2 0.193 quinol:fumarate reductase from wolinella succinogenes 
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2bs3 0.196 
glu c180 -> gln variant quinol:fumarate reductase from wolinella 
succinogenes 
2bs4 0.20~0.21 
glu c180 -> ile variant quinol:fumarate reductase from wolinella 
succinogenes 
2ck3 0.20~0.21 Azide inhibited bovine F1-ATPase 
2e2h 0.20~0.21 
RNA polymerase II elongation complex at 5 mM Mg2+ with 
GTP 
2e2j 0.20~0.21 
RNA polymerase II elongation complex in 5 mM Mg+2 with 
GMPCPP 
2eil 0.20~0.21 
Cadmium ion binding structure of bovine heart cytochrome C 
oxidase in the fully oxidized state 
2eim 0.20~0.21 
Zinc ion binding structure of bovine heart cytochrome C oxidase 
in the fully reduced state 
2ein 0.199 
Zinc ion binding structure of bovine heart cytochrome C oxidase 
in the fully oxidized state 
2hh1 0.20~0.21 
Reaction centre from Rhodobacter sphaeroides strain R-26.1 
complexed with dibrominated phosphatidylcholine 
2hit 0.20~0.21 
Reaction centre from Rhodobacter sphaeroides strain R-26.1 
complexed with dibrominated phosphatidylethanolamine 
2iou 0.20~0.21 
Major Tropism Determinant P1 (Mtd-P1) Variant Complexed 
with Bordetella brochiseptica Virulence Factor Pertactin 
extracellular domain (Prn-E). 
2ja5 0.20~0.21 CPD lesion containing RNA Polymerase II elongation complex A 
2jdi 0.20~0.21 
ground state structure of f1-atpase from bovine heart 
mitochondria (bovine f1-atpase crystallised in the absence of 
azide) 
2nvt 0.20~0.21 
RNA Polymerase II Elongation Complex in 150 mM Mg+2 with 
GMPCPP 
2nvz 0.20~0.21 
RNA Polymerase II elongation complex with UTP, updated 
11/2006 
2o8m 0.20~0.21 
Crystal structure of the S139A mutant of Hepatitis C Virus 
NS3/4A protease 
2ooy 0.20~0.21 
Crystal structure of the adenylate sensor from AMP-activated 
protein kinase complexed with ATP 
2pjy 0.20~0.21 
Structural basis for cooperative assembly of the TGF-beta 
signaling complex 
2qjb 0.20~0.21 
Crystal structure analysis of BMP-2 in complex with BMPR-IA 
variant IA/IB 
2qy0 0.20~0.21 
Active dimeric structure of the catalytic domain of C1r reveals 
enzyme-product like contacts 
2r6g 0.20~0.21 The Crystal Structure of the E. coli Maltose Transporter 
2v4j 0.20~0.21 
the crystal structure of desulfovibrio vulgaris dissimilatory sulfite 
reductase bound to dsrc provides novel insights into the 
mechanism of sulfate respiration 
2v7q 0.20~0.21 the structure of f1-atpase inhibited by i1-60his, a monomeric 
	   171	  
form of the inhibitor protein, if1. 
2w6h 0.163 
low resolution structures of bovine mitochondrial f1-atpase 
during controlled dehydration: hydration state 4a. 
2w6i 0.162 
low resolution structures of bovine mitochondrial f1-atpase 
during controlled dehydration: hydration state 4b. 
2wbl 0.20~0.21 three-dimensional structure of a binary rop-prone complex 
2wwx 0.20~0.21 
crystal structure of the sidm/drra(gef/gdf domain)-rab1 (gtpase 
domain) complex 
2xnd 0.20~0.21 crystal structure of bovine f1-c8 sub-complex of atp synthase 
2xok 0.20~0.21 refined structure of yeast f1c10 atpase complex to 3 a resolution 
2xsj 0.181 structure of desulforubidin from desulfomicrobium norvegicum 
3arc 0.20~0.21 
Crystal structure of oxygen-evolving Photosystem II at 1.9 
angstrom resolution 
3ayh 0.20~0.21 
Crystal structure of the C17/25 subcomplex from S. pombe RNA 
Polymerase III 
3b1j 0.20~0.21 
Crystal structure of Glyceraldehyde-3-Phosphate Dehydrogenase 
complexed with CP12 in the presence of copper from 
Synechococcus elongatus 
3d0g 0.20~0.21 
Crystal structure of spike protein receptor-binding domain from 
the 2002-2003 SARS coronavirus human strain complexed with 
human-civet chimeric receptor ACE2 
3dta 0.20~0.21 
E(L212)Q, N(M44)D double mutant structure of photosynthetic 
reaction center from Rhodobacter sphaeroides 
3dtr 0.20~0.21 
E(L212)Q, L(L227)F double mutant structure of photosynthetic 
reaction center from Rhodobacter sphaeroides 
3e5a 0.20~0.21 Crystal structure of Aurora A in complex with VX-680 and TPX2 
3ehb 0.20~0.21 
A D-Pathway Mutation Decouples the Paracoccus Denitrificans 
Cytochrome c Oxidase by Altering the side chain orientation of a 
distant, conserved Glutamate 
3fki 0.20~0.21 12-Subunit RNA Polymerase II Refined with Zn-SAD data 
3grw 0.141 FGFR3 in complex with a Fab 
3how 0.20~0.21 
Complete RNA polymerase II elongation complex III with a T-U 
mismatch and a frayed RNA 3'-uridine 
3hox 0.20~0.21 Complete RNA polymerase II elongation complex V 
3hoz 0.20~0.21 
Complete RNA polymerase II elongation complex IV with a T-U 
mismatch and a frayed RNA 3'-guanine 
3jza 0.20~0.21 
Crystal structure of human Rab1b in complex with the GEF 
domain of DrrA/SidM from Legionella pneumophila 
3kcg 0.20~0.21 
Crystal structure of the antithrombin-factor IXa-pentasaccharide 
complex 
3knl 0.20~0.21 
The structures of Capreomycin bound to the 70S ribosome. THIS 
FILE CONTAINS THE 30S SUBUNIT FOR MOLECULE I 
3m32 0.20~0.21 
Structural Insight into Methyl-Coenzyme M Reductase Chemistry 
using Coenzyme B Analogues 
3m4o 0.20~0.21 RNA polymerase II elongation complex B 
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3ogk 0.20~0.21 
Structure of COI1-ASK1 in complex with coronatine and an 
incomplete JAZ1 degron 
3or2 0.194 Crystal structure of dissimilatory sulfite reductase II (DsrII) 
3po2 0.20~0.21 Arrested RNA Polymerase II elongation complex 
3puv 0.20~0.21 
Crystal Structure of an outward-facing MBP-Maltose transporter 
complex bound to ADP-VO4 
3pux 0.20~0.21 
Crystal Structure of an outward-facing MBP-Maltose transporter 
complex bound to ADP-BeF3 
3puz 0.20~0.21 
Crystal Structure of a pre-translocation state MBP-Maltose 
transporter complex bound to AMP-PNP 
3raf 0.20~0.21 
Quinazolinedione-DNA cleavage complex of type IV 
topoisomerase from S. pneumoniae 
3rfr 0.20~0.21 
Crystal Structure of particulate methane monooxygenase 
(pMMO) from Methylocystis sp. strain M 
3ryc 0.20~0.21 Tubulin: RB3 stathmin-like domain complex 
3ryf 0.20~0.21 GTP-Tubulin: RB3 Stathmin-like domain complex 
3rzo 0.20~0.21 RNA Polymerase II Initiation Complex with a 4-nt RNA 
3s1r 0.20~0.21 
RNA Polymerase II Initiation Complex with a 5-nt 3'-deoxy RNA 
soaked with GTP 
3s2h 0.20~0.21 
RNA Polymerase II Initiation Complex with a 6-nt RNA 
containing a 2[prime]-iodo ATP 
3s3x 0.20~0.21 
Structure of chicken acid-sensing ion channel 1 AT 3.0 A 
resolution in complex with psalmotoxin 
3tdh 0.20~0.21 
Structure of the regulatory fragment of sccharomyces cerevisiae 
AMPK in complex with AMP 
3thm 0.20~0.21 
Crystal structure of Fas receptor extracellular domain in complex 
with Fab EP6b_B01 
3tje 0.20~0.21 
Crystal structure of Fas receptor extracellular domain in complex 
with Fab E09 
4a3g 0.20~0.21 
RNA Polymerase II initial transcribing complex with a 2nt DNA-
RNA hybrid 
4a3i 0.20~0.21 RNA Polymerase II binary complex with DNA 
4a3k 0.20~0.21 
RNA polymerase ii initial transcribing complex with a 7nt dna-
rna hybrid 
4a3l 0.20~0.21 
RNA polymerase ii initial transcribing complex with a 7nt dna-
rna hybrid and soaked with ampcpp 
4asu 0.155 
F1-ATPase in which all three catalytic sites contain bound 
nucleotide, with magnesium ion released in the Empty site 
4ayb 0.20~0.21 RNAP at 3.2Ang 
4b1o 0.20~0.21 Archaeal RNAP-DNA binary complex at 4.32Ang 
4b1p 0.20~0.21 Archaeal RNAP-DNA binary complex at 4.32Ang 
4efa 0.20~0.21 
Crystal Structure of the Heterotrimeric EGChead Peripheral Stalk 
Complex of the Yeast Vacuolar ATPase - second conformation 
4f61 0.20~0.21 Tubulin:Stathmin-like domain complex 
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4fhm 0.20~0.21 
Nup37-Nup120(aa1-961) complex from Schizosaccharomyces 
pombe 
4gms 0.20~0.21 
Crystal structure of heterosubtypic Fab S139/1 in complex with 
influenza A H3 hemagglutinin 
 
 
 
 
LDD 
 
PDB 
ID RMSD Protein 
1aa1 0.20~0.30 
activated spinach rubisco in complex with the product 3-
phosphoglycerate 
2djg 0.20~0.30 
Re-determination of the native structure of human dipeptidyl 
peptidase I (cathepsin C) 
2qjb 0.20~0.30 
Crystal structure analysis of BMP-2 in complex with BMPR-IA 
variant IA/IB 
3r8s 0.20~0.30 
Structures of the bacterial ribosome in classical and hybrid states 
of tRNA binding 
 
 
 
 
LDL 
 
PDB 
ID RMSD Protein 
1hys 0.20~0.30 
crystal structure of hiv-1 reverse transcriptase in complex with a 
polypurine tract rna:dna 
1ocr 0.20~0.30 bovine heart cytochrome c oxidase in the fully reduced state 
1ott 0.20~0.30 
Structure of the Escherichia coli ClC Chloride channel E148A 
mutant and Fab Complex 
1otu 0.20~0.30 
Structure of the Escherichia coli ClC Chloride channel E148Q 
mutant and Fab Complex 
1rjl 0.20~0.30 
Structure of the complex between OspB-CT and bactericidal Fab-
H6831 
1tzi 0.20~0.30 Crystal Structure of the Fab YADS2 Complexed with h-VEGF 
1uj3 0.20~0.30 
Crystal structure of a humanized Fab fragment of anti-tissue-factor 
antibody in complex with tissue factor 
2e2i 0.20~0.30 RNA polymerase II elongation complex in 5 mM Mg+2 with 2'-
N(R)N
O
O
(R) N
O
N(S)
O
(S) CONH2
N(S)N
O
O
(R)
N
O
N(S)
O
(S)
CONH2
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dGTP 
2exy 0.20~0.30 
Crystal structure of the E148Q Mutant of EcClC, Fab complexed 
in absence of bound ions 
2ez0 0.20~0.30 
Crystal structure of the S107A/E148Q/Y445A mutant of EcClC, 
in complex with a FaB fragment 
2gmr 0.20~0.30 
Photosynthetic reaction center mutant from Rhodobacter 
sphaeroides with Asp L210 replaced with Asn 
2hit 0.197 
Reaction centre from Rhodobacter sphaeroides strain R-26.1 
complexed with dibrominated phosphatidylethanolamine 
2htk 0.20~0.30 
Structure of the Escherichia coli ClC chloride channel Y445A 
mutant and Fab complex 
2nvx 0.20~0.30 
RNA polymerase II elongation complex in 5 mM Mg+2 with 2'-
dUTP 
2nxz 0.20~0.30 
HIV-1 gp120 Envelope Glycoprotein (T257S, S334A, S375W) 
Complexed with CD4 and Antibody 17b 
2ny0 0.20~0.30 
HIV-1 gp120 Envelope Glycoprotein (M95W, W96C, T257S, 
V275C, S334A, S375W, A433M) Complexed with CD4 and 
Antibody 17b 
2ny2 0.20~0.30 
HIV-1 gp120 Envelope Glycoprotein (T123C, T257S, S334A, 
S375W, G431C) Complexed with CD4 and Antibody 17b 
2ny4 0.20~0.30 
HIV-1 gp120 Envelope Glycoprotein (K231C, T257S, E268C, 
S334A, S375W) Complexed with CD4 and Antibody 17b 
2qqn 0.20~0.30 Neuropilin-1 b1 Domain in Complex with a VEGF-Blocking Fab 
2r0l 0.20~0.30 Short Form HGFA with Inhibitory Fab75 
2xtj 0.20~0.30 
THE CRYSTAL STRUCTURE OF PCSK9 IN COMPLEX WITH 
1D05 FAB 
2xwt 0.20~0.30 
crystal structure of the tsh receptor in complex with a blocking 
type tshr autoantibody 
3du3 0.175 
E(L212)A, D(L213)A, A(M249)Y triple mutant structure of 
photosynthetic reaction center 
3grw 0.20~0.30 FGFR3 in complex with a Fab 
3h3v 0.20~0.30 
Yeast RNAP II containing poly(A)-signal sequence in the active 
site 
3h42 0.20~0.30 
Crystal structure of PCSK9 in complex with Fab from LDLR 
competitive antibody 
3hox 0.20~0.30 Complete RNA polymerase II elongation complex V 
3hoy 0.20~0.30 Complete RNA polymerase II elongation complex VI 
3kr3 0.20~0.30 Crystal structure of IGF-II antibody complex 
3l4m 0.126 
Crystal Structure of the MauG/pre-Methylamine Dehydrogenase 
Complex. 
3m7n 0.20~0.30 
archaeoglobus fulgidus exosome with RNA bound to the active 
site 
3ma9 0.20~0.30 Crystal structure of gp41 derived protein complexed with fab 8066 
3mac 0.20~0.30 
crystal structure of GP41-derived protein complexed with fab 
8062 
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3mx
w 0.20~0.30 Crystal structure Sonic hedgehog bound to the 5E1 fab fragment 
3nps 0.20~0.30 
Crystal structure of membrane-type serine protease 1 (MT-SP1) in 
complex with the Fab Inhibitor S4 
3o2d 0.20~0.30 
Crystal structure of HIV-1 primary receptor CD4 in complex with 
a potent antiviral antibody 
3o4o 0.20~0.30 Crystal structure of an Interleukin-1 receptor complex 
3orv 0.122 
Crystal Structure of the Y294H-MauG/pre-Methylamine 
Dehydrogenase Complex 
3pxs 0.081 
Crystal Structure of Diferrous MauG in Complex with Pre-
Methylamine Dehydrogenase: 
3pxt 0.108 
Crystal Structure of Ferrous CO Adduct of MauG in Complex 
with Pre-Methylamine Dehydrogenase 
3pxw 0.072 
Crystal Structure of Ferrous NO Adduct of MauG in Complex 
with Pre-Methylamine Dehydrogenase 
3r1g 0.20~0.30 
Structure Basis of Allosteric Inhibition of BACE1 by an Exosite-
Binding Antibody 
3rlm 0.096 
Structure of the W199F MauG/pre-Methylamine Dehydrogenase 
complex after treatment with hydrogen peroxide 
3s3x 0.20~0.30 
Structure of chicken acid-sensing ion channel 1 AT 3.0 A 
resolution in complex with psalmotoxin 
3sle 0.096 
Crystal Structure of the P107C-MauG/pre-Methylamine 
Dehydrogenase Complex 
3thm 0.20~0.30 
Crystal structure of Fas receptor extracellular domain in complex 
with Fab EP6b_B01 
3ulu 0.20~0.30 
Structure of quaternary complex of human TLR3ecd with three 
Fabs (Form1) 
3v65 0.20~0.30 Crystal structure of agrin and LRP4 complex 
4a3e 0.20~0.30 
RNA Polymerase ii initial transcribing complex with a 5nt dna-rna 
hybrid and soaked with ampcpp 
4a3i 0.20~0.30 RNA Polymerase II binary complex with DNA 
4a3k 0.190 
RNA polymerase ii initial transcribing complex with a 7nt dna-rna 
hybrid 
4dn4 0.20~0.30 
Crystal structure of the complex between cnto888 fab and mcp-1 
mutant p8a 
4fxe 0.20~0.30 
Crystal structure of the intact E. coli RelBE toxin-antitoxin 
complex 
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LLD 
 
PDB 
ID RMSD Protein 
1ccw 0.20~0.30 
structure of the coenzyme b12 dependent enzyme glutamate 
mutase from clostridium cochlearium 
1fns 0.20~0.30 
crystal structure of the von willebrand factor (vwf) a1 domain 
i546v mutant in complex with the function blocking fab nmc4 
1fyz 0.20~0.30 
methane monooxygenase hydroxylase, form ii reduced by 
soaking 
1fz0 0.163 
methane monooxygenase hydroxylase, form ii mixed-valent 
grown anaerobically 
1fz1 0.164 methane monooxygenase hydroxylase, form iii oxidized 
1fz2 0.171 
methane monooxygenase hydroxylase, form ii mixed-valent 
generated by crystal soaking 
1fz3 0.20~0.30 
methane monooxygenase hydroxylase, form iii soak at ph 6.2 (0.1 
m pipes) 
1fz6 0.162 
methane monooxygenase hydroxylase, form ii soaked in 1 m 
methanol 
1fz7 0.20~0.30 
methane monooxygenase hydroxylase, form iii soaked in 0.9 m 
ethanol 
1fz8 0.20~0.30 
methane monooxygenase hydroxylase, form ii cocrystallized with 
dibromomethane 
1fz9 0.164 
methane monooxygenase hydroxylase, form ii cocrystallized with 
iodoethane 
1fzh 0.155 
methane monooxygenase hydroxylase, form ii pressurized with 
xenon gas 
1fzi 0.20~0.30 
methane monooxygenase hydroxylase, form i pressurized with 
xenon gas 
1g20 0.20~0.30 
mgatp-bound and nucleotide-free structures of a nitrogenase 
protein complex between leu127del-fe protein and the mofe 
protein 
1i6h 0.20~0.30 RNA polymerase ii elongation complex 
1j8h 0.20~0.30 
Crystal Structure of a Complex of a Human alpha/beta-T cell 
Receptor, Influenza HA Antigen Peptide, and MHC Class II 
Molecule, HLA-DR4 
1jeq 0.20~0.30 Crystal Structure of the Ku Heterodimer 
1k83 0.20~0.30 
Crystal Structure of Yeast RNA Polymerase II Complexed with 
the Inhibitor Alpha Amanitin 
1ken 0.20~0.30 
Influenza virus hemagglutinin complexed with an antibody that 
prevents the hemagglutinin low ph fusogenic transition 
N(R)N
O
O
(S) N
O
N(S)
O
(S)
CONH2
	   177	  
1kg0 0.20~0.30 
Structure of the Epstein-Barr Virus gp42 Protein Bound to the 
MHC class II Receptor HLA-DR1 
1klg 0.20~0.30 
Crystal structure of HLA-DR1/TPI(23-37, Thr28-->Ile mutant) 
complexed with staphylococcal enterotoxin C3 variant 3B2 
(SEC3-3B2) 
1klu 0.20~0.30 
Crystal structure of HLA-DR1/TPI(23-37) complexed with 
staphylococcal enterotoxin C3 variant 3B2 (SEC3-3B2) 
1ktz 0.20~0.30 
Crystal Structure of the Human TGF-beta Type II Receptor 
Extracellular Domain in Complex with TGF-beta3 
1kyi 0.20~0.30 HslUV (H. influenzae)-NLVS Vinyl Sulfone Inhibitor Complex 
1lo5 0.20~0.30 
Crystal structure of the D227A variant of Staphylococcal 
enterotoxin A in complex with human MHC class II 
1mty 0.20~0.30 
methane monooxygenase hydroxylase from methylococcus 
capsulatus (bath) 
1n8z 0.20~0.30 
Crystal structure of extracellular domain of human HER2 
complexed with Herceptin Fab 
1o97 0.20~0.30 
structure of electron transferring flavoprotein from methylophilus 
methylotrophus, recognition loop removed by limited proteolysis 
1occ 0.20~0.30 
structure of bovine heart cytochrome c oxidase at the fully 
oxidized state 
1oco 0.20~0.30 
bovine heart cytochrome c oxidase in carbon monoxide-bound 
state 
1ocr 0.196 bovine heart cytochrome c oxidase in the fully reduced state 
1ocz 0.20~0.30 bovine heart cytochrome c oxidase in azide-bound state 
1pyw 0.20~0.30 
Human class II MHC protein HLA-DR1 bound to a designed 
peptide related to influenza virus hemagglutinin, 
FVKQNA(MAA)AL, in complex with staphylococcal 
enterotoxin C3 variant 3B2 (SEC3-3B2) 
1s9k 0.20~0.30 
Crystal Structure of Human NFAT1 and Fos-Jun on the IL-2 
ARRE1 Site 
1sje 0.20~0.30 
HLA-DR1 complexed with a 16 residue HIV capsid peptide 
bound in a hairpin conformation 
1sqx 0.20~0.30 Crystal Structure Analysis of Bovine Bc1 with Stigmatellin A 
1sr5 0.20~0.30 antithrombin-anhydrothrombin-heparin ternary complex structure 
1t5x 0.20~0.30 
HLA-DR1 in complex with a synthetic peptide 
(AAYSDQATPLLLSPR) and the superantigen SEC3-3B2 
1ub4 0.20~0.30 crystal structure of MazEF complex 
1v54 0.20~0.30 Bovine heart cytochrome c oxidase at the fully oxidized state 
1xkb 0.20~0.30 
factor xa complexed with a synthetic inhibitor fx-2212a,(2s)-(3'-
amidino-3-biphenylyl)-5-(4-pyridylamino)pentanoic acid 
1xmg 0.20~0.30 
Crystal structure of apo methane monooxygenase hydroxylase 
from M. capsulatus (Bath) 
1xmh 0.173 
Structure of Co(II) reconstituted methane monooxygenase 
hydroxylase from M. capsulatus (Bath) 
1xu3 0.190 Soluble methane monooxygenase hydroxylase-soaked with 
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bromophenol 
1xu5 0.171 Soluble methane monooxygenase hydroxylase-phenol soaked 
1xvb 0.167 
soluble methane monooxygenase hydroxylase: 6-bromohexanol 
soaked structure 
1xvc 0.173 
soluble methane monooxygenase hydroxylase: 8-bromooctanol 
soaked structure 
1xvd 0.20~0.30 
Soluble methane monooxygenase hydroxylase: 4-fluorophenol 
soaked structure 
1xve 0.180 
soluble methane monooxygenase hydroxylase: 3-bromo-3-
butenol soaked structure 
1xvf 0.20~0.30 
soluble methane monooxygenase hydroxylase: chloropropanol 
soaked structure 
1xvg 0.20~0.30 
soluble methane monooxygenase hydroxylase: bromoethanol 
soaked structure 
1za1 0.20~0.30 
Structure of wild-type E. coli Aspartate Transcarbamoylase in the 
presence of CTP at 2.20 A resolution 
2dyr 0.20~0.30 Bovine heart cytochrome C oxidase at the fully oxidized state 
2fzg 0.20~0.30 
The Structure of Wild-Type E. Coli Aspartate Transcarbamoylase 
in Complex with Novel T State Inhibitors at 2.25 Resolution 
2fzk 0.20~0.30 
The Structure of Wild-Type E. Coli Aspartate Transcarbamoylase 
in Complex with Novel T State Inhibitors at 2.50 Resolution 
2i07 0.20~0.30 Human Complement Component C3b 
2iam 0.20~0.30 
Structural basis for recognition of mutant self by a tumor-
specific, MHC class II-restricted TCR 
2omt 0.20~0.30 Crystal structure of InlA G194S+S/hEC1 complex 
2pjy 0.20~0.30 
Structural basis for cooperative assembly of the TGF-beta 
signaling complex 
2pm9 0.20~0.30 
Crystal structure of yeast Sec13/31 vertex element of the COPII 
vesicular coat 
2v4j 0.20~0.30 
the crystal structure of desulfovibrio vulgaris dissimilatory sulfite 
reductase bound to dsrc provides novel insights into the 
mechanism of sulfate respiration 
2vaa 0.20~0.30 
mhc class i h-2kb heavy chain complexed with beta-2 
microglobulin and vesicular stomatitis virus nucleoprotein 
2vab 0.20~0.30 
mhc class i h-2kb heavy chain complexed with beta-2 
microglobulin and sendai virus nucleoprotein 
2vgl 0.20~0.30 ap2 clathrin adaptor core 
2vhm 0.20~0.30 
structure of pdf binding helix in complex with the ribosome (part 
1 of 4) 
2x5u 0.20~0.30 
80 microsecond laue diffraction snapshot from crystals of a 
photosynthetic reaction centre without illumination. 
2xn9 0.20~0.30 
crystal structure of the ternary complex between human t cell 
receptor, staphylococcal enterotoxin h and human major 
histocompatibility complex class ii 
2xts 0.179 crystal structure of the sulfane dehydrogenase soxcd from 
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paracoccus pantotrophus 
2yu9 0.20~0.30 
RNA polymerase II elongation complex in 150 mm MG+2 with 
UTP 
3ayx 0.20~0.30 
Membrane-bound respiratory [NiFe] hydrogenase from 
Hydrogenovibrio marinus in an H2-reduced condition 
3cqz 0.20~0.30 
Crystal structure of 10 subunit RNA polymerase II in complex 
with the inhibitor alpha-amanitin 
3gtp 0.20~0.30 Backtracked RNA polymerase II complex with 24mer RNA 
3k7a 0.20~0.30 Crystal Structure of an RNA polymerase II-TFIIB complex 
3lq5 0.20~0.30 Structure of CDK9/CyclinT in complex with S-CR8 
3mhs 0.20~0.30 
Structure of the SAGA Ubp8/Sgf11/Sus1/Sgf73 DUB module 
bound to ubiquitin aldehyde 
3mi9 0.20~0.30 Crystal structure of HIV-1 Tat complexed with human P-TEFb 
3oat 0.20~0.30 
Crystal structure of the E. coli ribosome bound to telithromycin. 
This file contains the 50S subunit of the first 70S ribosome with 
telithromycin bound. 
3ogk 0.20~0.30 
Structure of COI1-ASK1 in complex with coronatine and an 
incomplete JAZ1 degron 
3rzd 0.20~0.30 RNA Polymerase II Initiation Complex with a 5-nt RNA 
3s14 0.20~0.30 RNA Polymerase II Initiation Complex with a 6-nt RNA 
3s1m 0.20~0.30 
RNA Polymerase II Initiation Complex with a 5-nt RNA (variant 
1) 
3s1n 0.20~0.30 
RNA Polymerase II Initiation Complex with a 5-nt RNA (variant 
2) 
3s1q 0.20~0.30 
RNA Polymerase II Initiation Complex with a 5-nt 3'-deoxy RNA 
soaked with ATP 
3s2d 0.20~0.30 
RNA Polymerase II Initiation Complex with a 5-nt RNA 
containing a 5Br-U 
3sri 0.20~0.30 
Crystal structure of Plasmodium falciparum AMA1 in complex 
with a 29aa PfRON2 peptide 
3tnh 0.20~0.30 CDK9/cyclin T in complex with CAN508 
3tni 0.20~0.30 structure of CDK9/cyclin T F241L 
4a3d 0.20~0.30 
RNA polymerase ii initial transcribing complex with a 6nt dna-
rna hybrid 
4a3g 0.20~0.30 
RNA polymerase ii initial transcribing complex with a 2nt dna-
rna hybrid 
4a3k 0.20~0.30 
RNA polymerase ii initial transcribing complex with a 7nt dna-
rna hybrid 
4ec9 0.20~0.30 Crystal structure of full-length cdk9 in complex with cyclin t 
5prc 0.20~0.30 
photosynthetic reaction center from rhodopseudomonas viridis 
(atrazine complex) 
6prc 0.169 
photosynthetic reaction center from rhodopseudomonas viridis 
(dg-420314 (triazine) complex) 
7prc 0.20~0.30 
photosynthetic reaction center from rhodopseudomonas viridis 
(dg-420315 (triazine) complex) 
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LLL 
 
PDB 
ID RMSD Protein 
1bcp 0.20~0.30 binary complex of pertussis toxin and atp 
1e6v 0.20~0.30 methyl-coenzyme m reductase from methanopyrus kandleri 
1eex 0.20~0.30 
crystal structure of the diol dehydratase-
adeninylpentylcobalamin complex from klebsiella oxytoca 
1egv 0.20~0.30 
crystal structure of the diol dehydratase-
adeninylpentylcobalamin complex from klebsella oxytoca under 
the illuminated condition. 
1fzi 0.20~0.30 
methane monooxygenase hydroxylase, form i pressurized with 
xenon gas 
1hap 0.20~0.30 
complex of human alpha-thrombin with a 15mer oligonucleotide 
ggttggtgtggttgg (based on x-ray model of dna) 
1hbm 0.20~0.30 methyl-coenzyme m reductase enzyme product complex 
1hbn 0.20~0.30 methyl-coenzyme m reductase 
1hbo 0.20~0.30 methyl-coenzyme m reductase mcr-red1-silent 
1hbu 0.20~0.30 
methyl-coenzyme m reductase in the mcr-red1-silent state in 
complex with coenzyme m 
1i50 0.20~0.30 RNA polymerase ii crystal form ii at 2.8 a resolution 
1iwp 0.20~0.30 
Glycerol Dehydratase-cyanocobalamin Complex of Klebsiella 
pneumoniae 
1jmu 0.199 Crystal Structure of the Reovirus mu1/sigma3 Complex 
1jnr 0.20~0.30 
Structure of adenylylsulfate reductase from the 
hyperthermophilic Archaeoglobus fulgidus at 1.6 resolution 
1jnz 0.20~0.30 
Structure of adenylylsulfate reductase from the 
hyperthermophilic Archaeoglobus fulgidus at 1.6 resolution 
1mhy 0.20~0.30 methane monooxygenase hydroxylase 
1mro 0.20~0.30 methyl-coenzyme m reductase 
1mty 0.20~0.30 
methane monooxygenase hydroxylase from methylococcus 
capsulatus (bath) 
1oco 0.20~0.30 
bovine heart cytochrome c oxidase in carbon monoxide-bound 
state 
1ocr 0.20~0.30 bovine heart cytochrome c oxidase in the fully reduced state 
1qlb 0.20~0.30 
respiratory complex II-like fumarate reductase from Wolinella 
succinogenes 
1rjc 0.193 Crystal structure of the camelid single domain antibody cAb-
N(S)N
O
O
(S)
N
O
N(S)
O
(S)
CONH2
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Lys2 in complex with hen egg white lysozyme 
1rld 0.20~0.30 
solid-state phase transition in the crystal structure of ribulose 
1,5-biphosphate carboxylase(slash)oxygenase 
1sqp 0.20~0.30 Crystal Structure Analysis of Bovine Bc1 with Myxothiazol 
1sqq 0.20~0.30 
Crystal Structure Analysis of Bovine Bc1 with Methoxy 
Acrylate Stilbene (MOAS) 
1t36 0.20~0.30 
Crystal structure of E. coli carbamoyl phosphate synthetase 
small subunit mutant C248D complexed with uridine 5'-
monophosphate 
1tbg 0.20~0.30 beta-gamma dimer of the heterotrimeric g-protein transducin 
1twg 0.20~0.30 RNA polymerase II complexed with CTP 
1uc4 0.20~0.30 
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